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LONG NONCODING RNA MEG3 REGULATES MYOBLAST PLASTICITY 
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ABSTRACT 
Skeletal muscle formation is among the most striking examples of cellular 
plasticity in animal tissue development, where mononucleated, lineage-restricted 
progenitor cells are epigenetically reprogrammed to produce multinucleated myofibers. 
While some mediators of epithelial-mesenchymal transition (EMT) have been shown to 
function in myogenesis, regulation of this process at the interface of multipotency and 
myogenic differentiation remains poorly understood.  The long noncoding RNA 
(lncRNA) Meg3 is processed from the >200 kb Dlk1-Dio3 polycistron, and while many 
encoded miRNAs have been shown to regulate skeletal muscle differentiation, 
regeneration, and aging, the functional relevance of encoded lncRNAs in skeletal muscle 
remains elusive. Here, I demonstrate that Meg3 is enriched in proliferating post-natal 
myoblasts, where it epigenetically modulates aspects of cellular plasticity to facilitate 
myogenic differentiation in vitro, skeletal muscle regeneration in vivo, and safeguard 
myogenic identity. Chronic inhibition of Meg3 in C2C12 myoblasts compromised 
cytoarchitectural and transcriptomic cell-state transitions required for myogenic fusion 
and differentiation. These differentiation defects were primarily driven by TGFβ-
dependent Snai2 activation, which correlated with irregular Ezh2 activity and abnormal 
xi 
epigenetic marks in differentiating C2C12 cells. Similarly, adenoviral Meg3 knockdown 
compromised muscle regeneration in vivo, which manifested as abnormal mesenchymal 
gene expression, fibrosis, and interstitial cell proliferation in the regenerating milieu. 
Comparison of Meg3-depleted C2C12 myoblasts and injured skeletal muscle to literature-
derived gene sets suggest that Meg3-deficient samples deviate from controls towards 
abnormal transcriptional states, including immature satellite cell activation, muscle aging, 
and adoption of an osteoblast-like cell ontology. Thus, Meg3 regulates myoblast identity 
to maintain proper cell state transitions in postnatal myogenesis.  
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CHAPTER ONE: BACKGROUND 
1.1 Introduction  
 Myofibers are elongated, syncytial skeletal muscle cells that specialize in 
voluntary functional shortening, which mediates breathing, ambulation, and other 
physical interactions with our surroundings. While multinucleated myofibers themselves 
are terminally differentiated, various mononucleated cells reside in the surrounding 
interstitium, and are essential for maintaining and improving skeletal muscle strength. In 
response to external stresses or internal defects, resident progenitors called satellite cells 
undergo substantial epigenetic, transcriptional, and cytoarchitectural remodeling, which 
enables these cells to enjoin to preexisting myofibers or generate postnatal myotubes de 
novo. While this regenerative capacity is substantial, it is limited by size and severity of 
injury in acute muscle trauma, number of divisions in chronic disease, and accumulation 
of internal defects in aging. As regenerative capacity recedes, muscle loss accumulates, 
resulting in debilitating muscle weakness and loss of autonomy. In severe pathological 
myopathies, such as Duchenne Muscular Dystrophy (DMD), complications associated 
with respiratory failure are a primary cause of death (Calvert et al. 2006), whereas in 
healthy individuals, age-related sarcopenia gradually diminishes a patient’s autonomy 
(Santilli et al. 2014). Detailed understanding of how myoblast plasticity is regulated, as 
well as how it becomes dysregulated, is essential to formulate winning muscle 
regeneration strategies. Accordingly, the field of muscle biology is currently tasked with 




to improve quality of life to severely disabled patients and the globally ballooning 
geriatric population (NIH, 2011).  
1.2 Developmental myogenesis 
Somitogenesis  
In vertebrate development, all skeletal muscle cells originate from transient 
embryonic mesoderm structures called somites. During somitogenesis (Figure 1.1), 
mesenchymal mesoderm cells in the presomitic mesoderm respond to a posterior 
fibroblast growth factor (FGF) gradient that stimulates canonical Wnt signaling, thereby 
initiating oscillatory Notch expression. Briefly, Notch is cleaved and the resultant 
intracellular domain (ICD) upregulates Mesp2, which inactivates signaling via lunatic 
fringe (Lfng)-mediated Notch glycosylation. While Mesp2 is rapidly inactivated in the 
posterior presomitic mesoderm by FGF, an anteriorly opposing gradient of retinoic acid 
(RA) forms a determination front that enables for anterior Mesp2 signaling to persist. 
This enduring Mesp2 induces a stripe of Eph4-bearing cells (Maroto et al. 2012), and 
resultant Eph-ephrin engagement blocks the mesenchymal Rho-family GTPase Cdc42 to 
initiate mesenchymal-epithelial transition (MET) to establish an epithelium boundary 
encasing mesenchymal cells, known as a somite (Nakaya et al. 2004).  
Myoblast specification  
Each resultant somite is comprised of Pax3-expressing (Pax3+) progenitor cells, 
and as signals from the surrounding embryonic structures induce subdivision of somite 




of migratory skeletal muscle progenitors (Hernandez-Torrez et al. 2017). First, 
notochord-derived sonic hedgehog (Shh) signaling induces mesenchymal-epithelial 
transition (EMT) to de-epithelialize the ventral somite and specify sclerotome precursors 
for cartilage and bone. In contrast, the dorsal somite remains epithelial and is a transient 
embryonic structure called dermomyotome (Maroto et al. 2012). Dorsal Neurotrophin3 
signals from the ectoderm induce the central dermomyotome to resolve into dermatome, 
which gives rise to dermal layers of the skin, but distal folds of the dermomyotome – the 
nascent myotome – are spared of this signal, and give rise to muscle precursors 
(Bentzinger et al. 2012, Maroto et al. 2012). Unlike dermatome, myotome-destined cells 
undergo EMT to gradually invade the zone between nascent dermatome and sclerotome 
layers, and retain this mesenchymal identity to populate distant embryonic structures with 
skeletal muscle (Hernandez-Torrez et al. 2017). From the myotome, skeletal muscle 
fibers are formed in successive morphogenic waves: primary myogenesis, where a small 
population of migratory Pax3+/Pax7- myoblasts establish a primary muscle pattern 
scaffold observed on mouse embryonic day 11 (E11), and secondary myogenesis, 
wherein asynchronous waves of additional Pax3+/Pax7+ myoblasts populate along the 
surface of primary myofibers (Messina et al. 2009, Gros et al. 2005, Lee et al. 2013). 
Epaxial muscle formation  
Dorsal myoblasts, derived from the epaxial lip of the dermomyotome, undergo the 
least migration of all myoblasts to form deep back musculature. This process is aided by 
the dorsal ectoderm, which supplies Wnt6 to transiently preserve an epithelial state in the 




receive dorsomedial inductive signals. To this end, the floor plate of the neural tube and 
notochord supply Shh through the sclerotome, whereas the dorsal neural tube secretes 
Wnt1 and Wnt3a to induce canonical Wnt-β-catenin signaling. Together, these signals 
synergistically induce the myogenic determination gene Myf5 and subsequent myogenin-
based differentiation. Subsequent Wnt-induced planar cell polarity activation directs 
epaxial myocytes to elongate parallel to the neural tube, and differentiate into dorsal 
musculature (Deries et al. 2016, Hernandez-Torrez et al. 2017). 
Hypaxial muscle formation  
Unlike its epaxial counterpart, hypaxial myotome requires extensive migration to 
form musculature of the abdomen and limbs, and rather than Myf5, maturation is driven 
predominantly by the myogenic determination factor MyoD (Hernandez-Torrez et al. 
2017). Ventro-lateral ectoderm supplies Wnt7a to the hypaxial lips of the dermomyotome 
to initiates MyoD induction and promote hypaxial myoblast identity, and BMPs secreted 
by the neighboring lateral plate mesoderm aid in expansion of progenitor cells by 
suppressing myogenic differentiation. Transiting neural crest cells also stimulate muscle 
progenitor expansion via Neuregulin1 secretion (Deries et al. 2016).  
In successive waves, myoblasts delaminate from the ventro-lateral lip of the 
dermomyotome and myotome, to subsequently populate distal structures called limb 
buds. During this process, myoblasts express classical mesenchymal markers, N-cadherin 
and fibronectin, which modulate adhesion to surrounding embryonic structures as they 
delaminate (Deries et al. 2016, Bentzinger et al. 2012). Migration of these myoblasts is 




cells secrete Ephrin5a that engages Eph4 receptor-mediated repulsion, whereas SDF1 
expressed in the core limb bud mesenchyme promotes collective migration towards the 
proper anatomical location (Deries et al. 2016).  
To retain an undifferentiated state, autocrine SFRP2 signaling antagonizes Wnt 
signal transduction, and BMPs from the surrounding tissues suppress MyoD-mediated 
differentiation. However, the mesenchyme within the limb bud interior secretes Noggin 
to neutralize BMP activity, and by relief of MyoD repression, initiates myogenic 
differentiation. Shh signaling from the zone of polarizing activity further promotes 
differentiation of muscle precursors via induction of Myf5, and FGF18 secreted by the 
limb ectoderm and limb mesenchyme activate Erk/MAPK signaling that promotes 
Myf5/MyoD coexpression. To ensure that differentiation occurs in a proximal-distal 
wave, apical ectoderm ridge cells secrete FGFs that suppress differentiation in the distal-
most portion of the limb bud. Upon arriving to the correct anatomical location, the vast 
majority of myoblasts form syncitial myofibers and downregulate Pax7 expression 
(Deries et al. 2016).  
Specification of satellite cells  
In both hypaxial and epaxial skeletal muscle, a subset of myoblasts are retained to 
facilitate postnatal myogenesis. The origins of this muscle progenitor cell population, 
called satellite cells, are tied to neural crest cell migration. In the dermamyotome, a 
subset of nascent myoblasts are transiently subjected to Delta1-presenting neural crest 
cells (Bentzinger et al. 2012). Resultant Notch signaling inhibits S-phase entry and Ki67 




these satellite cell precursors experience the same inductive signals as other myoblasts, 
they ultimately do not contribute to prenatal skeletal muscle upon arriving to their 
anatomical destination. Instead, satellite cell specified myoblasts retain Pax7 expression, 
associate closely with prenatal myofibers, and inhabit the sub-lamina muscle interstitium. 
Postnatally, these Pax7+ progenitors respond to muscle injury by recapitulating 
embryonic myogenesis in postnatal skeletal muscle (Figure 1.3) and are essential for 
postnatal muscle retention and growth (Bentzinger et al. 2012). 
Epithelial-mesenchymal transition in myogenesis 
EMT encompasses a spectrum of cellular behavior and characteristic modulations, 
and while this process is not generally associated with muscle differentiation, classical 
EMT markers have been independently shown to modulate myogenesis (Table 1.1). The 
mesenchymal zinc finger proteins Snai1 and Snai2 are functionally redundant 
transcriptional repressors of epithelial E-cadherin in EMT (Hajra et al. 2002), and in 
myoblasts these factors repress MRF-mediated differentiation to promote satellite cell 
expansion. Snai2 expression is induced by c-met/focal adhesion kinase signaling to 
facilitate myoblast migration during myogenesis, and its expression is driven by TGFβ-
Erk signaling (Thorsteinsdottir et al. 2011). During muscle regeneration, Snai2 recruits 
HDAC1/2 to myogenic E-box-targets of MyoD to suppress precocious differentiation and 
bias MyoD towards pro-proliferative gene targets. Given its anti-myogenic function, 
transcriptional downregulation of Snai2 is a prerequisite for myogenic differentiation to 
proceed, and its timely depletion in satellite cells is mediated by myogenic regulatory 




The intermediate filament protein vimentin is a clinical marker of migratory 
mesenchymal character, and its expression in postnatal muscle is restricted to 
mesenchymal stromal cells, activated satellite cells and nascent myofibers (Wu et al. 
2007, Vater et al. 1994). This protein colocalizes with the tissue-specific intermediate 
filament proteins during early myogenesis and muscle regeneration, where it is thought to 
facilitate mechanical stability and desmin-dependent organization of sarcomeric muscle 
architecture (1980 Gard et al. 1980, Bornemann et al. 1992). Consistent with its early-
phase expression profiling, canonical TGFβ signaling transcriptionally activates vimentin 
in C2C12 myoblast differentiation (Wu et al. 2007). 
Cadherins are junctional, calcium-dependent adhesion proteins that modulate cell 
adhesion, and M- and N-cadherin are enriched at apical junctions of quiescent satellite 
cells, where they associate with myofibers. Cadherin displacement is hypothesized to 
function as shear-stress mechanoreceptors that drive satellite cell activation, and along 
these lines, N-cadherin knockout mice harbor satellite cells with chronic cell cycle 
activation in homeostatic muscle, suggesting this class of cadherin is an important 
regulator of satellite cell proliferation (Goel et al. 2017). Moreover, pan-cadherin 
intracellular domains sequester β-catenin to the cell surface, and both M- and N-cadherin 
have been shown to negatively regulate canonical Wnt signaling (Goel et al. 2017, 
Ozawa et al. 2015). Upon activation, satellite cells lose apical-basal cadherin polarity and 
upregulate both M- and N-cadherin, which is hypothesized to facilitate myogenic fusion. 
While studies have demonstrated that cadherins are required for myoblast fusion in vitro, 




(Goel et al. 2017). Interestingly, N-cadherin has been shown to couple myoblast adhesion 
to the activation of non-canonical TGFβ effectors p38 MAPK and RhoA, which both 
modulate aspects of myoblast activity during skeletal muscle regeneration (Lovett et al. 
2006, Lu et al. 2010).  
1.3 Skeletal muscle regeneration 
The regenerating microenvironment 
When skeletal muscle is injured, cellular expansion and signaling cascades 
facilitate necrotic cell clearance and muscle regeneration (Figure 1.4). First-responders to 
injured muscle tissue are neutrophils, which generate reactive oxygen species to degrade 
necrotic tissue and release pro-inflammatory cytokines to recruit macrophages (Tidball et 
al. 2010). While macrophages clear cellular debris, they also release factors such as 
TGFβ that suppress satellite cell differentiation and simultaneously stimulate expansion 
of mesenchymal stromal cells (MSCs) (Wosczyna et al. 2018).  
MSCs secrete a variety of factors that aid in satellite cell expansion and 
differentiation; IL-6 stimulates satellite cell proliferation through Jak2/Stat3 signaling 
(Joe et al. 2010), and WISP1 promotes asymmetric satellite cell division to preserve a 
pool of quiescent satellite cells for future instances of injury. Moreover, MSC-derived 
follistatin counteracts the anti-myogenic effect of local TGFβ ligands myostatin and 
activin A (Bifereli et al. 2019). While MSCs are required for satellite cell expansion and 
efficient muscle regeneration (Wosczyna et al. 2019), accumulation of MSCs in the 
regenerating microenvironment results in pathological ECM deposition, fatty 




which induces MSCs to apoptose; accordingly, MSC populations decline roughly three 
days post-injury (Lemos et al. 2012). After receiving stimuli from the injured 
microenvironment, activated Pax7+ satellite cells undergo substantial epigenetic and 
transcriptional remodeling to proliferate, fuse, and differentiate into functionally 
integrated skeletal muscle. 
Satellite cell self-renewal 
Satellite cells must expand mitotically and differentiate to reestablish 
musculature, but a subset of satellite cells must retain progenitor-cell characteristics in 
order for regeneration to be sustainable. To this end, a subset of satellite cells return to 
quiescent stem cell niche, and this can occur through a variety of mechanisms. A subset 
of satellite cells undergo asymmetric divisions, wherein one daughter cell retains 
quiescence in association with the basal lamina, while the apically dividing daughter cell 
takes on an activated cell identity. Endothelial growth factor receptor (EGFR) signaling 
has been shown to directly stimulate asymmetrical division through Aurora kinase A, 
which orient mitotic centromeres apical-basally (Wang et al. 2019). Asymmetrical 
distribution of par complexes also correlate with satellite cell self-renewal, where they 
facilitate apical p38α/β MAPK localization that suppresses MyoD induction in the 
basally-oriented satellite cell to preserve quiescence (Troy et al. 2012).  
Alternatively, a subset of myogenic progenitors can undergo horizontal symmetric 
divisions to drive expansion of quiescent populations, which ultimately increases the 
regenerative capacity of muscle. This phenomenon is coupled to activated satellite cells, 




fibronectin glycoprotein in the ECM (Bentzinger et al. 2013). When Fzd7-syndecan 4 co-
receptors engage fibronectin, resultant non-canonical Wnt signaling induces the 
symmetrical deployment of planar cell polarity component α7integrin. This increased 
adhesion promotes retention of contacts with the basal lamina, and ultimately maintains 
quiescence in both daughter cells (Bentzinger et al. 2013 , Grand et al. 2009). 
During early dispersal, myoblasts downregulate Erk1/2-mediated proliferation 
and signaling, upregulate a subset of myogenic differentiation genes, and migrate to 
injured muscle (Flamini et al. 2018). In committed activated satellite cells, basic helix-
loop-helix (bHLH) myogenic regulatory factors (MRFs) Myf5, MyoD, and myogenin are 
core mediators of satellite cell proliferation and differentiation, which recapitulate 
developmental myogenesis through transcriptional activation of target E-box consensus 
sequences (Bentzinger et al. 2012, Zammit et al. 2017). In quiescent satellite cells, Myf5 
transcripts are stored in RNP granules, whereas the other MRFs transcripts are low. Upon 
injury, Insulin-like growth factor (IGF) and calcium influx liberate Myf5 transcripts for 
translation (Goel et al. 2017), and resultant Myf5 protein subsequently transcribes MyoD.  
MyoD has temporally distinct roles; in proliferating myoblasts, repression of 
myogenic E-box targets shunts MyoD activity towards synergy with Myf5 to facilitate 
cell-cycle reentry (Fu et al. 2015, Zammit et al. 2017). When myogenic E-box domains 
become transcriptionally accessible, MyoD activates myogenin expression, and in doing 
so, triggers a shift from satellite cell expansion towards myogenic differentiation. After 




programs that facilitate the maturation of nascent myofibers (Zammit et al. 2017, 
Bentzinger et al. 2012). 
Interestingly, single-cell sequencing has revealed incredible transcriptomic 
heterogeneity within activated satellite cell populations, and even migratory delaminated 
satellite cells are capable of reverting back to a quiescent state (Cho et al. 2017). In such 
instances, these dispersed myoblast subtypes upregulate p53 activity and cell-adhesion 
genes, which promotes association with preexisting myofibers and return to the satellite 
cell niche (Flamini et al. 2018).  
Satellite cell fusion 
Fusion requires carefully regulated adhesion, cytoskeletal alterations, and signal 
transduction to successfully adjoin plasma membranes without compromising viability. 
While myogenic fusion has been extensively characterized in Drosophila melanogaster 
(Kim et al. 2015, Segal et al. 2016, Deng et al. 2017), specific drivers of myogenic fusion 
in vertebrates were only recently identified. This is largely because differentiation 
impairments are generally accompanied by fusion defects, making it challenging to 
uncouple myogenic differentiation from fusion (Sampath et al. 2018). In a landmark 
paper, Millay et al. identified a muscle-specific membrane protein called myomaker, 
which is required for myoblast fusion in a differentiation-independent manner. Further 
characterization of this myogenic fusion protein demonstrated that ectopic myomaker 
expression is sufficient to induce fibroblast syncytium formation, and determined that 
actin polymerization was a requisite step for myomaker-dependent fusion-competence 




thereafter, and it was observed that myomaker and myomixer co-expression correlate 
with actin stabilization at the cell wall periphery (Zhang et al. 2017). Given both of these 
proteins require actin stabilization to facilitate fusion, it is hypothesized that Rac 
signaling is an important prerequisite to myogenic fusion (Sampath et al. 2018). Along 
these lines, downregulation of the fusion-inhibiting protein Rspo1 upregulates Rac1 
signaling to enhance directional migration and a results in a hyper-fusion phenotype 
(Lacour et al. 2017). 
Regeneration impairments in aging 
When muscle’s regenerative capacity is reduced, incurred muscle loss results in 
debilitating weakness. This is particularly striking in Duchenne Muscular Dystrophy 
(DMD), a congenital dystrophin disorder that results in catastrophic depletion of the 
satellite cell pool – but in truth, all people are subject to debilitating muscle weakness if 
they live long enough. Normal aging is accompanied by progressive reductions in muscle 
mass and function, driven by both intrinsic factors, such as cell-autonomous satellite cell 
malfunction, and alterations in extrinsic factors, such as cell signaling and ECM, that 
accompany muscle aging.  
The regenerating microenvironment changes substantially with age, as muscle 
fibers are progressively replaced with adipose and fibrotic tissues (Parker et al. 2015). 
Myofibers secrete more FGF as they age, which has been shown to drive p38 MAPK 
hyperactivity, and functionally promote satellite cells to break quiescence with 
heightened frequency (Chakkalakal et al. 2013). Unbridled p38 activity is proposed to 




(Bernet et al. 2014). Upon activation, geriatric satellite cells are subject to heightened 
TGFβ signaling, which is associated with age-related Notch downregulation, and this 
suppresses quiescent satellite cell activation and activated satellite cell differentiation (Xu 
et al. 2018). When delaminated satellite cells are unable to return to the satellite cell 
niche or contribute to muscle, canonical Wnt3a signaling promotes satellite cells take on 
an alternative fibrogenic cell fate (Sousa-Victor et al. 2014, Subramaniam et al. 2013, 
Brack et al. 2007) Increased TGFβ signaling builds upon this fibrotic phenotype by 
stimulating fibroblast proliferation and ECM deposition (Xu et al. 2018). Interestingly, 
aged fibroblasts secrete a more rigid ECM that promotes fibrogenic conversion in 
satellite cells (Stearns-Reider et al. 2017). Taken together, it appears aberrant TGFβ, p38, 
and Wnt signaling, as well as abnormal fibroblast activity, promote age-related 
sarcopenia and fibrosis.  
While extrinsic factors certainly facilitate age-related myopathies, satellite cell 
transplantation studies have shown that geriatric myoblasts retain activation and 
differentiation deficits when transplanted to youthful microenvironments, suggesting age-
related phenotypes are also caused by cell-autonomous defects (Sousa-Victor et al. 2014, 
Bernet et al. 2014). Along these lines, epigenetics play a pathological role in aged-related 
myoblast dysfunction. Even though chromatin compaction regulates transcriptional 
repression in quiescent satellite cells, only a minority of loci harbor the epigenetically 
repressive H3K27me3 marks. In contrast to youthful myoblasts, aged satellite cells 
exhibit abnormal accumulation of H3K27me3 marks (Liu et al. 2013). Given polycomb 




satellite cells (Juan et al. 2011), H3K27me3 accumulation is putatively facilitated by 
increased basal cell-cycle reversions and decreased cell cycle kinetics in aged satellite 
cells (Chakkalakal et al. 2013, Kimmel et al. 2020). Interestingly, mice fed HDAC 
inhibitors enhanced retention of myofibers into old age, which coincided with reduced 
apoptosis and restoration of oxidative metabolism (Walsh et al. 2014). Taken together, 
these data suggest that chromatin remodeling plays a pathological role in skeletal muscle 
aging. 
 
1.3 Regulation of post-natal myogenesis 
Epigenetic regulation of satellite cells 
 
Similar to embryonic stem cells, quiescent satellite cells have a high nucleus-to-
cytoplasm ratio, and upon activation these cells profoundly shift from condensed 
heterochromatin to euchromatin (Ryall et al. 2015). In spite of this chromosomal 
compaction, ChIPseq studies have shown that quiescent satellite cells harbor very few 
genes that are epigenetically repressed by H3K27me3, and the prevalence of bivalent 
H3K27me3 epigenetic marks reflects a permissive chromatin landscape (Liu et al. 2013). 
Quiescent satellite cells have high baseline SIRT1 deacetylase activity, and when 
activated satellite cells upregulate glycolytic metabolism, resultant downregulation of 
SIRT1 activity is required for genome accessibility to myogenic regulatory factor loci 
(Ryall et al. 2015). Satellite cells also de-repress proliferative and myogenic gene 
programs via downregulating Suv4-20h1-dependent HK420me2, though the mechanisms 




PRC2 switches from quiescence-associated Ezh1, which mediates compaction without 
methyltransferase activity, to Ezh2 which mediates H3K27me3 repressive marks (Juan et 
al. 2011, Boonsay et al. 2016). Accordingly, H3K27me3 marks are greatly upregulated in 
activated satellite cells, as indicated by immunofluorescence and ChIPseq analyses (Liu 
et al. 2013).  
Conditional knockout studies have demonstrated that Ezh2-specific PRC2 activity 
facilitates satellite cell expansion and safeguards the transcriptional identity of satellite 
cells via suppression of non-myogenic gene programs (Juan et al. 2011, Woodhouse et al. 
2013). PRC2 also facilitates myogenic differentiation by modulating myogenic gene 
programs; PRC2 is required for β-catenin nuclear localization via repression of Wnt 
antagonist SFRP1, which is directly required for MyoD transcriptional activation, and 
subsequent Myogenin expression (Adhikari et al. 2018). In later stages of regeneration, 
TNF-induced p38 signaling induces Ezh2 phosphorylation, resulting in PRC2 recruitment 
to the Pax7 promoter, and denotes a switch from satellite cell expansion to differentiation 
(Palacios et al. 2011). As satellite cells mature into nascent myofibers, Ezh2 is 
downregulated to undetectable levels (Juan et al. 2011). 
TGFβ at the interface of quiescence and activation 
Chronic satellite cell activation risks exhaustion of the stem cell reservoir, 
whereas failure to activate compromises skeletal muscle maintenance and function; 
accordingly, activation must be regulated to ensure that regeneration is triggered by 
appropriate stimuli. TGFβ1 is a potent inhibitor of myogenic differentiation signaling, 




(Allen et al. 2011). Pre-processed TGFβ family ligands such as myostatin and activin A 
are readily bioavailable in the ECM surrounding myoblasts, and their affinity and 
availability for TGFβ receptors is proteolytically regulated (2016 Delaney). Downstream 
canonical TGFβ signaling phosphorylates the Smad-2/3 complex, which translocates to 
the nucleus and transcriptionally activates effector proteins. Non-canonical TGFβ 
signaling also modulates satellite cell activity through activation of small GTPase 
proteins Rho, Rac, and Cdc42, as well as p38 MAPK, which modulate actin cytoskeleton 
remodeling and gene expression (Xu et al. 2018).  
Functionally, treatment of satellite cells with TGFβ ligands has been shown to 
induce cell-cycle exit and repress early differentiation marker MyoD, which is thought to 
suppress inadvertent activation in the face of exercise-related pH stress (Allen et al. 
2011). Though Smad2/3-induced CDK inhibitors promote satellite cell-cycle arrest, this 
anti-proliferative effect is regulated by Notch and pro-proliferative BMP4 signaling 
pathway antagonism. While BMP and TGFβ are integrated with numerous signaling 
pathways, the biological outcomes of this crosstalk have largely context-dependent 
outcomes (Guo et al. 2009, Dituri et al. 2018). More broadly, antagonism between these 
two signaling cascades is a paradigm in stem cell biology, wherein TGFβ signaling 
generally suppresses somatic reprogramming and stimulates EMT, while opposing BMP 
signaling promotes MET and differentiation (Xu et al. 2018). Along these lines, various 




Regulation of muscle regeneration by p38 MAPK 
The MAPK p38 is a nodal modulator of cellular activities that are required for 
myogenic differentiation. Asymmetrically dividing satellite cells restrict p38 MAPK to 
apical daughter cells, and proliferating satellite cells lacking p38 return to quiescence 
(Troy et al. 2012). In activated myoblasts, p38 MAPK activity downregulates Erk/MAPK 
signaling to curtail mitotic expansion of satellite cells (Chen et al. 2005). Moreover, p38 
upregulates Myf5 transcription and enhances the pro-myogenic transcriptional activities 
of MyoD, and Mef2 to potentiate myogenic identity (Keren et al. 2006, Chen et al. 2005). 
Although p38 MAPK has been designated as pro-myogenic, a recent study demonstrated 
that p38 inhibition enhances myotube formation in developing limb buds. Moreover, p38 
inhibition enhances myoblast cell-cell contacts and spindle-like morphology, which 
suggests p38 may suppress fusion (Weston et al. 2018). Consistent with this finding, p38 
inhibition in human muscle stem cells reversibly prevents differentiation to facilitate 
expansion, suggesting regulation of p38 is required for satellite cell self-renewal 
(Charville et al. 2015) 
Modulation of regenerating actin-cytoskeleton by RhoA 
RhoA and its effectors Rock1/2 are transiently expressed in activated satellite 
cells, where they modulate actin-cytoskeleton dynamics pertinent to myogenic fusion. 
During myoblast proliferation, RhoA activation is coupled to N-cadherin, and sequesters 
β-catenin to the plasma membrane to restrict Wnt signaling and promote MyoD induction 
(Charrasse et al. 2002). While RhoA activity is high in proliferating myoblasts and 




expansion for fusion to occur (Nishiyama et al. 2004, Castellani et al. 2006, Charrasse et 
al. 2006, Fortier et al. 2008). Mediating its anti-fusion properties are RhoA effectors 
ROCK1/2, which suppress myoblast aggregation by impairing cadherin dependent 
adhesion and cell-cell contacts (Lu et al. 2010) Furthermore, while ROCK1/2 activity 
facilitates directional migration for efficient muscle regeneration, it can also decelerate 
myoblast migration by promoting focal adhesions between myoblasts and the ECM 
(Goetsch et al. 2014). 
1.4 The Dlk1-Dio3 noncoding RNA locus 
Discovery and composition  
The maternally imprinted Dlk1-Dio3 locus (Figure 1.5) was originally mapped in 
Callipyge sheep, which exhibit a hypertrophic hindquarter muscle phenotype driven by 
paternally expressed genes (Charlier et al. 2001). This 250kb locus encodes the largest 
known mammalian cluster of noncoding RNAs (ncRNAs), encoding three annotated 
lncRNAs (Meg3, Rian, Mirg), numerous small nucleolar RNAs (snoRNAs), and over 60 
miRNAs (da Rocha et al 2008, Dill et al. 2018, Malnou et al. 2019). Two protein-coding 
genes, Dlk1 and Dio3, flank the ncRNA locus and are reciprocally expressed from the 
methylated paternal allele (Schmidt et al. 2000), which is conserved between mice and 
humans on chromosomes 12 and 14q, respectively (Miyoshi et al. 2000). In recent years, 
this locus has emerged as a key regulator of cellular processes as diverse as pluripotency 
and metabolism (Liu et al 2010, Kameswaran et al. 2014, Benetatos et al. 2014, Qian et 




The MADS-box protein Mef2 (myocyte enchancer factor 2) is a central 
component of muscle gene regulatory networks, and the only myogenic transcription 
factor known to be associated with differentiation of all muscle cell types (Olson et al. 
2006). In regenerating muscle, Mef2 isoforms dimerize with MRFs and other cofactors to 
potentiate myogenic differentiation and install cell fate (Potoff et al. 2007). Our lab 
demonstrated that Dlk1-Dio3 ncRNAs are dysregulated in Mef2A knockout mice, which 
display severe muscle regeneration impairments due to Wnt signal inhibition (Snyder et 
al. 2013). Others have shown that Mef2A-dependent Dlk1-Dio3 ncRNA expression 
regulates mitochondrial activity in satellite cells (Wust et al. 2018, Castel et al. 2018).  
In 2010, Zhou et al. generated transgenic maternal Dlk1-Dio3 knockout mice, and 
found that only maternal knockout mice die perinatally and exhibit severe skeletal muscle 
defects. The emergence of immature muscle fibers indicates that maternally expressed 
ncRNAs are required for muscle maturation. Dysregulation of Dlk1-Dio3 ncRNA 
expression has also been documented in muscular dystrophies, sarcopenia and in rare 
congenital growth disorders with pleiotropic organ defects including hypotonia 
(Eisenberg et al. 2007, Ogata et al. 2008, Ioannides et al. 2014, Mikovic et al. 2018). 
Interestingly, a partial deletion of the Dlk1-Dio3 locus at the 3’end – harboring 22 
miRNAs (miR-379/miR-544) – in mice resulted in skeletal muscle hypertrophy (Gao et 
al. 2015), but not in mice with an additional 17 miRNAs removed from the 3’ end (miR-
379/miR-410) (Labialle et al. 2014). Given the vast array of ncRNAs with distinct 
regulatory activities encoded by this massive and unusually complex locus, much remains 





Discovery and structure  
The most upstream transcript in the Dlk1-Dio3 locus is the lncRNA Maternally 
Expressed Gene 3 (Meg3), was identified with a gene trap locus experiment prior to 
identification of the locus proper. Therein, Schuster-Gossler et al. reported various splice 
variants and polyadenylation, but as subsequent publications confirmed, the short length 
of ORFs and lack of a strong Kozak consensus sequence indicated the processed 
transcript did not encode a protein, but rather functioned as a lncRNA (Schuster-Gossler 
et al. 1998, Miyoshi et al. 2000).  
Long noncoding RNAs are defined as transcripts ranging from 200 nucleotides to 
several kilobases long. These transcripts fold into complex secondary and tertiary 
structures suitable for interacting with macromolecule surfaces, such as protein, DNA, 
and other RNA molecules in the nucleus (Ma et al. 2013, Geisler et al. 2013). 
Accordingly, lncRNAs modulate transcription through interactions with miRNAs and 
transcriptional components, and reprogram epigenetics through interactions with 
chromatin remodeling proteins and DNA-loops (Bonasio et al. 2014, Mercer et al. 2013).  
In 2018, Sherpa et al. used predictive RNA-folding software to examine the 
putative landscape of human MEG3, and identified six domains with high secondary 
structure (Figure 1.6). Sequence alignments with orangutan, pig, rat, and mouse 
homologs revealed conserved sequences that yielded strikingly similar structural motifs 




mouse and human cell types, suggest that in spite of being unencumbered by protein-
coding conventions, Meg3 structure is fairly conserved across mammals. 
Modulation of p53 activity was among the first functions ascribed to Meg3 (Zhou 
et al. 2007), whereas RNA-immunoprecipitation sequencing (RIP-seq) later identified 
Meg3 as a prominent RNA cofactor of PRC2 in mouse embryonic stem cells (Zhao et al. 
2010, Kaneko et al. 2014). Mechanistically, the MEG3 M-IV domain shown in Figure 1.6 
interacts with p53 (Zhang et al. 2010, Uroda et al. 2019, Bauer et al. 2020), whereas 
contact sites between MEG3 and the catalytic PRC2 subunit Ezh2 are mediated by 
conserved motifs in the M-III domain (Mondal et al. 2015, Sherpa et al. 2018). Because 
PRC2 lacks a DNA-binding domain, its recruitment to loci is dictated by RNA cofactor 
binding. Along these lines, the DNA-contacting MEG3 M-I domain shown in Figure 1.6 
encodes GA/CU-rich sequences that have been shown to recruit PRC2 H3K27me3-
transferase activity to the enhancers of Smad2, TGFβR1, and TGFβ2 loci (Sherpa et al. 
2018, Mondal et al. 2015). Although the specific effects of these interactions are 
contingent upon cellular context, these interactions mediate the vast majority of Meg3’s 
roles in modulating carcinogenesis and differentiation. 
Meg3 in carcinogenesis  
In a variety of cancers, Meg3 expression is abnormally downregulated, which can 
occur through gene deletion, promoter hypermethylation, or hypermethylation of the 
Dlk1-Dio3 intergenic differentially methylated region (IGDMR) (Zhang et al. 2010). 




p53 and suppressing TGFβ activity, which modulate apoptosis, proliferation, and 
invasiveness (Zhou et al. 2012).  
MEG3 overexpression in cancer cell lines activates p53-dependent transcriptional 
activity and reduces Mdm2-mediated p53 degradation, and disruption of this MEG3-p53 
axis has been observed in human metastatic colorectal cancer (Zhou et al. 2007, Zhang et 
al. 2010) non-small lung cell carcinoma (Lu et al. 2013), pancreatic (Hu et al. 2016), and 
breast cancers (Zhang et al. 2018). While Meg3 certainly enhances p53 signaling to 
ultimately promote apoptosis and suppress proliferation in tumor cells, it has also been 
reported that Meg3 biases p53 activity towards a particular subset of gene targets, which 
often exclude the well-characterized p53 target p21 (Zhou et al. 2007, Zhang et al. 2010, 
Lu et al. 2013). Moreover, deletion studies by Uroda et al. revealed that, while p53-
interacting MEG3 domains were required for p53 luciferase-reporter activity, deletions of 
non-interacting MEG3 terminal domains counterintuitively enhanced p53 reporter 
activity, suggesting MEG3 can both activate and suppress p53 signaling (Uroda et al. 
2019). Overall, these findings reflect that Meg3 stimulates p53 in a variety of cancers, but 
also hint at complex interplay between Meg3 and p53 in normal cells. 
While p53 was among the first pathways identified to interact with Meg3, p53 is 
dispensable for MEG3-mediated inhibition of cancer cell proliferation (Zhou et al. 2007), 
and several other mechanisms have been tied to its tumor-suppressing activity. In human 
cells, MEG3 recruits Ezh2 to GA-rich enhancers of TGFβ loci to suppress TGFβ-
mediated invasiveness in breast cancer cells (Mondal et al. 2015). MEG3-mediated PRC2 




(Terashima et al. 2016).and PRC2 recruitment to the GA/GT-rich loci, such as the 
chemoattractant receptor c-Met, has been shown to epigenetically suppress migration in 
pancreatic neuroendocrine tumor cell. Interestingly, gain-of-function studies in pancreatic 
β cells revealed that, in addition to epigenetic c-Met repression, MEG3 also enhanced 
proliferation (Iyer et al. 2017), underlying the context-dependent effect of Meg3 on 
proliferation. 
Little is known about the functional role of Meg3 in rhabdomyosarcomas, where 
transcriptional alterations differ between histological subtypes: embryonic 
rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS). Unlike most 
other cancers, MEG3 expression is upregulated in ERMS tumor tissue; and even more so 
in ARMS tumors, which display higher metastatic potential (Schneider et al. 2013). 
These conflicting transcriptional alterations, which are driven by reduced Dlk1-Dio3 
IGDMR methylation, demonstrate that Meg3 is not a pan-tumor suppressor, and further 
indicate that muscle progenitor cells are sensitive to Meg3 dosage. 
Meg3 in stem cells  
Early in situ hybridization experiments in mouse embryos showed that Meg3 is 
uniformly expressed at the 1-, 2-, and 8-cell stage, and that its expression later becomes 
restricted to the inner cell mass of blastocysts, suggesting Meg3 is enriched in pluripotent 
progenitor cells that give rise to all embryonic tissues (Schuster-Gossler et al. 1998). In 
embryonic stem cells, Meg3 recruits Ezh2 to the Dlk1-Dio3 intergenic differentially 
methylated region to block DNA methyltransferase activity on the maternal chromosome 




Epigenetic repression by PRC2 H3K27me3-transferase activity is crucial for maintaining 
stem cell pluripotency (Li et al. 2012), and induced pluripotent stem cells (iPSCs) that 
exhibit abnormal Dlk1-Dio3 ncRNA silencing contribute poorly to chimeras (Stadtfeld et 
al. 2010). Importantly, restoration of Dlk1-Dio3 ncRNA expression by Meg3 restores the 
ability for iPSCs to aggregate, and restores the capacity to form all-iPSC mice, 
suggesting Meg3 is required stem cell pluripotency (Stadtfeld et al. 2012, Das et al. 
2015).  
Meg3 in differentiation and homeostasis  
Though its expression is initially uniform, on E9.5 Meg3 expression becomes 
restricted to specialized embryonic tissues associated with neurogenesis, epithelial ducts, 
and myogenesis (Schuster-Gossler et al. 1998), and it comes as no surprise that Meg3 has 
been shown to regulate cell types residing in these tissues. Embryoid bodies derived from 
MEG3-deficient ESCs display reduced ectoderm marker expression and form abnormal 
neurites (Mo et al. 2015), and in post-mitotic motor neuron cells, MEG3 recruits PRC2 to 
repress alternate cell-fate Hox genes and downregulate neural progenitor cell gene 
expression (Yen et al. 2018).  
Meg3 has also been shown to regulate the activity of epithelial tissues – 
particularly in blood vessels. In vascular endothelial cells, which line the interior of blood 
vessels, Meg3 is required for proper cell-sprouting morphology (Kruijsdijk et al. 2016), 
and restricts p53 activity to limit DNA-damage, suppress p53-mediated apoptosis, and 
promote proliferation (Ali et al. 2018). Meg3 also restricts p53 activity in vascular 




promote proliferation and migration required for postnatal pulmonary artery remodeling 
(Sun et al. 2017). In the lungs, epithelial alveolar cells with high MEG3 expression 
transdifferentiate into basal progenitor cells – and adopt a more migratory profile (Gokey 
et al. 2018). Similarly, MEG3 is enriched in the stromal compartment of breast tissues, 
and ectopic overexpression in breast epithelial duct cells promotes EMT, reprograming 
these cells to adopt a basal progenitor cell identity (Budkova et al. 2020). Taken together, 
Meg3 has dynamic cell-context-specific roles in modulating cellular plasticity and EMT.  
While enrichment was noted in neural and epithelial tissues, Schuster-Gossler et 
al. noted that the most striking correlation between Meg3 expression and tissue 
differentiation was observed in the myoblast lineage. Initially, Meg3 is expressed 
throughout the presomitic mesoderm, but as somites undergo subdivision of territories, 
Meg3 expression becomes increasingly restricted to the dermamyotome, myotome, and 
resultant myogenic structures (Figure 1.7). Given this expression profiling greatly 
resembles that of myogenic regulatory factors (Schuster-Gossler et al. 1998), it has long 
been conjectured that Meg3 regulates aspects of muscle differentiation and homeostasis. 
Meg3 in striated muscle  
In spite of its striking enrichment in skeletal muscle development, the precise 
roles of Meg3 in myogenesis remain uncharacterized. In 2018, the Chan-Zuckerburg 
Tabula Muris consortium performed a large-scale single-cell RNA sequencing (scRNA-
seq) screen of numerous postnatal mouse tissues including skeletal muscle (Schaum et al. 
2018). Although the syncytial nature of skeletal myofibers precluded its analysis by 




be present in the interstitium of muscle tissue. Analyses shown in Figure 1.8 revealed 
that, among all three Dlk1-Dio3 encoded lncRNAs, Meg3 was the most enriched in 
satellite cells and mesenchymal stromal cells. Moreover, Meg3 transcripts were largely 
undetectable in muscle endothelial cells and immune cells (Schaum et al. 2018). Given 
these two cell populations are major determinants of muscle regeneration, it appears 
likely that Meg3 functions in these cells to facilitate myogenic processes. In humans, 
transcriptomic profiling of aged activated satellite cells listed Meg3 as the fourth most 
downregulated transcript (Kimmel et al. 2020), and Meg3 downregulation has also been 
documented in aged mouse satellite cells that exhibit impaired myogenic potential (Liu et 
al. 2013).  
In the agricultural industry, where lab-grown meat is a priority, modulations of 
Meg3 expression was recently demonstrated to promotes myogenic differentiation in 
bovine and porcine cells (Liu et al. 2019, Cheng et al. 2019). These reports provide the 
first evidence that Meg3 functionally contributes to postnatal myogenesis in vitro.  
1.6 Statement of Thesis Rationale 
 To date, Meg3 is one of the most comprehensively characterized Dlk1-Dio3 
ncRNAs and has been shown to interact with PRC2 to regulate chromatin structure in 
pluripotent embryonic stem cells and neuronal cells (Zhao et al. 2010, Kaneko et al. 
2014, Das et al. 2015, Yen et al. 2018). An epigenetic function of Meg3 has also been 
reported in human breast and lung cancer cell lines, where MEG3 activity suppresses 
invasive properties (Mondal et al. 2015, Terashima et al. 2017). And yet, while Meg3 




development (Schuster-Gossler et al. 1998), roles for Meg3 in promoting myogenesis 
were only recently described in pig and bovine muscle differentiation in vitro, (Liu et al. 
2019, Cheng et al. 2019). While their characterizations fell short of examining well-
established Meg3-dependent mechanisms for roles in myogensis – namely p53 and PRC2 
activity – they hold promise for further work investigating the role of Meg3 in muscle 
regeneration, where human and mouse characterizations are lacking. 
Given the enrichment of Meg3 in muscle satellite cells and its epigenetic function, 
I hypothesized that Meg3 regulates myoblast cell identity during differentiation and 
regeneration. To this end, I knocked down Meg3 in C2C12 myoblasts and regenerating 
skeletal muscle. In both model systems, Meg3-deficiency resulted in marked myogenic 
impairments and abnormal upregulation of EMT-related genes. Increased EMT gene 
expression correlated with enhanced mesenchymal character in Meg3-deficient C2C12 
myoblasts, and Meg3 knockdown increased proportions of mesenchymal stromal cells in 
regenerating muscle. Importantly, I show that Meg3 interacts with Ezh2 in myoblasts, 
and is required for H3K27me3-mediated repression of TGFβ loci, as well as 
downregulation of TGFβ-dependent EMT marker Snai2. Finally, I compare and contrast 
my RNAseq data with transcriptomic data derived from existing literature, and report on 
survey cell-identity shifts pertaining to satellite cell state transitions, various tissue 
identities, and muscle aging - illuminating a key role for Meg3 muscle cell identity in 








Figure 1.1: Somitogenesis. In developing vertebrates, the mesenchymal pre-somitic mesoderm 
(U-shaped boxes) elongates down the midline of the embryo (gray oval), and is exposed to 
opposing gradients of retinoic acid (RA, yellow) and fetal growth factor (FGF, cyan) that form a 
determination front (dotted line) for somite-segmentation patterning. Posterior FGF induces 
Wnt3a/β-catenin nuclearization (green), which activates Notch intracellular domain (ICD) 
signaling. Transcriptional activation by Notch ICD induces Mesp2, which in turn activates Lfng 
to glycosylate the Notch ICD. While posterior Mesp2 is ultimately inhibited by FGF, anterior-
most Mesp2 escapes FGF repression, and induces a stripe of EphA4-bearing cells (cobalt). These 
Eph4 receptors engage with an anterior stripe of EphB2-bearing cells (navy) that was previously 
induced by Notch, and results in relief of epithelial repression by Cdc42 inactivation. This leads 
to expression of integrin-α4, deposition of fibronectin-rich ECM, and mesenchymal-epithelial 
transition (MET) to establish somite boundaries. Once glycosylated, Notch ICD is replaced, and 







Figure 1.2 Myotome induction and myocyte invasion. Presomitic mesoderm undergoes 
mesenchymal-epithelial transition (MET) to yield an epithelial boundary encasing mesenchymal 
mesoderm cells, called somites. Somites are situated on either side of neural tube and notochord, 
which provide inductive signals for somite substructures; the ventral somite undergoes epithelial-
mesenchymal transition (EMT), resulting in dispersion of bone-prescursor cells, while the dorsal 
somite retains epithelial character, resulting in a transient structure called dermamyotome. As 
somite maturation progresses posterior-to-anterior, EMT on the dorsal and ventral lips of the 
dermamyotome yield a de novo layer of myogenic precursor cells called myotome. 
Differentiation of myogenic precursors is suppressed until these cells migrate to their proper 
anatomical location; dorsal myoblasts form the hypaxial muscles of the back, whereas ventral 
myoblasts destined for limb-muscle undergo extensive migration towards the apical ectodermal 







Figure 1.3 Temporal expression of myogenic genes in muscle formation. Temporal expression 
are shown in boxes, where green is expressed by all myoblasts, red is expressed exclusively in 
muscle-destined myoblasts, and yellow is expressed exclusively by satellite cells. All muscle 
precursors arise from Pax3+ myoblasts, which express the hepatocyte-growth factor receptor c-
met to facilitate migratory behavior. When myoblasts are specified, they all co-express Pax7, 
Myf5, and/or MyoD, but due to extrinsic antimyogenic signals, do not differentiate as they 
undergo expansion. Myoblasts (red): Upon migrating the proper anatomical location, the vast 
majority of myoblasts (red cells) MyoD activity is shunted from pro-proliferative transcriptional 
targets, and instead direct MyoD activity towards pro-differentiation gene programs. These cells 
align their cell membranes (commitment), and also begin expressing Mef2C, which forms a 
heterodimer with MyoD to subsequently induce Myogenin (Myog) expression. Myog promotes 
fusion of mononucleated myoblasts into multinucleated myotubes (differentiation). MyoD, 
Mef2C, and Myog also initiate myogenic differentiation genes such as muscle creatine kinase 
(Ckm) and skeletal muscle actin (Acta1), which facilitate metabolic and cytoarchitectural 
remodeling required to form functionally-shortening muscle cells (myofibers, red). Satellite cells 
(yellow):In the dermamyotome, a subset of myoblast precursors engage their Jagged1 receptors 
with Delta-1 ligand presented by migrating neural crest cells; resultant Notch signaling initiates 
commitment to the satellite cell lineage (yellow cells). These satellite cell myoblasts migrate to 
the same anatomical location as other myoblasts, but do not participate in myogenic 
differentiation. Instead, satellite precursor cells retain Pax7 expression until muscle is 
differentiated, and reside in the myofiber interstitium encased in laminin (green). Upon injury, 
satellite cells recapitulate expression profiling as muscle-destined myoblasts to form post-natal 






Figure 1.4 Phylogeny of postnatal muscle regeneration. Upon mild muscle injury, white blood 
cells (purple) remove cellular debris and release TGFβ, which suppresses inappropriate satellite 
(yellow) cell activation. However, when injury is significant, TGFβ accumulates enough to 
trigger mesenchymal stromal cells (blue) to expand, and when injury is significant enough, 
mesenchymal stromal cells promote satellite cell activation by follistatin-mediated TGFβ 
neutralization, as well as satellite cell stimulation with interleukin-6 (IL-6). Once activated, 
satellite cells escape the basal lamina (green) and proliferate extensively. While the vast majority 
of resultant cells express myogenic regulatory factors (red), cell-autonomous p53 upregulation 
can reverse myogenic commitment, and a subset of satellite cells adhere to pre-existing myofibers 
and return to the satellite cell niche. As committed myoblasts recapitulate myogenic fusion and 
differentiation, TNF-α released from late-stage white blood cells (purple-gray) induce 
mesenchymal stromal cell apoptosis, which subsequently reduces satellite cell activation in the 
regenerating microenvironment. This process not only replaces muscle cells, but also 
reestablishes cell proportions of the regenerating milieu for future instances of injury. Assets 







Figure 1.5 Dlk1-Dio3 noncoding RNA locus. The mouse Dlk1-Dio3 ncRNA locus on mouse 
chromosome 12 harbors sixty-one miRNAs (miRs) and three lncRNA genes. Several miRNAs 
reside within lncRNA Meg3, anti-Rtl1, Rian, and Mirg coding regions (shaded in light purple), 
whereas many miRNAs (shaded in light blue) exist between the aforementioned coding regions. 
This locus is regulated by a 5’ intergenic differentially methylated region (IG-DMR), which is 
upstream of the Gtl2-DMR that regulates the Meg3 proximal promoter. While most lncRNAs are 
homologous between mouse and human gene annotations, it is important to note the mouse Mirg 
lncRNA harbors miRNAs, whereas the human equivalent, Meg9, does not; instead, Meg9 resides 
downstream of all annotated human locus miRNAs. All ncRNAs in this locus are expressed from 
the non-methylated maternal allele (open lollipops), whereas methylation of the IG-DMR in the 
paternal chromosome (not depicted) is associated with transcriptional silencing. Protein-coding 
genes (shaded in black) are expressed predominantly from the paternal allele Adopted from Dill 






Figure 1.6 MEG3 structure and sequence conservation. 3D modeling of Meg3 lncRNA 
suggests five large domains (M-1 – M-V) arise from base-pairing secondary and tertiary 
structure. The M-I domain (red) contains evolutionarily conserved GA/CT rich sequences that are 
essential to DNA-recruitment function, and when coupled with the M-III Ezh2-binding domain 
(blue), recruits the PRC2 to GA-rich loci. The M-II domain (orange) has been shown to suppress 
DNA-synthesis through unknown mechanisms. The M-V (brown) and M-IV (green) domains 
participate in p53-interactions required for modulatory functions. An evolutionarily-conserved 
motif in the M-IV region (black box) takes on similar predicted folding structures (bottom panel), 
suggesting Meg3 is evolutionarily constrained by secondary structures that impart lncRNA 






Figure 1.7 Expression of Meg3 in mouse embryonic development. In contrast to negative 
controls (A), in-situ hybridization for Meg3 transcripts indicate global Meg3 enrichment at the 1-, 
2-, and 8-cell stage (D) embryos that is later restricted to the somatic blastocyst tisue (E). By 
embryonic day 10.5 (F), Meg3 transcripts are vividly enriched in somites, and later enriched on 
embryonic day 12.5 in skeletal muscle, surface ectoderm, and parts of the central nervous system. 
myogenic tissues. In maturing somites (H-J), Meg3 expression becomes increasingly restricted to 






Figure 1.8 Expression of Dlk1-Dio3 lncRNAs in limb muscle interstitial cells. Violin plots 
from single cell RNA-seq (Schaum et al. 2018) depict cell-specific enrichment for Dlk1-Dio3 
megacluster-encoded lncRNAs Meg3, Rian, and Mirg, with the most enriched cell ontology 
mulberry colored. All lncRNAs showed enrichment in satellite (sat.) and mesenchymal (mes.) 
cell types, with Meg3 as the most abundant. Other interstitial muscle cell ontologies, such as 
endothelial cells (endo.) and white blood cells were largely devoid of lncRNA expression. CPM = 






Table 1.1 Epithelial-mesenchymal transition markers in myogenesis. Three classic 
mesenchymal markers are conveyed, which have been characterized in developmental 





CHAPTER TWO: MATERIALS AND METHODS 
2.1 Recombinant DNA Techniques 
Annealing single-stranded oligonucleotides 
 To generate shRNA hairpin transgenes, single-stranded oligonucleotides 
targeting an evolutionarily conserved segment of MEG3 (Mondal et al. 2015) were 
designed to contain a four-nucleotide bridge and four-nucleotide overhangs for ligation 
into the BLOCK-iT pENTR-U6 shRNA vector (Table 2.1). Double-stranded oligos were 
generated by combining 5 µL 200 µM top strand oligo, 5 µL 200 µM bottom strand 
oligo, 2 µL 10X annealing buffer, and brought up to 20 µL with sterile nuclease-free 
water in a 1.5 µL tube. Annealing reactions were placed on a 65 °C heat block that was 
subsequently turned off and gradually allowed to cool to room temperature for 2 hours 
before storing on ice until ligation.  
Polymerase chain reaction  
For cloning purposes, Q5 High-Fidelity DNA Polymerase was used (New 
England Biolabs). 10 μL 5X Q5 Reaction Buffer, 1 μL 10 mM dNTPs, 2.5 μL 100 μM 
forward primer, 2.5 μL 100 μM reverse primer, 1 ng template DNA, 0.5 μL Q5 High-
Fidelity DNA Polymerase, and sterile nuclease-free water up to a final reaction volume of 
50 μL was added and mixed in a 0.65 mL PCR tube. General thermocycling parameters 
(PTC-100 Thermal Cycler, MJ Research) were as follows: step 1, 98 °C for 30 sec; step 
2, 98 °C for 30 sec; step 3, annealing temperature for 30 sec; step 4, 72 °C for proper 




step 7, hold at 4 °C; step 8, end program. Optimal annealing temperatures were calculated 
using NEB Tm calculator (https://tmcalculator.neb.com), and extension times were 
dependent upon product length.  
Restriction digest 
 DNA was digested using restriction enzymes from New England Biolabs. 5 μL of 
appropriate 10X NEB Buffer, 2 μg DNA substrate (plasmid or gel-extracted PCR 
product), 1 μL restriction enzyme, and brought up to 50 μL final reaction volume with 
sterile nuclease-free water in a 1.5 mL tube. Samples were sealed with parafilm and 
incubated for 3 hours at 37 °C via water bath. For restriction digest with incompatible 
enzymes, sequential digest was performed, where low salt enzyme reactions were 
performed at 25 μL, and high salt buffer and enzyme were subsequently added to bring 
the final reaction to 50 μL. 
Gel extraction  
Digested plasmid DNA and PCR products were prepared for gel electrophoresis 
by adding 10 μLof 6X Orange-G loading buffer to each sample. Samples were loaded 
onto a 0.8% agarose gel in 1X TAE buffer (40 mM Tris, 50 mM sodium acetate, 1 mM 
EDTA pH 8.0) containing 1 μL 10 mg per mL ethidium bromide. After electrophoretic 
migration at 120 V, gel slices containing DNA bands of interest were visualized with UV 
light for brief durations to mitigate thymine dimer formation, excised using a clean razor 
blade, and collected to pre-weighed 1.7 mL microcentrifuge tubes. DNA of interest from 




the manufacturer’s instructions. The DNA concentration of gel extraction samples was 
determined using a NanoDrop 1000, and stored at -20 °C.  
Ligation 
For ligation, gel-extracted insert and vector were mixed at a 3:1 μg ratio, and 
DNA volume was adjusted to 7 μL with sterile nuclease-free water. To each ligation 
reaction, 1 μL 10 mM ATP, 1 μL 10X T4 DNA Ligase Buffer (New England Biolabs), 
and 1 μL T4 DNA Ligase (New England Biolabs) was added in a 0.65 mL thermocycling 
tube. Ligation reactions were incubated at 16 °C overnight. 5 – 10 μL of ligation 
reactions were used to transform chemically competent E. coli. 
To ligate double-stranded shRNA insert, 13 µL of annealing reaction was 
combined with  4 µL 5X DNA ligase buffer (BLOCK-iT), 2 µL linearized U6-pENTR 
vector (BLOCK-iT), and 1 µL T4 DNA ligase (BLOCK-iT) in a 0.65 mL thermocycling 
tube, and incubated at 16 °C overnight. 5 – 10 μL of ligation reactions were used to 
transform chemically competent E. coli. 
 
Transformation of chemically competent E. coli  
100 μL Top10 or Stbl2 competent E. coli (Invitrogen) were thawed on ice for 
5 min, and 100 – 200 ng of plasmid DNA (or 5 – 10 μL of ligation reaction) were added 
to labeled cell aliquots and mixed by gentle flicking. Tubes were then incubated on ice 
for 10 min, heat shocked in a 42 °C water bath for 30 sec, and then immediately placed 




incubated in a shaking incubator at 225 rpm for 1 h (ampicillin) or 1.5 h (kanamycin) at 
37 °C. Recovered bacteria were then plated on LB agar plates containing the appropriate 
antibiotic selection drug and incubated overnight at 37 °C. After confirmation of colony 
growth, LB agar plates were stored in the cold room at 4 °C for a maximum of 48 h 
before proceeding to plasmid purification.  
   
Plasmid purification 
For mini preps, one transformed colony was inoculated into a vent-capped flask 
containing 3 mL of antibiotic supplemented LB. Inoculated cultures were placed in a 
shaking incubator at 225 rpm for 12 – 16 h at 37 °C. Resultant cultures were vortexed 
briefly, and 1 mL of culture was transferred into a 1.5 mL microcentrifuge tube for 
centrifugation at 13,500 rpm for 1 min. The supernatant was decanted from each tube, 
and pellets were resuspended with 100 μL Resuspension Buffer (50 mM glucose, 10 mM 
EDTA pH 8.0, 25 mM Tris pH 8.0) by vortexing repetitively with brief pulses. 200 μL 
Lysis Buffer (0.2 M NaOH, 1% SDS) was added to each tube, and gently inverted 6 – 8 
times. The lysis reaction was allowed to proceed for no longer than 5 min, and 150 μL 
Neutralization Buffer (3 M potassium acetate, 2 M acetic acid) was subsequently added 
to each tube with 6 – 8 times gentle inversion. 400 μL bottom layer of phenol/chloroform 
was then added to each tube, and vigorously shaken by hand for 30 – 60 sec. Samples 
were then centrifuged at 13,500 rpm for 1 min at room temperature, and 400 μL aqueous 
phase from each sample was transferred into a new 1.5 mL tube. 1 mL (2.5 volumes) of 




and . Following 13,500 rpm centrifugation for 30 min at 4 °C, the supernatant was 
discarded, and DNA pellets were washed with 200 μL 70% ethanol. Samples were 
centrifuged at 13,500 rpm for 1 min at room temperature. The supernatant from each tube 
was discarded, and DNA pellets were allowed to air dry for 30 min. Air-dried pellets 
were resuspended in 25 μL sterile water containing 100 μg/mL of RNase. Mini preps 
were incubated for 15 min at 37 °C for complete RNA degradation. Samples were stored 
at -20 °C. 
 For midi preps, 3 mL of antibiotic supplemented LB was inoculated with a single 
colony. Inoculated tubes were placed in a shaking incubator at 225 rpm for 12 – 16 h at 
37 °C. 100 mL of antibiotic supplemented LB was inoculated with 3 mL of previously 
grown inoculated culture. 100 mL of inoculated culture was placed in a shaking incubator 
at 225 rpm for 12 – 16 h at 37 °C. Cells were harvested by centrifugation at 6,000 g for 
15 min at 4 °C. Plasmid DNA was isolated using the NucleoBond Midiprep Kit 
(Macherey-Nagel) following the manufacturer’s instructions. Plasmid DNA 
concentration was determined using a NanoDrop,1000, and plasmid DNA was stored 
at -20 °C. A list of plasmids used in this thesis can be found in Table 2.2.. 
2.2 Adenovirus production 
HEK293-A cell culture 
HEK293A cells were cultured in 10cm tissue culture plates (CellStar) containing 
growth medium (1X DMEM, 10% FBS, 1X penicillin/streptomycin/glutamine) in a 
humidified incubator at 37 °C with 5% CO2. Near confluence, cells were detached by 




pre-warmed 0.25% trypsin EDTA (Life Technologies). Cells were resuspended in 5 mL 
growth media (1X DMEM, 10% FBS, 1X penicillin/streptomycin/glutamine) and 
passaged at a ratio of 1:2 to 1:10. 
FuGENE-6 transfections 
 To generate adenovirus, HEK293A cells were seeded onto ten 10cm plates (500k 
cells per plate), containing antibiotic-free growth mediums (1X DMEM, 10% FBS). Each 
10cm plate subsequently transfected with 1 μg pAd construct using a 1 μg DNA: 3 μL 
FuGENE-6 : 100 μL DMEM ratio. Transfection mix was prepared in the laminar flow 
hood using column-purified DNA diluted to 500 ng per μL for uniform volume, and the 
corresponding volume of FuGENE-6 transfection reagent (Promega) was added with 
minimal exposure to plastic surfaces. DNA-FuGENE-6 mixture was incubated in a 
1.5 mL tube at room temperature for 5 min, and subsequently cold DMEM (Life 
Technologies) was added to the solution. The mixture was incubated for an additional 
15 min. at room temperature, and the reaction was mixed by gentle flicking before being 
added dropwise to HEK293A culture plates. 24 hr post-transfection, culture medium was 
gently changed to growth medium (1X DMEM, 10% FBS, 1X 
penicillin/streptomycin/glutamine) and examined for cytopathic effect over the course of 
30 days. 
Generation of crude lysate  
To generate crude lysate, transfected 10cm HEK293A plates were dislodged by 




from all 10 plates were collected into a sterile 50 mL conical tube. Dislodged cell 
suspensions were then exposed to 4 freeze-thaw cycles by alternating incubation in a -
80 °C freezer and and 37 °C water bath. Crude lysates were stored at -80 °C. 
To amplify virus for CsCl purification, either 100 μL crude lysate or 0.1 μL 
purified virus was inoculated into each 10cm plates containing 90% confluent HEK293A 
cultures, with a minimum of 30 10cm HEK293A plates per virus batch. Once cytopathic 
effect was evident, crude lysate was collected and stored at -80 °C until CsCl purification 
and dialysis. 
CsCl purification and dialysis of virus 
 Crude lysate was thawed at 37 °C in a secondary container waterbath, and pooled 
into a graduated cylinder to measure volume. Triton X-100 was then added to a final 
concentration of 0.5%, and cell suspension was incubated in an orbital shaker for 15 min. 
to lyse cells to completion. Lysate was then centrifuged at 2,000 g for 15 minutes at 
4 °C(Beckman centrifuge, JA-14 rotor), and supernatant was collected into a large flask 
containing 0.5 volumes precipitation solution (20% PEG-8000, 2.5 M NaCl). 
Precipitation was allowed to proceed overnight at 4 °C on an orbital shaker, with flasks 
secured to a secondary container for vigorous shaking. 
The resultant precipitate was centrifuged for 15 min. at 20,000 g (Beckman 
centrifuge, JA-14 rotor) and supernatant was discarded to biohazardous waste. Precipitate 
adhering to the walls of centrifuge bottles was resuspended by a series of cold 1 mL 1X 
PBS washes. The solution was collected into a 15 mL conical tube, and brought to a final 




up to 5 mL, and loaded into an ultracentrifuge tube with a p1000 pipette, such that no 
bubbles were trapped between solution and rubber stopper. The tube was then loaded into 
an ultracentrifuge, and centrifuged using the NVT-90 rotor at 70,000 rpm for a minimum 
of 16 hr at 18 °C to create a cesium chloride density gradient. After observing a cloud of 
viral band, the cap was removed, and a 21-gauge syringe was used to puncture and 
retrieve the virus-containing band from the bottle. If additional syringe-volumes or 
vantage-points were required, additional syringes were used without removing previous 
syringes, to avoid gradient collapse. Once all virus was retrieved, the contents of each 
syringe were collected into a sterile 2 mL tube and stored on ice.  
Purified virus was desalted by two 2 hr dialysis steps at 4 °C in a stir-plate beaker 
containing no less than 250 mL dialysis solution (10 mM Tris-HCl pH 8 autoclaved, 
1 mM MgCl2, 10% glycerol; cooled to 4 °C prior to dialysis). Dialyzed virus was 
removed from dialysis membrane and stored in 100 μL aliquots in cryovials at -80 °C 
until titering. 
Quantification of viral titer  
Viral titer was determined by end-point dilution assay. Briefly, one day prior 
transduction, HEK293A cells were seeded onto a 96-well plate at a density of 10,000 
cells per well in 100 μL media using a multi-channel pipette. For transduction, culture 
media was replaced with serial dilutions between 10-5 and 10-12 virus, one per row A-H 
on the 96-well plate, using purified adenovirus and growth medium (1X DMEM, 10% 
FBS, 1X penicillin/streptomycin/glutamine). For all rows, columns 11 and 12 were used 




well was subsequently scored for cytopathic effect (CPE). The fraction of CPE-positive 
wells for each dilution was summed, and used to calculate viral titer using the Spearman-
Karber method, where viral titer = 10X + 0.8 pfu/mL.  
2.3 C2C12 cell culture techniques 
C2C12 cell culture 
C2C12 myoblasts were cultured in growth medium (1X DMEM, 10% FBS, 1X 
penicillin/streptomycin/glutamine) at 37 °C with humidity and 5% CO2. To avert 
premature differentiation, C2C12 myoblasts were split 1:2 upon reaching 30% 
confluence, and redistributed with 0.25% trypsin-EDTA when subconfluent cells were 
observed to form regions with close proximity. 
C2C12 transductions 
 For transient transduction, C2C12 cells were seeded for differentiation on 
6-well culture plates (CellStar) at a density of 150k cells per well in growth medium. 
24 hr post-seeding, confluent C2C12 myoblasts were transduced at the MOI indicated in 
Table 2.3, by inoculating cultures with appropriate volume of pure adenovirus to reach . 
FuGENE-6 transfections 
 For transient transfections, C2C12 myoblasts were seeded for differentiation on 6-
well culture plates (CellStar) at a density of 150k cells per well in antibiotic-free growth 
medium, and subsequently transfected with 500 ng plasmid using FuGENE-6 transfection 




G418 Selection  
To generate stably integrated clones, C2C12 cells were seeded at 20% confluence 
on 10cm culture plates (CellStar), and transfected with FuGENE-6 using DNA mix 
containing 9 μg transgene-containing plasmid : 3 μg G418-resistance plasmid pGL3b 
(Promega), at a total of 12 μg DNA transfected per 10cm plate. For co-transfections, 
FuGENE-6 transfection was performed using a DNA mix containing 9 μg CMV-
transgene plasmid : 3 μg shRNA-transgene plasmid : 1 μg G418-resistance plasmid 
pGL3b (Promega), and a total of 13 μg DNA transfected per 10cm plate. 
24 hr post-transfection, culture medium was changed to antibiotic-free growth 
medium containing 0.18 mg/mL Geneticin (Gibco), and this G418 medium was replaced 
every 24 hr for 12 consecutive days. For heterogeneous experiments, cells were used for 
differentiation 48 hr following selection.  
Isolation and expansion of stable integrant clones 
For clonal experiments, clones were isolated from heterogeneous populations 
resulting from G418 selection. Briefly, culture medium was replaced with warm 1X PBS, 
and with the aid of a microscope, 100 μL 0.25% trypsin-EDTA was added to locally 
detach cells, and a p200 pipette was used to obtain several detached cells. Cells were then 
transferred to one well in a 96-well plate, and serial diluted 1:10 by transferring 1/10th 
well contents to adjacent wells containing 100 μL growth medium. A total of 12 serial-
diluted C2C12 clones were obtained from each selection plate for subsequent expansion 
into cell lines. Ethanol-sterilized surfaces, reduced air-flow, and a medical face mask was 




wells containing 1 C2C12 myoblast. From these clonal populations, cells were 
trypsinized and expanded into larger well formats, and duplicate cell stocks were frozen 
down to confirm transgene. 
 
C2C12 differentiation  
 To differentiate C2C12 myoblasts into C2C12 myotubes, subconfluent C2C12 
myoblasts were seeded in a 6-well plate at 150k cells per well, in 2 mL growth medium. 
48 hrs post-seeding, medium was washed once with 1X PBS and changed to 
differentiation medium (1X DMEM, 2% horse serum, 1X 
penicillin/streptomycin/glutamine). Differentiation was changed every 72 hrs. 
Chemical inhibitor and growth factor treatment 
All chemical inhibitors were resuspended according the vendor’s specifications, 
and added to cells at the indicated concentration by diluting into culture medium. Final 
concentrations in culture medium are as follows: Pifithrin-α hydrobromide (30μM, 
Tocris), LY2157299 (10 μM, Sigma), Y-27632 (40 μM Sigma), SB203580 (10 μM, 
Calbiochem), SIS3 (5 μM, Calbiochem), BMP4 (50 ng/µL Life Technologies), Unc1999 
(2 μM Sigma). 
For myoblast treatments, subconfluent cells were treated 48 hrs prior to sample 
collection and analysis, regardless of treatment type. For mygenic differentiation, 
inhibitors were added at specific times relative to onset of differentiation as follows: 




differentiation medium. Pifithrin-α hydrobromide (Pifithrin) was added once, 40 minutes 
prior to differentiation, and washed away upon changing to differentiation medium. All 
other chemical inhibitors were added to media upon switching to differentiation medium. 
Media was replaced daily (with one wash) to circumvent degradation. 
 
2.4 RNA techniques 
RNA isolation 
To isolate RNA from cultured cells, media was removed by aspiration and 
washed with 1X PBS before addition of 1mL Trizol reagent (Life Technologies). Trizol 
was allowed to incubate with the cells for 1 min at room temperature before collection 
with a cell scraper. Trizol-lysate mix was then stored at -80 °C until RNA isolation  
To isolate RNA from dissected tissues, freshly dissected tissue was washed twice 
in chilled sterile 1XPBS, and transferred to a 1.5 mL tube on dry ice. Snap-frozen tissue 
was stored at -80 °C. For homogenization, frozen tissue was transferred to a sterile 
culture tube containing 2 mL Trizol reagent, and quickly subjected to Polytron 
homogenization for three 10 sec. pulses. The resultant Trizol-lysate mix was then split 
across two 1.5 mL tubes for RNA isolation.  
To isolate RNA from Trizol-lysate mixtures, 200 μL chloroform was added to 
each 1 mL sample, shaken vigorously for 15 sec, and allowed to incubate at room 
temperature for approximately 3 mins. Samples were then centrifuged at 13,500 rpm for 
15 min at 4 °C.. The top aqueous layer was transferred to a new tube containing 500 μL 




of 1 hr, precipitated samples were centrifuged at 13,500 rpm for 30 min at 4 °C. 
Supernatant from each tube was carefully removed, and each pellet was washed with 
1.5 mL cold 70% ethanol and subsequently centrifuged at 13,500 rpm for 5 min at 4 °C. 
After a total of 3 ethanol washes, the supernatant from each tube was carefully removed, 
and pellets were allowed to air dry for 10 min. Pellets were resuspended in 20 μL of 
sterile nuclease-free water. RNA concentration was determined by Nanodrop 1000 
(Thermo Fisher Scientific), and quality was determined by gel electrophoresis 
visualization of ribosomal RNA band integrity. 
cDNA synthesis 
For cDNA synthesis, 0.5-2 μg of RNA was brought to a final volume of 9.3 μL 
with sterile nuclease-free water in a 0.65 mL thermocycler tube. To each tube, 1.25 μL 
10 mM dNTPs and 6.75 μL 15.4 μM random primers were added, incubated for 5 min at 
65 °C, and incubated on ice for 5 min. Subsequently, 6 μL 5X M-MLV Reaction Buffer, 
1 μL M-MLV reverse transcriptase (Promega), and 1 μL RNasin (Promega) was added to 
each tube, and samples were incubated for one hour at 37 °C. Resultant cDNA samples 
were stored at -20 °C.   
Quantitative PCR 
Relative gene expression levels were measured by quantitative RT-PCR 
performed in technical triplicate wells. Briefly, 15 μL SYBR Green Master Mix (Applied 
Biosystems), 4 μL sterile nuclease-free water, 6 μL primer mix, and 5 μL diluted cDNA 




and divided across technical triplicates by pipetting 8.5 μL reaction mix into each of three 
wells of a 384-well plate. Quantitative RT-PCR reactions were performed and read in a 
7900HT sequence detection system (Applied Biosystems), and resultant data were 
analyzed using the ΔΔCT method (Livak & Schmittgen 2001). For quality control 
purposes, primer dissociation curves of Applied Biosystems SDS files were examined for 
single melting peaks, and 15 μL sample of final qPCRs (combined volume from technical 
replicates) were electrophoresed on a 4% agarose gel in 1X TAE to check for single band 
amplicons. 
RNA immunoprecipitation 
For RNA immunoprecipitation (RNA-IP), sixty 10cm plates of C2C12 cells were 
trypsinized, washed with cold 1X PBS, and collected into a single 50 mL conical tube by 
iterative centrifugation, with pellets stored on ice during intermediate cell collections. 
Once all cells were collected into a single pellet, the pellet was transferred to a 1.5 mL 
tube on ice, and dounce homogenized in 500 μL RNase-free AT buffer (20% glycerol, 
1mM EDTA, 0.15M NaCl, 20nM HEPES pH 7.7, DTT, Protease inhibitors, RNAsin). 
Following homogenization, lysate was brought up to a total of 1.5 mL with AT buffer, 
and incubated on ice for 10 min. Lysates were then centrifuged at 13,500 rpm for 5 min 
at 4 °C, and 500 μL supernatant containing cleared lysate was transferred to a new 
1.5 mL tube containing 45 μL Protein G beads (Santa Cruz SC2002) preincubated with 
0.5μL Ezh2 antibody (Millipore 07-689) or normal mouse IgG antibody (Santa Cruz 
SC2025). The total volume was adjusted to 1 mL by addition of AT buffer, tubes were 




16 hr. The next day, beads were spun down with 200 rcf centrifugation for 1 min, and 
45μL supernatant was collected in a 1.5 mL tube and stored at -80 °C for downstream 
normalization controls. Beads were then washed with sterile AT buffer four times, using 
a p1000 to slowly remove supernatant with 100 μL bead clearance. After the final wash, 
residual supernatant was removed with a p200 pipette, and bead conjugates were 
vortexed briefly in the presence of 1mL Trizol, and incubated at room temperature for 
5 min before purification of immunoprecipitated RNA. 
RNA sequencing  
A minimum of 100 ng RNA per sample was provided to the Boston University 
Microarray and Sequencing Resource Core. Briefly, samples were evaluated for quality 
by Bioanalyzer to confirm RIN scores were above 7. Subsequently, second-strand 
synthesis was prepared using TruSeq mRNA stranded library preparation kit, and 
samples were subsequently sequenced by high-output 75 bp paired-end read Illumina 
NextSeq500 sequencing. Raw counts were then preprocessed using the Illumina 
BaseSpace RNA Express application, to assess for quality via FastQC and RSeQC, and 
aligned to mouse genome build mm10 via STAR. Quantification of pairs uniquely 
aligned to each Ensembl gene (via HTSeq) produced counts, which were converted to 
regularized algorithm (rlog) transformed expression values (via DESeq2) for statistical 





2.5 Protein techniques 
Protein isolation 
To collect protein, C2C12 cells were detached by trypsinization, and collected 
into cell pellets by centrifugation at 1,000 rpm. Resultant cell pellets were subsequently 
resuspended in 1 mL cold 1X PBS, transferred to 1.5 mL tubes, and pelleted at 
3,000 rpm. Supernatant was discarded, and 200 μL ELB (50 mM HEPES, 250 mM M 
NaCl, 5 mM EDTA, 0.1% NP-40, 1 mM PMSF, 1 mM DTT, and 1X Roche protease 
inhibitor) was added to each tube without disrupting the cell pellet. Following dounce 
homogenization, lysates were incubated on ice for 10 min, and subsequently clarified by 
centrifuging at 13,500 rpm for 10 min at 4 °C. Clarified lysate (supernatant) was 
collected into a new 1.5 mL tube, and stored at -80 °C. 
Bradford assay 
To generate a protein standard curve, 5 μL sample volumes containing defined 0 - 
5 μg concentrations of bovine serum albumin in 0.5 μg increments were dispensed into 
separate wells of a 96-well plate. For protein samples, 5 μL sample volumes were 
dispensed into separate wells. To each well, 200 μL of diluted Bradford reagent (Bio-
Rad, diluted 1:5 in deionized water) was added to each well by multichannel pipette, and 
Bradford reactions were incubated for a minimum of 2 min. Bradford assay plate was 





Protein samples were resolved on denaturing SDS polyacrylamide gels. For each 
lane, 40 μg of clarified lysate was transferred to a 1.7 mL microcentrifuge tube stored on 
ice and brought to a final volume of 30 μL with deionized water. To each sample, 5 μL of 
6X SDS-PAGE loading dye (250 mM Tris pH 6.8, 10% SDS, 40% glycerol, 5% β-
mercaptoethanol, 0.02% bromophenol blue) was added. Immediately prior to loading, 
samples were denatured by heating at 95 °C for 5 min.  
Samples were then loaded onto a discontinuous gel (5% stacking gel, 10% 
resolving gel). To collect samples at the interface of stacking and resolving gel, 80 V 
current was applied, and once samples reached stacking gel, voltage was adjusted to 
180 V until the bromophenol blue dye front reached the lower tenth of the gel. SDS 
polyacrylamide gels were subsequently removed from the glass plates, and stacking gel 
was removed. Resolving gel was then insulated with Whattman paper (Bio-Rad), and 
transferred onto a PVDF membrane (Bio-Rad) by overnight treatment with 20 V at 4 °C 
in cold transfer buffer (20 mM Tris, 150 mM glycine, 20% methanol).  
Western blot membranes were blocked for 30 min with 1X TBS (50 mM Tris pH 
7.5, 150 mM NaCl) containing 5% nonfat dry milk with oribital shaking at room 
temperature. Blocking solution was discarded, and replaced with 1X TBS containing 5% 
nonfat dry milk and suitably diluted primary antibodies. Primary incubation was 
conducted overnight with orbital shaking at 4 °C, for a minimum of 16 hr. The next day, 
membranes were washed for 5 min with 1X TBST (1X TBS containing 0.1% Tween-20), 




remove residual TBST. For secondary solution, Licor 680-anti mouse and 800-anti rabbit 
were added to cold 1X PBS at 1:10,000 dilution, and shielded from light. 10 mL solution 
was added to each membrane, with subsequent incubation conducted at room temperature 
for one hour shielded from light. Following incubation with Licor secondary, membranes 
were washed three times with cold 1X PBS with minimal light exposure, and membranes 
were dried by pressing firmly between two sheets of Whattman paper. Gel images were 
acquired using Azure Sapphire Biomolecular Imager, and protein band densitometry was 
quantified using ImageJ. Protein band values were normalized to internal β-tubulin 
controls.  
The following dilutions were used for antibody incubation: β-tubulin (1:5000, 
Cell Signaling technology mAb #3873), MF20 (0.2 μg/mL, DSHB MF-20 supernatant), 
Cdh1 (1:1000, Abcam ab40772), Cdh2 (1:1000, Abcam ab76011), Vimentin (1:2000, 
Abcam ab92547). Secondary dyes: Rabbit 800  (1:10,000, Licor 926-32211), Mouse 680  
(1:10,000, Licor 926-68070) 
Chromatin Immunoprecipitation (ChIP) 
For chromatin immunoprecipitation, thirty 10cm plates of C2C12 myotubes were 
cross-linked by addition of freshly prepared p-formaldehyde solution, with a final 
concentration of 1%. Plates were incubated with gentle orbital shaking for exactly 
9.5 min, and fixation was quenched by 0.125M glycine treatment with additional 5 min 
orbital shaking at room temperature. Supernatant was then discarded, washed twice with 
cold 1X PBS, and plates were then stored atop shallow ice baths in pyrex dishes during 




1X PBS was added to cells for scraping. Cross-linked lysates were collected into a 50 mL 
conical tube, and centrifuged at 3,000 rpm for 5 min at 4 °C. Supernatant was discarded, 
and cells were resuspended in 1 mL cold 1X PBS. Tubes were centrifuged again at 
3,000 rpm for 5 min at 4 °C, supernatant was discarded, and dry cross-linked cell pellet 
was stored at -80 °C until sonication. 
For nuclear DNA sonication, dry cell pellets were resuspended in 642 μL cold 1X 
PBS. The cell suspension was then transferred to a 2 mL microcentrifuge tube and 
642 μL ChIP Lysis Buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA pH 8, 
1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS) and 214.2 μL 7X protease 
inhibitors (Roche) were added to the sample. Samples were then incubated on ice for a 
minimum of 20 min, and subsequently sonicated until an average chromatin size range of 
300-700 bp was obtained, as confirmed by gel electrophoresis.  
For immunoprecipitation, 10 μg of H3K27me3 antibody (mAbcam 6002), Ezh2 
antibody (Millipore 07-689), or normal mouse IgG (Santa Cruz SC2025) was incubated 
with 40 μL herring-sperm preadsorbed Protein-G beads. Subsequently, 25 μg of sonicated 
chromatin DNA were added to bead-antibody complexes, and 500 μL 7X protease 
inhibitors, 100 μL 100 mM PMSF, 100 μL 100 mM DTT was transferred to at 15 mL 
conical tube and the final volume was adjusted to 10 mL with IP Dilution Buffer (0.01% 
SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.1, 167 mM NaCl). 100 μL 
of immunoprecipitation was removed and used as 1% INPUT and then 3 μg of MEF2A 




Immunoprecipitations were incubated overnight at 4 °C on a Nutator. The next 
day, beads were allowed to settle by gravity for 10 min on ice. Supernatant was 
discarded, and pellets were resuspended in 1 mL Wash Solution I (0.1% SDS, 1% Triton 
X-100, 2 mM EDTA, 20 mM Tris pH 8.1, 150 mM NaCl) and incubated on ice for 5 min 
with intermittent flicking. After settling by gravity for 10 min on ice, supernatant was 
slowly removed via p1000, and beads were were resuspended in 1 mL Wash Solution II 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.1, 500 mM NaCl) and 
incubated on ice for 5 min with intermittent flicking. After settling by gravity for 10 min 
supernatant was removed and beads were resuspended in 1 mL Wash Solution III 
(250 mM LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris pH 8.1) and 
incubated on ice for 5 min with intermittent flicking. After settling by gravity for 10 min 
on ice, supernatant was removed and beads were resuspended in 1 ml of 1X TE, 
incubated for 5 min at room temperature with intermittent flicking, and supernatant was 
removed after settling by gravity for a total of three TE washes. After removing 
supernatant, pellets were resuspended in 250 μL Elution Buffer (1% SDS, 100 mM 
sodium bicarbonate), vortexed for 45 sec, and incubated at 65 °C for 15 min. Samples 
were then centrifuged at 2,000 g for 5 min, and the supernatant was collected into a 
1.7 mL microcentrifuge tube. Elutions were then reverse-cross-linked overnight, treated 
with RNase and proteinase K, and released DNA was subsequently purified by phenol-
chloroform extraction and ethanol precipitation. Resultant DNA was resuspended in 





 ChIP-qPCR CT values (CTIP) were normalized to 1% input CT values (CT1%IN). 
Briefly, 1% input CT values were adjusted to 100% input CT values (CT100%IN) by 
subtracting 6.64, i.e., log2(100). Then, CT100%IN values were subtracted from CTIP values 
(ΔCT100%IN – IP). Percent chromatin immunoprecipitated relative to total input chromatin 




2.6 Biological Assays 
CellTiter-Blue viability assay 
For CellTiter-Blue viability assays,  C2C12 myoblasts were seeded in growth 
medium at 20,000 cells per well in a 96-well plate. To initiate assays, growth medium 
was replaced with freshly prepared growth medium containing 10% CellTiter-Blue 
reagent (Promega) by multichannel pipette, and incubated at 37 °C for one hour. The 
plate was then read on a Victor3 plate reader (PerkinElmer Life Sciences) at a 
wavelength of 590 nm, and treatment values were normalized to internal controls.   
Cleaved caspase 3 assay 
For cleaved caspase 3 assays, C2C12 cells were seeded in 12-well plates 
(CELLSTAR) at a density of 42,000 cells per well. Upon reaching the desired timepoint, 
supernatant was collected in labeled 1.5 mL tubes, and adherent C2C12 cells were treated 




collected into the same tube. Samples were then centrifuged at 13,500 rpm for 5 min at 
4 °C, and supernatants were collected into new labeled 1.5 mL tubes. Lysates were then 
mixed with fluorogenic caspase-3 substrate Ac-DEVD-7-amido-4-methylcoumarin (BD 
Biosciences) to a final concentration of 50 μM, and incubated for 1 hr at 37 °C. 
Fluorescence was subsequently measured using a Victor3 plate reader (PerkinElmer Life 
Sciences) at a wavelength of 480nm. For signal normalization, lysate protein 
concentrations were determined by Bradford.  
Trypsinization assay 
For trypsinization assays, subconfluent C2C12 myoblasts were cultured in a 12-
well plate containing 0.5 mL growth medium. Cells were washed 3 times with 1X PBS, 
and upon initiating a timer, 100 μL pre-warmed trypsin was added to each well, and 
incubated at 37 °C for one minute. At 2 min, cell suspensions were collected into 1.5 mL 
tubes containing 200 μL cold growth medium, and stored on ice. An additional 100 μL 
pre-warmed trypsin was added and incubated until the timer reached 4 min, at which 
point cell suspensions were transferred to an additional set of 1.5 mL tubes. This process 
was repeated until no adherent cells were visible in the well, as confirmed by brightfield 
microscopy. Collected cell suspension concentrations were then quantified by loading 
10 μL suspension onto a glass hemocytometer, and resultant cells per mL concentrations 
were multiplied by 0.3 to obtain the total number of cells for that sample. After cell 
counts were collected, the number of cells per time point of interest was divided over the 






For scratch wound assays, C2C12 myblasts were seeded in 12-well plates at high 
confluence, and with the aid of a microscope, a sterile p200 pipette tip was used to induce 
a single scratch across the middle of the well. Wells were subsequently washed to remove 
dislodged cells, and growth medium was replaced. Using brightfield microscopy, cells 
were imaged at intervals of time at the center of the sample, until 100% closure of the gap 
was observed. Resultant images were analyzed with the MRI Wound Healing tool 
(https://github.com/MontpellierRessourcesImagerie/imagej_macros_and_scripts/wiki/Wo
und-Healing-Tool) to evaluate wound closure. Areas measured were screened manually 
to ensure that peripheral regions were not incorporated into measurements. 
 
2.7 Tibialis anterior regeneration 
Cardiotoxin-induced injury 
 Tibialis anterior (TA) muscle of Swiss-Webster mice (female, 25 g weight, 
Taconic Labs) were conducted in accordance with IACUC protocol number 16-019. 
Briefly, mice were administered Buprenex solution (Buprenorphine, 0.3 mg/mL in sterile 
saline) at 0.1 mg per kg mouse weight. After being anesthetized with nose-cone 0.25% 
isoflurane gas, mice were injected with 10 µM cardiotoxin (Naja nigricollis, EMD 
chemicals) in saline solution containing 5×1010  pfus adenovirus. Intamuscular injections 
were administered at a total volume of 50 µL per TA muscle. Ears were notched in 
specific positions for identification purposes, and animals were monitored closely until 




injury, and muscles were harvested 3, 7, and 14 days post-injury. Food, water, and 
bedding were overseen by technicians and staff at the Boston University Charles River 
Campus Animal Science Center.  
Tissue dissection 
Mice were triple-killed by incubation with isoflurane-saturated cloth in a bell-
chamber, followed by cervical dislocation and decapitation, in accordance with IACUC 
protocol number 16-019. Bodies were wetted with ethanol, and sterile surgical 
instruments were used to de-glove limbs. Subsequently, TA muscles were isolated by 
placing fine forceps between the muscle and rostral tibia bone, and by pushing towards 
the bone in a caudual motion, tendon was disconnected. Surgical scissors were used to 
remove TA muscle from its location originating from the patella, and isolated tissue was 
washed in a series of ice cold 1X PBS baths. Muscle gross-anatomy was subsequently 
imaged using a Samsung Galaxy S7 camera, and approximately 1 mm2 tissue from the 
injured region (if applicable) was excised and snap-frozen for RNA isolation.  
Cryosectioning 
Muscle tissue was submerged in a 1.5 mL tube containing 1 mL 30% sucrose 
solution for a minimum of 2 hrs to minimize freeze-fracture. Muscle was then slowly 
lowered by the caudual tendon into to a 2cm x 3cm aluminum cast filled with O.C.T. 
medium (ThermoFisher). Once the muscle was completely submerged and erect in the 




nitrogen until O.C.T. turned solid white. Samples were temporarily stored on a flat 
aluminum bed atop dry ice, and transferred to -80 °C for long term storage. 
For cryosectioning, O.C.T.-embedded muscle blocks were removed from 
aluminum molds, and mounted to a -25 °C cooled chuck using O.C.T. as a binding 
reagent. The sample was oriented for transverse sections, and sectioned at thickness of 
16 μm (Leica CM 1850, Sturkey low-profile blades). Cryosections were carefully 
transferred onto charged slides with the aid of a cooled paintbrush, and stored at -80 °C 
for long-term storage. 
 
2.8 Cell staining 
Immunofluorescence 
C2C12 myoblasts and transverse TA muscle cryosections (16 μm) were fixed by 
15-20 min cold 4% para-formaldehyde incubation with gentle orbital shaking, followed 
by three cold 1X PBS washes. Samples were subsequently incubated with cold blocking 
buffer (3% normal donkey serum (Sigma), 0.3% Triton X-100, 1X PBS) for 1 hr. 
Samples were then washed three times with 1X PBS, and treated for 1 hr with primary 
antibody suitably diluted in antibody dilution buffer (1% BSA, 0.3% Triton X-100, 1X 
PBS). Samples were then washed four times with cold 1X PBS, and treated for 30 min 
with suitably diluted secondary antibody in antibody dilution buffer (1% BSA, 0.3% 
Triton X-100, 1X PBS) while shielded from light. Samples were then washed four times 




medium. Samples were sealed with nail polish and stored at 4 °C in slidebooks shielded 
from light.  
The following dilution factors were used for primary antibodies: MYH4 (1:200, 
Proteintech 20140-1-AP), α-actinin (1:1000, Sigma A7811), BrdU (1:500, Invitrogen 
MoBU-1), Ki67 (1:2000, Abcam ab15580), Laminin (1:2000, Sigma L9393), Pax7 
(1:200, DSHB PAX7), PDGFRα (1:200, Proteintech 60045-1-Ig), Cdh1 (1:500, Abcam 
ab40772), Cdh2 (1:500, Abcam ab76011), Snai2/Slug (1:500, Abcam ab85936), 
Vimentin (1:1000, Abcam ab92547). Secondary antibodies:  donkey anti-mouse Alexa-
Fluor 488 IgG (1:2000, Invitrogen), donkey anti-mouse Alexa-Fluor 568 IgG (1:2000, 
Invitrogen), donkey anti-rabbit Alexa-Fluor 488 IgG (1:2000, Invitrogen), donkey anti-
rabbit Alexa-Fluor 555 IgG (1:2000, Invitrogen).  
For samples prepared with Pax7, immunostaining was modified to follow the 
manufacturer’s protocol for Mouse on Mouse Immunodetection kit (Abcam).  
BrdU incorporation 
For BrdU, proliferating subconfluent C2C12 myoblasts were pulsed with 10μM 
BrdU (BD Pharmingen) for 60 minutes, followed by 15-20 min fixation with 4% p-
formaldehyde. Samples were washed three times with 1X PBS, and subsequently 
incubated with 2.5 M HCl solution at 37 °C for 20 min. Samples were then washed four 





MitoTracker reagent (Cell Signaling Technology) was resuspended by 
manufacturer’s protocol in DMSO, and added to C2C12 cultures to a final concentration 
of 50 μM. Following 30 min incubation, cells were fixed and subjected to 
immunostaining with α-actinin to identify myocytes. Signal was acquired with uniform 
settings across all samples compared for quantification. 
  
2.9 Computational and statistical methods 
Custom Gene Set Enrichment Analyses (GSEA) 
To generate custom gene sets for GSEA, gene set lists were compiled for a 
particular phenotypic category, and gene symbols were converted to HUGO terms using 
HGNC multi-symbol checker (https://www.genenames.org/tools/multi-symbol-checker/). 
Unmatched gene symbols were discarded. Gene set matrices were organized in excel 
spreadsheets using format parameters defined by GSEA wikiformats 
(https://software.broadinstitute.org/cancer/software/gsea/wiki/index.php/Data_formats), 
saved as a tab-deliminated file, and converted to a .gmx format by manually editing the 
file extension. 
For GSEA analyses, dataset matrices were generated from RNAseq analysis data 
using Ensembl gene symbol (Mouse Ensemble gene ID human orthlogs MSigDBv7.2 
chip) and corresponding rlog transformed values. Enplots and corresponding heat maps 
depict the abundance of up- and down-regulated genes from the gene set. For data 




statistical thresholds. Size = number of genes in set; NES = normalized enrichment score; 
NOM p-val = nominal p-value, FDRq-val = false discovery rate. 
 
Statistical methods 
All numerical quantification is representative of the mean ± S.E.M. of at least 
three independently performed experiments. Bar graph data are presented as mean ± std. 
error. Statistically significant differences between two populations of data were 
determined using two-tailed Student’s t-test. P-values of < 0.05 were considered to be 



























Table 2.1: Single stranded oligonucleotides used to generate shRNA transgenes. 
Oligonucleotides are listed 5’ to 3’, and designed to contain a 4-nucleotide bridge (bold) for 







Table 2.2: Plasmids used in this thesis. Plasmids were either purchased as part of a kit, 





pENTR-U6 vector Invitrogen BLOCK-iT kit 
pENTR-U6 shLacZ Previously cloned in-lab (Dr. Christine Snyder) 
pENTR-U6 shMeg3 Cloned in-lab 
pAd U6-shMeg3 Cloned in lab 
Overexpression constructs 
Plasmid Source 
pShuttle-CMV vector Agilent AdEasy adenoviral vector system 
pShuttle-CMV β-galactosidase Previously cloned in-lab (Dr. Christine Snyder) 
pShuttle-CMV MEG3 Cloned in-lab 
pCI-MEG3 Addgene Plasmid #44727 






Table 2.3: Adenoviruses and MOIs used for in vitro transduction experiments used in this 






Promoter/Transgene MOI in vitro Source 
U6/shLacZ Matched to treatment Naya lab (Dr. Nelsa Estrella) 
CMV/EGFP Matched to treatment Naya lab (Dr. Cody Desjardins) 
CMV/β-galactosidase Matched to treatment Ken Walsh lab (Boston University) 
U6/shMeg3 60 Naya lab (Tiffany Dill) 
CMV/MEG3 60 Naya lab (Tiffany Dill) 
CMV/Notch-ICD 25 Igor Prudovsky lab (Maine Medical 
Research Institute) 







Gene name  Forward (5’→3’) Reverse (5’→3’) 
18S  CATTCGAACGTCTGCCCTAT  CCTCCAATGGATCCTCGTTA  
Gtl2  GACTTCACGCACAACACGTT  TTACAGTTGGAGGGTCCTGG  
Myf5  CCTGTCTGGTCCCGAAAGAAC  GACGTGATCCGATCCACAATG  
MyoD  CCACTCCGGGACATAGACTTG  AAAAGCGCAGGTCTGGTGAG  
Mef2C  GTGGTTTCCGTAGCAACTCCTAC  GGCAGTGTTGAAGCCAGACAGA  
Myog  GAGACATCCCCCTATTTCTACC  GCTCAGTCCGCTCATAGCC  
Ckm  GGCTTCACTCTGGACGATGTCA  CCTTGAAGACCGTGTAGGACTC  
Acta1  ACCATCGGCAATGAGCGTTTCC  GCTGTTGTAGGTGGTCTCATGG  
MEG3  TTGAGTAGAGACCCGCCCTC  CTGTGCTTTGGAACCGCATC  
Cdh1  TGCAGGTCTCCTCATGGCTTTG  CTTCAAATCTCACTCTGCCCAGG  
Cdh2  ACTTGAGAGCACATGCAGTGG  CATACGTCCCAGGCTTTGATCC  
Plakophilin  TGAGTCACTCCAACCGAGGTTC  CTTGAGGGTCCCATTGTAGATCGG  
PatJ  AGTGTAGCAGACAGGGATCACAG  CACACCGTTTCTGGCAGAGTT  
Fibronectin  AGCAAATCGTGCAGCCTCAATC  CTCAGGCTTGCTCTCGCAGTTA  
Twist2  AGCAAGAAATCGAGCGAAGATGG  GATCTTGCTGAGCTTGTCAGAGG  
Snai2  AACTACAGCGAACTGGACACAC  GTAATAGGGCTGTATGCTCCCGAG  
Mmp9  AGTGAGAGACTCTACACGGAGC  CCTGGTCATAGTTGGCTGTGGT  
Rian  TCTGAGGTCCATAGCAGAAGATGCC  CCTTTCCGTGCATGGAGATTTGTATCTTG  
Mirg  GGCAAGGTCTAGGATGGACA  CGCCAAGCTTCTGAATACTCC  
Table 2.4: qPCR expression profiling primers used in this thesis. Primers were 
designed using FASTA reference sequences (RefSeq, www.ncbi.nlm.nih.gov ) as 
template; APE (https://jorgensen.biology.utah.edu/wayned/ape/) was used to evaluate for 
amplicon length, melting temperature, and GC-content. Primer pairs were evaluated with 
NCBI primer BLAST tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) against the 






Primer name  Forward  (5’→3’) Reverse  (5’→3’) 
Jag1 DE  ACTCAGCAGAAATGCATCACAT  AAGGAAAGACTTTTTGAAGAGGGT  
Smad2 DE  CCCCTCTCAGCCCGATCAT  GAACAGGTACTTGGGCAGCAC  
Nfatc1 DE  CTTGGCATAGCAAAAGCAGATGA  TTACGTGGTGTGCACTTTCGT  
Smad6 DE  CTGCGTGCACGTTAGAAACC  CAAAGTGCCGTTAGCAACCC  
PDK3 DE  TGCTCCCTTCTCTGTCCTGT  AACCTCCTCCAGGCTCAGAT  
CASK DE  GAGAGAGTCCTGCCCTGAAC  GTCTTGGATCAGTTCCACTCCA  
Chrdl1 DE  CTGATTACATATTCATCACTCGGGC  GAGGTAGATGATGAAGGCAGGTT  
NFIB DE  GCTACTGACGAGCTGAACACA  CACTTAGGCAATAGATGGCAGTG  
Tgfbr1 DE  GTGTGCTGACTCCTGCATTTC  ACATTGCCGGTGACCGAAG  
Olfm1 DE  AGGGGGAAGCTAGAGACCTG  GAAAGGAGCCTCAGGCCAAA  
Fgfr2 DE  ACTCTGCAGGAGGAGTCAGT  TCTCTTCCTGGTCTGGCTCA  
Dock1 DE  CCAGATACCCTGCCAACAGAT  TTGACTGCACTTCATGGGAGG  
IL6st DE  CCAAAAGCTTCTCCCTTCTCAG  ACTACATGGGTTTGATCTGATCCT  
Fgf18 TSS  TGGAGTCCCACACATCACTC  CTAGGAGCTACTGCTTGAGCC  
Clmn TSS  CACGCTTGGTGGATACGGG  AGATCAGCGACATCCGTGTG  
Smurf1 TSS  TTACGGCCACGGGCT  TGGTCTCCGGCCCAAC  
Tnfrsf1b DE  GTACTTTTAGGTGCTGGGGGA  TGACCAGCAGGTGGGATTTT  
Pbx1 DE  TGTGTGGTCAAGGGGAATCG  ACTAGCGTTCAAGCTGCCAT  
Tgfb2 TSS  TAGCACAACCACCGTTGAGAAA  CCCTTTATGGCTCCTTGGGATT  
Akt3 DE  CACATAAGGCAGACTTGTAGGAGG  CTGTATGGTGAGAAGCAGGGTATG  
Id4 DE  TGCATTATGTATTATCCCAGAAGCC  TGCCTCTGTGATGCTCTGAC  
Sox4 DE  AGGCACAACTTGCACCTAATTT  TTGGGCTTAACTGCTTTTTGGTT  
Cadm1 DE  GGGACGTGCTCATCAAAGGA  CCTTTCACTCGGCTGGACTT  
Cbx4 DE  TGAAGCATGTGACCATTTGTGG  TCCCCACTCTCACTCACAGA  
Litaf TSS  GATGGGGTGGGGTCTAGGAG  TCAGGTCGTAGCTTCATCCCT  
Table 2.5: ChIP-qPCR primers for enhancer analysis. ChIP qPCR primer sets 
targetting TSS and distal enhancers (DE) in the mouse genome with homology to human 
loci interacting with MEG3 and Ezh2, as reported by Mondal et al. 2015. Homologous 
loci reported by Mondal et al. were used as queries for BLASTn alignment tool 
(https://blast.ncbi.nlm.nih.gov)with on Mus musculus genome transcriptome data. Priority 
was placed on sequences with analogous chromosome location (for example, if human 
Jag1 homolog resides on Chromosome 2 in mice, priority was given to Chromosome 2 
alignments with the highest score). Distal enhancers lacking homology were substituted 
with Ensembl transcription start sites (TSS). Primers were designed using primerBLAST 
tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) with a range spanning ± 200 





Primer name  Forward  (5’→3’) Reverse  (5’→3’) 
Adamts13 TSS  AGCAACCCTCAAGGGTGAAG  CTCTGCGTCTGTTGACTCCA  
Aldh1a2 TSS  CACGTCCAATAAGAAGCGCC  ATCTCGCTGGAAGTCATGGG   
Arg2 TSS  GCTGTAGTCCTCCGAGAAGGT  CTTCGATGCTTCACTAGGCGA  
Cdc3 TSS  TCTGGACCCTTTTTAAGCGTGG  CACGGCTAGCTCTTCGGC  
Coro1a TSS  CCCCAGGACCATTGAGGTTC  CTATGAGGATGTGCGCGTCT  
Cdh11 TSS  CGGAATTAGGGAGCGCATTCT  TTCACCGATTTCCCCGCAA  
E2f8 TSS  AAATCACCGCGATGCCAAAG  GGCTTACTGATTGGCTCGGA  
Embigin TSS  AATTGCGCTGGGAGCGT  CCCTGTGTACACTTGCTGGTA  
Fbn2 TSS  AGAGCACTGTCGGAGACCAA  CTACACCAGGACACCGCAAG   
Fhod3 TSS  GGCGTTTCTGCGCGTTGATT  GACAGGGAATGCGAGAGTCGT  
Gch1 TSS  TAGCCTCAGCTACAGAGTACGG  AGAGATTGCTGGAGATCTAACTGAC  
Gda TSS  CCTCCTGGATGCCAATAGGATT  AACACATCCAAAACCAACGCA  
Icam1 TSS  AGAGACTATAAAAGCGCCGCC  ACGGGTTGAAGCCATTGCAG  
IL10RB TSS  AGAAACAGAAGCGCGGATTG  GGCGGCCTCAAGCTAAGT  
Kcnf1 TSS  TCCAGAGCTTTAAGGCCAGC  GACAGAAGGAGTGTGCCCAA  
Lef1 TSS  CAACCCAAAGAAAGGGTGGTTT  CCATCGGGACAGAGAAGGTAAC  
Ltbp2 TSS  GTAAGGGCTGTATGGCGTGA  CCTTCGGTTCCCCTTCAGAC  
Ltbp4 TSS  GTCACGTTTCGGGCCAAGAT  GACGTCGCGAGTGCTACTTT  
Mcoln2 TSS  CTCCTGGAATATCTCCCGCC  GCGCTGTCACGAAGGACT  
Mctp1 TSS  AGTTCAGAGCTGCAAGTGCT  AGACTTGGCTGTCTTCGCAA  
Mkx TSS  CCGGAGTCGTCTCTGCTTTA  GGGAACATGGATACCGCGT  
Mybl1 TSS  ACACCCACCGAACAGGAAAA  GAAGGATGGCGAAGAGGTCG  
Pdgfra TSS  GCTTACTGGGACGAACACCA  GCGGGCGACGAATGAAAATA  
Pik3ap1 TSS  AAGTGAGAAGTCCACACGACC  TGGCTGCCTGCTTTCGG  
Pkp2 TSS  AGTCCCTCCTGGTCACTCC  GTCCAGGTGACCCAGGATCT  
Ppp1r14c TSS  GTCGACATATTTCGTGCGCC  GTCGTCCGAGGTGGAGAATC  
Ptk2b TSS  TCCTTAAAGGGTGGGGTGTG  GAATTGCAGGCGGCATCTAT  
Rnd1 TSS  ACTAGCACACTAGCGCGG  ATAGCGGAGCCTTACGAGC  
Sfrp2 TSS  TCGAGTACCAGAACATGCGG  GAACTTCTTGGTGTCCGGGT  
Slc9a2 TSS  ACTGGGAGGCAGATGGTTTG  GGAAAAGCGGGATTCTCCCA  
Tead4 TSS  CGATTTCCCGCTCTCATCCAG  GGAGGGGACGGTTTTCGG  
Tgfb1 TSS  CCCTCCCTCGGGCTACTAA  ACCCACGATGAAAGCAGGC  
Table 2.6: ChIP-qPCR primers for transcription start site (TSS) analysis. ChIP 
qPCR primer sets targetting transcription start sites harboring H3K27me3 identified in 
mouse satellite cells by Liu et al. 2013. TSS sequence coordinates were obtained using 
Ensembl Biomart tool (https://uswest.ensembl.org/index.html). Primers were designed 
using primerBLAST tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) with a range 





CHAPTER THREE: MEG3 IN C2C12 MYOBLAST DIFFERENTIATION 
 
3.1 Introduction  
 C2C12 myoblasts are an immortalized muscle progenitor cell line derived from 
female mouse skeletal muscle tissue. When seeded at high density and subjected to 
serum-starvation conditions, C2C12 myoblasts undergo myogenic differentiation in vitro, 
yielding multinucleated contractile myotubes expressing characteristic muscle proteins.  
In this chapter, I examined temporal Meg3 expression and evaluated the efficacy 
of Meg3 knockdown methodologies in this cell line. I then established a stable C2C12 
cell line harboring a constitutively active shMeg3 transgene, which results in chronic 
Meg3 knockdown. After subjecting this cell line to differentiation conditions, I found 
significant reduction in myogenic marker expression and fusion index, which could be 
rescued with chronic human MEG3 overexpression, suggesting Meg3 is required for 
myotubes formation in vitro. Homeostatic perturbations of cell proliferation, viability, 
and metabolism were also observed in Meg3-deficient C2C12 myoblasts, and increased 
cell-cell contacts was unable to restore myogenic differentiation to these cells. To 
understand the transcriptional basis of myogenic dysregulation in shMeg3 myoblasts, 
RNA sequencing (RNAseq) was performed and computationally analyzed for 
dysregulation of cellular processes and signaling pathways. Epithelial-mesenchymal 
transition was among the most upregulated cellular processes, and this transcriptional 
pattern was corroborated by evaluation of mesenchymal characteristics: adhesion and 




dependent dysregulation. These results demonstrate that Meg3 is required for proper 
EMT downregulation and subsequent myogenic differentiation in C2C12 myoblasts. 
 
3.2 Investigation of Meg3 knockdown modalities in C2C12 myoblasts  
 To investigate the role of Meg3 in regulating myoblast identity, I first examined 
its expression at various differentiation stages in C2C12 myoblasts. As shown in Figure 
3.1, proliferating C2C12 myoblasts were enriched for Meg3, and its expression was 
downregulated with differentiation conditions. This suggests that Meg3 is expressed in 
activated myoblasts during satellite cell expansion, which correlates with early phases of 
myogenic differentiation.  
 I then sought to inhibit Meg3 in proliferating C2C12 myoblasts in order to 
investigate the functional relevance of Meg3 in C2C12 myoblasts. Given that the Dlk1-
Dio3 ncRNAs are transcribed as a large polycistronic primary RNA (Tierling et al. 2006, 
Zhou et al. 2010, Luo et al. 2016), processed Meg3 transcripts were directly targeted for 
degradation using various modalities to circumvent unwanted effects on expression of 
adjoining RNAs in the cluster. Although I had previously determined that anti-Meg3 
GapmeRs were sufficient for Meg3 knockdown in rat cardiac fibroblasts (data not 
shown), this targeting method was not sufficient for Meg3 knockdown in mouse C2C12 
myoblasts (Figure 3.2). In stark contrast, a Meg3-specific short hairpin RNA (shRNA) 
(Mondal et al. 2015) under the U6 promoter resulted in significant depletion of Meg3 
transcripts compared to shLacZ control myoblasts regardless of the shRNA delivery 
method (Figure 3.2A). Interestingly, transient adenovirus transduction and lipofectamine 




observed by brightfield microscopy (Figure 3.2B). Considering myotubes can arise from 
unaffected cells at low confluence, I surmised this phenotypic variability reflected 
incomplete transfection and transduction efficiencies, and subjected myoblasts to G418 
selection to stably integrate the shRNA and eliminate untransfected populations from 
analysis. Resultant heterogeneous shMeg3 populations exhibited consistent 
morphological defects when induced to differentiate (Figure 3.2 A&B “het.”). To further 
ensure homogeneity in the cell populations studied, numerous clonal myoblast 
populations were derived from G418-selcted cultures (Figure 3.2 A&B clones).  
 To evaluate whether shMeg3 treatment was specific to the Meg3 lncRNA, and not 
other lncRNAs encoded by the Dlk1-Dio3 polycistron, I performed qPCR expression 
profiling on a subset of knockdown modalities. As shown in Figure 3.3, variable 
downregulation of neighboring lncRNAs was observed with transient knockdown 
methods (Adenovirus, FuGENE6), whereas chronic Meg3 knockdown (clones) resulted 
in significant downregulation of all three polycistron-encoded lncRNAs. These data 
suggest that, while Meg3 is the primary target of transient shMeg3 knockdown, chronic 
Meg3 depletion results in downregulation of neighboring locus lncRNAs. 
3.2 Meg3 is required for C2C12 myotube formation  
 To determine the functional consequences of chronic Meg3-depletion on myoblast 
differentiation, the ability of shMeg3 and shLacZ C2C12 clones to form myotubes was 
examined in greater molecular detail. Three days after initiating differentiation, qPCR 
analysis revealed that while Myf5 transcript levels were unchanged, myogenic regulatory 




muscle creatine kinase (Ckm) and skeletal α-actin (Acta1) transcripts were severely 
downregulated in shMeg3 myotubes (Figure 3.4 A). Moreover, myosin heavy chain 
protein (MF20), a differentiation marker expressed in myotubes but not myoblasts, was 
greatly depleted in day 3 shMeg3 myotubes, as determined by western blot (Figure 3.4 
B). These data indicate that Meg3 is required for myoblasts to express molecular 
hallmarks of myogenic differentiation. 
Noting morphological defects observed in differentiated shMeg3 myotubes 
(Figure 3.2 B), I performed immunostaining to examine cytoarchitectural differences in 
detail (Figure 3.5). Assessments of myosin heavy chain using a different antibody 
(MYH4) corroborated MF20 western blot findings, as this contractile protein was largely 
absent from the cytoplasmic compartment of day 3 shMeg3 myotubes (Figure 3.4). 
Moreover, staining for the muscle-specific molecular brace protein α-actinin revealed that 
shMeg3 myotubes were largely mononuclear, in stark contrast to control shLacZ 
myotubes, which predominantly contained ≥3 nuclei. Notably, extending the 
differentiation timeline to day 7 did not improve myotube formation (Figure 3.5). These 
data suggest that the capacity for myogenic differentiation and fusion competence are 
severely impaired in shMeg3 myoblasts.  
Because I had observed that other Dlk1-Dio3 lncRNAs were downregulated in 
stable shMeg3 clones, rescue experiments were performed to evaluate the specificity of 
the Meg3 knockdown phenotype. Transient overexpression of human MEG3 during 
differentiation conditions failed to reverse differentiation defects in established shMeg3 




transfection of human MEG3 or β-galactosidase plasmids with either shMeg3 or shLacZ 
expression plasmids. Following G418 selection, expression of human MEG3 was 
confirmed by qPCR, and found to be more than 50-fold in shLacZ + MEG3 controls, but 
increased only 3-fold in shMeg3 + MEG3 myoblasts (Figure 3.8). Comparatively low 
MEG3 levels in myoblasts co-transfected with shMeg3 was not unexpected, as shMeg3 
targets an evolutionarily conserved Meg3 sequence shared by mouse, rat, and human 
transcripts. Examination of endogenous Meg3 expression in shMeg3 + MEG3 myoblasts 
also revealed that these transcripts were restored to relatively normal levels.  
Stably integrated myoblasts were subsequently induced to differentiate, which 
resulted in rescue of cytosolic MYH4 expression and fusion index in clones harboring co-
integration of shMeg3 and human MEG3 (Figure 3.9A). In agreement with improved 
myotube formation, expression of MyoD, myogenin, Mef2c, and muscle creatine kinase 
was augmented in shMeg3 myoblasts by overexpression of human MEG3, but not to the 
extent observed in shLacZ controls (Figure 3.9B). These results clearly demonstrate that 
Meg3 functions in myogenic differentiation, and furthermore, shows that the shMeg3-
induced phenotype is not caused by off-target effects. Collectively, these results indicate 
a major disruption in myogenic differentiation. 
 
3.4 Meg3 is required for C2C12 homeostasis  
 To further explore the functional consequences of Meg3 depletion in C2C12 
myoblasts, I examined general cellular processes of proliferation, viability, and 
metabolism. Meg3 is predicted to function as a tumor-suppressor via its interaction with 




myoblasts, yet during routine cell expansion, I found that Meg3-deficient cells grew more 
slowly than control shLacZ myoblasts. To determine whether Meg3 depletion modulates 
proliferation, I performed BrdU incorporation assays and found that shMeg3 clones 
exhibit markedly reduced proliferation (Figure 3.10). Moreover, assays for cleaved 
caspase 3 (Figure 3.11, left) and cell viability (Figure 3.11, right) suggest that Meg3 
depletion also resulted in increased cell death. These data suggest that Meg3 is required 
for C2C12 cell proliferation and viability. 
The CellTiter-Blue viability assay measures aerobic respiration as a readout of 
cell viability, and considering Dlk1-Dio3 locus expression levels have been shown to 
correlate with changes in mitochondrial activity in satellite cells (Wust et al. 2018), I 
examined whether Meg3 depletion affected mitochondria in C2C12 myoblasts. C2C12 
clones were pulsed with MitoTrackerCMXRos and analyzed for mitochondrial mass at 
proliferating (myoblasts) and day 3 differentiation (myotubes). While Mitotracker Red 
CMXRos signal increased in response to differentiation conditions within each treatment 
group, shMeg3 clones displayed lower mitochondrial signal when compared with shLacZ 
clones for early but not late timepoints (Figure 3.12). These data suggest that Meg3 is 
required for maintaining normal mitochondrial activity in proliferating, but not 
differentiating myoblasts. 
Reasoning that impaired myogenic differentiation could be an artifact of low 
myoblast density, I seeded shMeg3 clones at high cell numbers and subsequently 
examined for their ability to differentiate. As shown in Figure 3.13, impaired myogenic 




by low cytoplasmic MYH4 expression and fusion index. Taken together, these data 
suggest that Meg3 is required for normal cell expansion, viability, and metabolism, and 
while shMeg3 C2C12 cells fail to yield myotubes, this is not attributable to reduced cell 
density. 
 
3.5 Transcriptomic profiling of shMeg3 C2C12 myotubes  
 To explore the molecular underpinnings of shMeg3 differentiation impairments in 
an unbiased manner, I collected RNA from day 3 differentiation samples for Illumina 
RNA-sequencing (RNA-seq). Globally, shMeg3 C2C12 cells harbored thousands of 
differentially expressed transcripts with a similar abundance of up- and down-regulated 
transcripts (Figure 3.14, left). Hallmark gene set enrichment analysis (GSEA) of 
upregulated transcripts in shMeg3 C2C12 myotubes revealed significant enrichment in 
metabolism (glycolytic), epithelial-mesenchymal transition (EMT), p53 signaling (p53 
pathway), and apoptosis, whereas transcriptional profiling negatively correlated with cell 
cycle (G2M checkpoint), myogenesis, Notch signaling, cell polarity (apical surface), and 
sonic hedgehog signaling (Table 3.1). These results were consistent with the 
aforementioned phenotypic characterizations, and also highlighted a broader gene 
regulatory effect of Meg3 in C2C12 cells.  
To obtain a more focused picture of altered pathways in shMeg3 C2C12 cells, I 
performed Ingenuity Pathway Analysis (IPA). This analysis revealed a significant 
enrichment in axonal guidance and Rho signaling (Figure 3.15), and predicted TGFβ1 as 




relationship between TGFβ and Rho activity in cytoskeletal remodeling in cell migration 
(Ungefroren et al. 2018), the integrated GSEA and IPA results indicated that EMT is a 
key pathway affected by Meg3-deficiency in differentiating C2C12 cells. 
 
3.6 EMT dysregulation in shMeg3 C2C12 myotubes  
 I next verified expression levels of genes related to EMT. Initially, I used qPCR to 
profile selected epithelial and mesenchymal marker genes. As shown in Figure 3.16, both 
Plakophilin (a cytoskeletal protein that anchors cadherins to intermediate filaments) and 
PatJ (a cell-polarity protein crucial for tight-junctions) were downregulated in shMeg3 
C2C12 cells, while mesenchymal markers Fibronectin (an integrin-binding extracellular 
matrix glycoprotein) and Snail2 (a transcriptional repressor of epithelial genes in 
developmental cell migration and cancer) were both upregulated. Meg3 knockdown did 
not affect transcript levels of Twist2 (a bHLH transcription factor associated with 
carcinogenic EMT) or Mmp9 (an adhesion-related matrix metallopeptidase).  
To further explore EMT marker dysregulation, I subsequently examined protein 
expression in shMeg3 C2C12 myotubes. Expression of cadherins, key mediators of 
calcium-dependent cell adhesion, was examined for cadherin switching – a well-
characterized signature of EMT where N-cadherin becomes enriched (Lamouille et al. 
2014). As shown in Figure 3.17, expression of mesenchymal N-cadherin (Cdh2) 
transcript and protein levels were significantly upregulated in day 3 shMeg3 C2C12 cells. 




transcripts, protein was difficult to detect by western blot. These data suggest that Meg3 
knockdown myoblasts have undergone cadherin-switching.  
I then examined vimentin, an intermediate filament protein that modulates cell 
shape and motility, for expression in day 3 C2C12 clones (Figure 3.18). Interestingly, no 
significant change was observed in shMeg3 C2C12 cells. This suggests that, while a 
EMT gene programs are upregulated in shMeg3 cells, levels of the EMT marker vimentin 
remains unchanged. 
Considering Snai2 is regulated, in part, through nucleo-cytoplasmic shuttling 
(Lamoiulle et al. 2014), I evaluated both proliferating and differentiating C2C12 clones 
for differences in Snai2 nuclear localization, to determine whether upregulated Snai2 
transcripts coincided with increased Snai2 transcriptional repressor activity. As shown in 
Figure 3.19, Snai2 nuclear enrichment was observed in both proliferating and 
differentiated shMeg3 C2C12 cells. These data suggest that Snai2, a transcriptional 
repressor, is aberrantly active in shMeg3 C2C12 cells.  
Having confirmed EMT marker enrichment, I next sought to examine cellular 
behaviors associated with EMT such as adhesion and migration in greater detail. To 
analyze migration, I performed scratch-wound assays, but measurement of wound closure 
using the Volkner Wound Healing Tool (ImageJ) indicated no difference in the rate of 
wound-closure between control and Meg3 knockdown C2C12 cells (Figure 3.20, line 
plot). However, the number of infiltrating cells sharing fewer than two borders with 
neighboring cells was significantly increased in shMeg3 C2C12 cells, which was most 




cells formed sheets reminiscent of collective migration behavior (Campbell and Casanova 
2016). These data suggest that Meg3 is required for normal C2C12 migration. 
During passaging, I noted that shMeg3 myoblasts required more time to 
trypsinize, and quantified their rate of detachment (Figure 3.21). Reasoning that increased 
adhesion could translate into preferential adhesion to cell culture substrates – and not 
other myoblasts – during differentiation, I plated C2C12 clones on substrate-free glass 
coverslips. As shown in Figure 3.22, differentiation on a glass substrate slightly improved 
fusion of cells with 2 nuclei, but not ≥3 nuclei, and did not improve MYH4 expression. 
Taken together, these observed changes in migration and adhesion characteristics indicate 
that activation of EMT in shMeg3 myoblasts correlate with mesenchymal behaviors that 
deviate from control shLacZ cells. 
3.8 Discussion  
 In this chapter, I established a model system to examine the loss-of-function 
effects of Meg3 in C2C12 myoblast differentiation, and found that Meg3 is required for 
proper formation of multinucleated myotubes and myogenic differentiation marker 
expression. While downregulation of neighboring lncRNAs was an undesired outcome in 
this model system, this observation is not surprising given the autoregulatory role Meg3 
plays in locus expression (Das et al. 2015). Moreover, rescue experiments demonstrate 
that this phenotype is specific to knockdown of Meg3. 
Looking beyond myogenic perturbations, numerous pathways and processes were 
dysregulated with shMeg3 treatment. While Meg3 is classified as a tumor suppressor, I 




stem from N-cadherin upregulation (Goel et al. 2017) or loss of satellite-cell specific 
Ezh2 function (Juan et al. 2011; Woodhouse et al. 2013). While cell death was 
upregulated in shMeg3 cells, increasing cell-cell contacts at the onset of differentiation 
did not improve differentiation or fusion, suggesting myogenic dysregulation is endemic 
to shMeg3 cells. Although mitochondrial defects were observed in shMeg3 C2C12 cells, 
it is difficult to disentangle this functional perturbation from other noncoding RNAs in 
the locus, which are presumably downregulated in response to chronic Meg3 knockdown 
(Wust et al. 2018, Das et al. 2015). 
RNAseq revealed that thousands of transcripts were differentially expressed in 
shMeg3 C2C12 cells. Despite the expected repressive function of Meg3 based on its 
interaction with Ezh2 in C2C12 myoblasts, RNAseq did not indicate bias towards 
transcriptional up- or down-regulation. These results are consistent with a satellite cell-
specific knockout of Ezh2, which also did not result in global derepression of the 
transcriptome (Juan et al. 2011). 
Analyses of the shMeg3 transcriptome revealed reprogramming of epithelial-
mesenchymal gene expression, which was corroborated by analyses of EMT markers and 
cellular behavior assays. I found that, while vimentin protein levels remained unchanged, 
N-cadherin and Snai2 were both upregulated in shMeg3 C2C12 cells. Given these two 
markers have been shown to modulate aspects of myogenic differentiation progression 
(Table 1.1), their enrichment could pose as bottlenecks to myogenic differentiation. 
Functional EMT characterization revealed that shMeg3 C2C12 cells display enhanced 




fusion complexes. However, seeding these cells on glass yielded modest fusion 
improvements and did not improve differentiation marker expression in shMeg3 cells. 
Taken together, these data suggest that shMeg3 C2C12 cells undergo an identity shift 
towards enhanced mesenchymal character and internal defects that suppress myogenic 







Figure 3.1 Meg3 is enriched in proliferating C2C12 myoblasts. Meg3 transcripts were most 
enriched during proliferation (prolif.), downregulated upon reaching confluence (day 0 diff.), and 






Figure 3.2 Evaluation of various Meg3 knockdown modalities in C2C12 cells. In proliferating 
C2C12 myoblasts, qPCR expression profiling revealed that GapmeRs were not sufficient for 
Meg3 knockdown. In contrast, shRNA-based Meg3 knockdown strategies targeting a conserved 
motif in Meg3 M-IV domain achieved significant Meg3 transcript downregulation. Brightfield 
microscopy on day 3 differentiation showed that transient shMeg3 knockdown modalities by 
adenoviral transduction (Adenovirus) or lipofectamine transfection (FuGENE6) yielded modest 
myogenic impairments, but both heterogenous (het.) and clonal (clone) populations derived from 







Figure 3.3 Chronic Meg3 knockdown downregulates Dlk1-Dio3 lncRNAs in C2C12 
myoblasts. Expression profiling of downstream Dlk1-Dio3 locus lncRNAs Rian and Mirg 
indicated that, while only one or the other lncRNA was downregulated with transient shMeg3 
knockdown modalities, such as adenoviral transduction (Adenovirus) or lipofectamine 
transfection (Fugene 6), chronic Meg3 knockdown (FuGENE6 + G418) resulted in pan-







Figure 3.4 Meg3 is required for expression of numerous myogenic transcripts and 
contractile protein expression in C2C12 myotubes. A. Expression profiling by qPCR indicated 
unchanged Myf5 transcript levels, but significant reduction in other myogenic differentiation 
markers in day 3 differentiated shMeg3 myotubes (n=3). B. Western blot quantification of MF20 







Figure 3.5 Meg3 is required for contractile protein expression and myogenic fusion of 
C2C12 cells. Immunofluorescence quantification at day 3 differentiation revealed that MYH4 is 
markedly reduced i shMeg3 C2C12 clones. Quantification of nuclei within α-actinin cell-






Figure 3.6 Extended differentiation timeline does not improve shMeg3 phenotype. 
Immunofluorescence quantification at day 7 differentiation revealed that MYH4 is markedly 
reduced in shMeg3 C2C12 clones. Quantification of nuclei within α-actinin cell-boundaries show 








Figure 3.7 Transient human MEG3 overexpression is not sufficient to rescue shMeg3-
dependent differentiation and fusion impairments. Immunofluorescence quantification at day 
3 differentiation revealed that MYH4 downregulation and reduced fusion index persists with 







Figure 3.8 Stable human MEG3 overexpression profiling. qPCR quantification confirmed 
overexpression of human MEG3 in shLacZ and shMeg3 myoblasts relative to β-galactosidease 
controls (left panel), and quantification of endogenous Meg3 transcript levels (right panel) 







Figure 3.9 Stable MEG3 overexpression is sufficient to rescue shMeg3-dependent 
differentiation and fusion impairments.  A. Human MEG3 restored both MYH4 expression and 
fusion index in shMeg3 myotubes (n=6 MYH4, n=3 fusion index). B. qPCR expression profiling 
of heterogeneous rescue clones revealed an increase in Mef2C, Ckm, MyoD and Myog levels in 
shMeg3 + MEG3 myotubes. MYH4 = myosin heavy chain 4 (Proteintech antibody), MF20 = 
myosin heavy chain 4 (DHSB antibody), Myf5 = myogenic factor 5, MyoD = myogenic 
differentiation 1, Mef2C  = myogenic enhancing factor-2 C, Myog = Myogenin, Ckm = Muscle 







Figure 3.10 Meg3 modulates C2C12 myoblast proliferation. Quantification of BrdU+ nuclei 







Figure 3.11 Meg3 modulates C2C12 myoblast proliferation and viability. Cleaved caspase 3 
assay (left) revealed higher apoptosis in shMeg3 myoblasts and myotubes relative to control 
(n=3). Cell Titer Blue viability assay (right) indicated reduced viability in shMeg3 myoblasts and 







Figure 3.12 shMeg3 myoblasts display reduced mitochondrial mass. C2C12 myoblasts and 
myotubes were pulsed with MitoTracker CMXRos, and co-stained with α-actinin. Quantification 
of Mitotracker (restricted to α-actinin+ cells) indicated reduced mitochondrial signal in shMeg3 
myoblasts, but not myotubes (n=3). Both treatment groups displayed increased MitoTracker 







Figure 3.13 Increased confluence is not sufficient to rescue shMeg3-dependent 
differentiation and fusion impairments. shMeg3 myoblasts were seeded at increasing densities 
to counteract the effect of cell death and reduced proliferation. Functional improvements in 






Figure 3.14 Transcriptomic profiling of shMeg3 C2C12 myotubes. RNAseq yielded a global 
heatmap (left) of 4884 dysregulated transcripts, with 2561significantly upregulated (red) and 
2323 significantly downregulated (blue) as defined by p < 0.05. Heatmap of Broad GSEA 








Figure 3.15 Dysregulated biological pathways in shMeg3 C2C12 myotubes indicated by 
Ingenuity Pathway Analysis. Stacked bar graphs indicate proportions of upregulated (red) and 
downregulated (green) genes that comprise the top 20 dysregulated biological pathways, which 
include RhoA-related pathways (RhoA signaling, RhoGDI signaling, Signaling by Rho Family 







Figure 3.16 shMeg3 C2C12 myotubes display reduced epithelial, and subset of increased 
mesenchymal transcripts. qPCR expression profiling indicated significant downregulation of 
epithelial Plakophilin and PatJ transcripts in shMeg3 myotubes, with simultaneous upregulation 







Figure 3.17 Mesenchymal marker N-cadherin is enriched in shMeg3 C2C12 myotubes. 
Cadherin switching was assessed by qPCR (left) and Western blot (middle, right) quantification 
of E-cadherin (Cdh1) and N-cadherin (Cdh2) in day 3 myotubes. Cdh1 transcripts were 
significantly downregulated in shMeg3 myotubes relative to shLacZ controls (n=3), but Cdh1 
protein signal from myotubes lysates was extremely faint (n=4). Cdh2 transcripts were 







Figure 3.18 Mesenchymal marker Vimentin is not changed in shMeg3 C2C12 myotubes. 







Figure 3.19 Mesenchymal marker Snai2 is upregulated in shMeg3 C2C12 myoblasts and 
myotubes. Subconfluent C2C12 myoblasts and day 3 differentiated myotubes were examined for 
Snai2 nuclear intensity, and immunofluorecent quantification indicated that Snai2 was 







Figure 3.20 Cell-cell contacts are reduced in migrating shMeg3 C2C12 myoblasts. Scratch-
wound assays revealed no detectable change in wound-healing efficiency, as measured by % 
scratch area (n=3). Brightfield (BF) microscopy of wound-healing morphology differed between 
shLacZ control and shMeg3 clones, with a higher proportion of myoblasts invading the scratch 







Figure 3.21 shMeg3 myoblasts require longer trypsinzation to detach. Quantification of cells 
recovered over time during trypsinization revelaed that shMeg3 myoblasts require significantly 







Figure 3.22 Substrate deprivation has modest effects on shMeg3 C2C12 fusion. When 
differentiated upon a substrate-deprived surface (glass), shMeg3 myoblasts had no change on 
MYH4 expression (n=3) or fusion of cells with ≥3 nuclei, but did exhibit reduced quantities of 
myotubes with 1- and 2- nuclei relative to shMeg3 controls differentiated on 0.1% gelatin (n=3). 
Differentiation atop glass also significantly reduced shLacZ MYH4 signal and quantity of 






Table 3.1 Hallmark gene set summary for shMeg3 C2C12 myotubes. Table conveying the top 
10 up (red) and down (blue) - regulated Hallmark biological states and cellular processes, as 







Table 3.2 Ingenuity Pathway Analysis summary for shMeg3 C2C12 myotubes. Qiagen 
Ingenuity Pathway Analysis (IPA) software performed with significantly dysregulated transcripts 
(p<0.05) lists TGFβ1 and p53 activation as Top Upstream Regulators, and lists various Rho 






CHAPTER FOUR: MOLECULAR MECHANISMS OF DIFFERENTIATION 
DEFECTS OBSERVED IN MEG3-DEFICIENT C2C12 MYOBLASTS 
 
4.1 Introduction  
 During myogenesis, input from numerous signaling pathways are integrated to 
fine-tune proliferation, fusion, and differentiation of muscle cells. In postnatal myoblasts, 
Notch signaling is required for proper spindle assembly and mitotic expansion myoblasts 
(Liu et al. 2018), whereas downregulation of Shh is associated with impaired MyoD 
expression and fibrosis (Straface et al. 2009, Piccioni et al. 2014). Moreover, while p53 
signaling is essential for proper myoblast expansion, its upregulation has also been shown 
to reverse myoblast activation and return to quiescence (Liu et al. 2018, Flamini et al. 
2018). TGFβ signaling suppresses myogenic differentiation, and is considered a major 
driver of EMT (Rathbone et al. 2011, Delaney et al. 2016, Bakin et al. 2002). 
Orchestrating a subset of transcriptomic changes is Ezh2, the catalytic subunit of PRC2, 
which is deployed transiently as myoblasts proliferate, and gradually downregulated upon 
myotube formation (Juan et al. 2011).  
 In this chapter, I examine functional mechanisms that contribute to shMeg3 
C2C12 differentiation impairments. Using RNAseq data as a guide, I attempt to restore 
myogenic differentiation to shMeg3 C2C12 cells by tempering the activity of four 
signaling pathways perturbed by shMeg3 treatment. After identifying TGFβ signaling as 
a key bottleneck to myogenic fusion and differentiation, I examined this pathway in 
detail, by evaluating canonical and non-canonical signaling contributions and identifying 




dysregulation by showing that Meg3 interacts with Ezh2 in wildtype myoblasts, and that 
shMeg3-dependent changes in H3K27me3 deposition are consistent with myogenic 
differentiation impairments. 
4.2 p53 and TGFβ activation drive myogenic differentiation defects  
 In the previous chapter, Hallmark GSEA and IPA analyses indicated 
downregulation of Notch and Shh signaling pathways, and activation of p53 and TGFβ 
signaling pathways (Table 3.1, Table 3.2). Considering these pathways regulate aspects 
of myogenic differentiation, I set out to rectify these signaling pathways by adenoviral 
transgene expression and chemical inhibition.  
Immunofluorescence analysis of day 3 differentiation C2C12 clones transduced 
with constitutively active Notch (Notch-ICD) indicated improved fusion of cells with 2 
nuclei, but not ≥3 nuclei. Moreover, this treatment did not improve cytosolic MYH4 
expression (Figure 4.1). These data suggest that, in spite of shMeg3-dependent Notch 
downregulation, reactivation of this pathway is not sufficient to restore myogenic 
differentiation to these cells. Similarly, adenoviral overexpression of a constitutively 
active Shh transgene (Shh-N) was not sufficient to restore any aspects of myogenic 
differentiation, and this treatment even downregulated MYH4 expression in shLacZ 
control myotubes (Figure 4.2). Chemical inhibition of p53 DNA-binding activity with 
pifithrin completely restored cytoplasmic MYH4 expression to shMeg3 C2C12 
myotubes, yet no change in fusion index was observed (Figure 4.3). Inhibition of the 




cytosolic MYH4 (Figure 4.4). Taken together, these data indicate that aberrant activation 
of p53 and TGFβ signaling pathways drive shMeg3 C2C12 differentiation impairments. 
 
4.3 TGFβ drives myogenic differentiation defects via EMT marker Snai2 
 Considering that TGFβ is a driver of EMT, and encouraged by 
immunofluorescent readouts of differentiation, I then examined the extent of LY-
mediated rescue in further detail. Expression profiling of day 3 differentiation LY-treated 
shMeg3 C2C12 cells by qPCR revealed that TGFβR1 inhibition enhanced all myogenic 
transcripts surveyed relative to untreated shLacZ controls, with the exception of MyoD 
which was only improved relative to untreated shMeg3 controls (Figure 4.5). Moreover, 
expression analysis of day 3 differentiation myotubes by Western blot indicated that 
Myh4 expression was restored in LY-treated shMeg3 C2C12 myotubes (Figure 4.6). 
BrdU incorporation assays revealed that TGFβR1 inhibition with LY was sufficient to 
improve cell-cycling in proliferating shMeg3 C2C12 myoblasts, yet CellTiter-Blue 
viability assays suggested that LY-treatment reduced viability in both shLacZ and 
shMeg3 C2C12 cells (Figure 4.7). Taken together, these data suggest that TGFβR1 
inhibition is sufficient to restore numerous aspects of myoblast homeostasis and 
myogenic differentiation to shMeg3 C2C12 cells. 
Given that EMT was enhanced in shMeg3 C2C12 cells, I examined LY-treated 
cells for attenuation of EMT markers. Expression profiling by qPCR indicated that 
epithelial markers were enriched in LY-treated C2C12 cells, and yet only fibronectin 
transcript levels were restored in day 3 LY-treated shMeg3 C2C12 cells. Examination of 




expression was counterintuitively enhanced with LY treatment, regardless of shRNA 
background, while epithelial E-cadherin was unaffected, and very lowly expressed in day 
3 myotubes (Figure 4.9). As shown in Figure 4.10, vimentin expression was 
downregulated in shLacZ myotubes treated with LY, yet shMeg3 C2C12 myotubes were 
unaffected, suggesting that unlike shLacZ cells, shMeg3 cells express vimentin in a 
TGFβR1-independent manner. Immunofluorescent examination of nuclear Snai2 protein 
intensity showed that nuclear Snai2 was downregulated with LY treatment in both 
proliferating and differentiated C2C12 cells, regardless of shRNA background (Figure 
4.11). Taken together, these data suggest that TGFβR1 signaling is required for shMeg3-
dependent upregulation of mesenchymal marker Snai2, but not N-cadherin or vimentin. 
To evaluate the functional contributions of TGFβR1-dependent Snai2 
upregulation, I treated differentiating C2C12 clones with siRNAs targeting Snai2. As 
shown in Figure 4.12, siSnai2 treatment significantly downregulated Snai2 protein levels 
in both proliferating myoblasts and differentiated myotubes, regardless of shRNA 
background. Immunofluorescent analysis of siSnai2-treated cells revealed improved 
fusion index, and no change in cytosolic MYH4 levels (Figure 4.13), which was 
consistent with LY-treated rescue shown in Figure 4.4. These data strongly suggest that 
shMeg3-mediated TGFβR1 activation drives aberrant Snai2 upregulation, which impairs 
myogenic fusion. Finally, combination of siSnai2 treatment with p53 inhibitor pifithrin 
improved MYH4 levels and restored fusion to shMeg3 cells (Figure 4.14), suggesting that 





4.4 Non-canonical TGFβ RhoA activation drives cytoarchitectural defects 
 TGFβ signaling is an integration of canonical Smad2/3 signaling, and non-
canonical branches of p38 MAPK and RhoA-mediated signaling (Xu et al. 2018, Dituri 
et al. 2018, Guo et al 2009). To evaluate these branches of TGFβ signaling for 
contributions to shMeg3 C2C12 differentiation impairments, I treated cells with chemical 
inhibitors targeting these pathways. As shown in Figure 4.15, inhibition of canonical co-
factor Smad3 with SIS3 treatment did not improve cytosolic MYH4, nor did it improve 
fusion index. Treatment with SB203580, a p38 MAPKα/β inhibitor, improved fusion of 
cells with 2 nuclei, but not ≥3 nuclei, and had no effect on MYH4 expression (Figure 
4.16). Treatment with Y-27632, an inhibitor of RhoA-mediated ROCK1/2 activity, fully 
restored fusion index, and did not improve MYH4 expression in day 3 shMeg3 C2C12 
myotubes (Figure 4.17). Taken together, these data suggest that fusion defects observed 
in shMeg3 C2C12 cells are contingent on non-canonical TGFβ-mediated RhoA signaling. 
 Considering RhoA modulates actin-cytoskeleton dynamics, I examined α-actinin-
stained samples for organizational changes. Confocal microscopy revealed that α-actinin 
was ventrally enriched in shMeg3 C2C12 myotubes –resembling stress fibers – whereas 
α-actinin distribution was much more uniform in control shLacZ myotubes, which is 
more consistent with sarcomeric organization (Figure 4.18). Importantly, treatment with 
ROCK1/2 inhibitor Y-27632 depolarized α-actinin enrichment in shMeg3 C2C12 cells 
(Figure 4.17). These data suggest that aberrant RhoA signaling promotes ventral α-actinin 




4.5 Meg3 interacts with PRC2 in C2C12 myoblasts  
 Based on the established interaction between Meg3 and the PRC2 subunit Ezh2 
(Zhao et al. 2010, Kaneko et al. 2014, Das et al. 2015), I aimed to evaluate shMeg3 
C2C12 clones for perturbations in PRC2 activity. Immunofluorescent examination of 
Ezh2 in C2C12 clones indicated that nuclear Ezh2 is unchanged in proliferating shMeg3 
clones, but export of Ezh2 to the cytoplasmic compartment was greatly reduced in 
shMeg3 clones on day 3 differentiaiton (Figure 4.19). To assess whether Meg3-PRC2 
interactions exist in C2C12 myoblasts, I performed native RNA-immunoprecipitation 
(RNA-IP) to determine whether Meg3 interacts with PRC2 in proliferating and 
differentiated C2C12 cells. As shown in Figure 4.20, Meg3 transcripts were enriched 30-
fold in EZH2 RNA-IP assays from wild type C2C12 myoblasts, but other locus lncRNAs 
were not enriched relative to IgG mock controls. Consistent with Ezh2 cytoplasmic 
export observed on day 3, this enrichment was downregulated with differentiation in wild 
type cells (Figure 4.20). These data demonstrate that the previously established Meg3-
PRC2 interaction is conserved in myoblasts, suggesting that Meg3 may serve as an 
epigenetic scaffold in muscle. 
4.6 PRC2 activity is modified in Meg3-deficient C2C12 cells  
 To assess for PRC2-mediated changes underlying the shMeg3 clone phenotype, I 
performed chromatin immunoprecipitatipn (ChIP) for the PRC2 catalytic component 
Ezh2 (Figure 4.21), as well as its signature epigenetic mark H3K27me3 (Figure 4.22) on 
day 3 differentiation. Because COVID19 imposed restrictions on sequencing resource 




25 distal enhancers with homology to human loci reported by Mondal et al. 2015 (Table 
2.5), and 32 transcription start site (TSS) loci with documented H3K27me3 enrichment in 
mouse muscle progenitor cells (Table 2.6). As shown in Figure 4.21, enrichment over 
IgG-mock was detected for a subset of Ezh2-precipitated loci, with shMeg3 broadly 
enriched over shLacZ clone immunoprecipitated-loci. Unfortunately, Ezh2 
immunoprecipitates yielded generally low percentage of input for all loci surveyed, 
which correlated with cytoplasmic localization of Ezh2 at day 3 differentiation (Figure 
4.19). In contrast, H3K27me3 immunoprecipitates were robustly enriched over IgG-mock 
(Figure 4.22), and differences in enrichment were observed across  a spectrum of loci. 
These data suggest that Meg3 interacts with PRC2, and is required for its normal 
H3K27methyltransferase activity.  
Several TGFβ loci were subsequently examined for repressive H3K27me3 
enrichment (Figure 4.23). Notably, TGFβ signal ligands Tgfβ1 and Tgfβ2, as well as 
canonical signaling component Smad2 exhibited reduced H3K27me3 enrichement in 
their TSS and distal enhancers, respectively. Moreover, H3K27me3 was enriched at the 
TSS of Ltbp2 and, to a lesser extent, Ltbp4, which are required for restriction of TGFβ 
ligand bioavailability. These findings suggest that abnormal Ezh2 recruitment to TGFβ-
loci contributes to aberrant TGFβ activation observed in shMeg3 C2C12 cells, and 
prompted further investigation into Ezh2 activity. 
The distal enhancer of BMP4-antagonist Smad6, which competes with the TGFβ 
cofactor Smad4 for Smad1/5/8 binding, displayed markedly reduced H3K27me3 




Smad6 activity, I treated differentiating myoblast clones with BMP4, and examined for 
phenotypic improvements with immunofluorescence imaging. As shown in Figure 4.24, 
BMP4-treated shMeg3 C2C12 cells showed a modest increase in MYH4, but did not 
display any fusion enhancements in response to BMP4 treatment. Given the robustness of 
this shMeg3 C2C12 myogenic impairment with BMP4 treatment, these observations 
reinforce that epigenetic perturbations likely drive the aberrant TGFβ signaling observed 
in shMeg3 cells. 
To more definitively examine whether Ezh2 activity contributes to shMeg3 
C2C12 differentiation impairments, I inhibited Ezh2 catalytic activity with the small 
molecule Unc1999. Immunofluorescent assessment of H3K27me3 confirmed that 
Unc1999 treatment significantly reduced accumulation of this signature PRC2 epigenetic 
mark (Figure 4.25). Unexpectedly, H3K27me3 was enriched in the nuclei of shMeg3 
C2C12 myoblasts and myotubes. Subsequent differentiation of Unc1999-treated shMeg3 
cells revealed that both MYH4 and fusion were improved with Ezh2 inhibition (Figure 
4.26), suggesting that abnormal Ezh2 activity contributes to the shMeg3 C2C12 
differentiation phenotype. Importantly, the TGFβ-dependent EMT marker Snai2 was only 
downregulated with Unc1999 treatment in shMeg3 myotubes, suggesting Ezh2 activity is 
altered to promote TGFβ-dependent Snai2 in shMeg3 cells, but not shLacZ cells (Figure 
4.25, bottom panel). These findings, coupled with data previously shown in Figure 4.22 
and 4.23, strongly suggest that Meg3 is required for maintenance of a myogenesis-
competent epigenetic state in proliferating myoblasts, in part via H3K27me3-depdendent 




4.7 Discussion  
 In this chapter, I deeply interrogated the pathways and molecular 
mechanisms driving the phenotypic perturbations observed in shMeg3 C2C12 cells. By 
oppositely adjusting up- and down-regulated pathways dysregulated in shMeg3 cells, I 
determined that upregulation of p53 and TGFβ signaling drive shMeg3 myogenic 
differentiation impairments. By examining EMT-markers in TGFβ-inhibited clones, I 
identified Snai2 upregulation as a key output of TGFβ-mediated EMT dysregulation. By 
combining siSnai2 treatment with p53 inhibition, I was able to restore myogenic 
differentiation hallmarks to shMeg3 C2C12 cells. I also found that non-canonical TGFβ 
RhoA signaling perturbed myogenic α-actinin organization required for fusion-
competence. Using RNA-IP, I confirmed that Meg3 interacts with Ezh2 in C2C12 
myoblasts, and using ChIP-qPCR, I identified numerous loci with abnormal H3K27me3 
enrichment in shMeg3 clones. Consistent with these observations, I found that Ezh2 
inhibition improves myogenic differentiation in shMeg3 cells, in part by downregulating 
Snai2 activity. These findings collectively reinforce that, while the phenotypic outputs 
may be cell-context specific, Meg3 has a robust role in modulating p53 and PRC2 
recruitment to TGFβ-loci in a variety of cellular contexts, including myogenic 






Figure 4.1 Activation of downregulated pathway Notch is not sufficient to rescue shMeg3 
differentiation defects. Following adenoviral transduction with EGFP control or constitutively 
active Notch (Notch-ICD, MOI 25), immunoflurescent analyses indicated no change in MYH4 







Figure 4.2 Activation of downregulated pathway Shh is not sufficient to rescue shMeg3 
differentiation defects. Following adenoviral transduction with EGFP control or constitutively 
active Shh (Shh-N, MOI 25), immunoflurescent analyses indicated no improved change in MYH4 







Figure 4.3 Pharmacological inhibition of p53 restores MYH4 but not fusion competence in 
shMeg3 C2C12 myotubes. Following incubation with 30 µM p53 inhibitor Pifithrin-α 
hydrobromide (Pifithrin), myoblasts were induced to differentiate and examined for MYH4 
expression and fusion index. MYH4 in shMeg3 myotubes was restored to shLacZ control levels. 
While multinucleated myotubes occasionally observed, these improvements were not abundant 







Figure 4.4 Pharmacological inhibition of TGFβR1 restores MYH4 and fusion competence in 
shMeg3 C2C12 myotubes. Following incubation with 10µM TGFβR1 inhibitor LY2157299 
(LY), myoblasts were induced to differentiate and examined for MYH4 expression and fusion 
index. LY-treated shMeg3 myotubes adopted an elongated morphology, and displayed increased 
MYH4, decreased myotubes with 1-nuclei, and increased myotubes with 2- and ≥3 nuclei relative 







Figure 4.5 Pharmacological inhibition of TGFβR1 restores myomarker transcript levels in 
shMeg3 C2C12 myotubes. qPCR expression profiling of LY-treated myotubes indicate 
significant upregulation of all myogenic markers surveyed (Myf5, MyoD, Mef2C, Myog, Ckm, 







Figure 4.6 Pharmacological inhibition of TGFβR1 restores MYH4 levels in shMeg3 C2C12 
myotubes Western blot for MYH4 (MF20 antibody) indicated that LY-treatment restored MYH4 







Figure 4.7 Pharmacological inhibition of TGFβR1 improves proliferation, but worsens 
viability in shMeg3 C2C12 myotubes. Immunofluorescent quantification revealed that BrdU 
incorporation (left) is upregulated shMeg3 myoblasts treated with LY. CellTiter-Blue viability 







Figure 4.8 Pharmacological inhibition of TGFβR1 modulates epithelial-mesenchymal 
transcript levels in shMeg3 and shLacZ C2C12 myotubes. qPCR profiling indicated 
upregulation of epithelial transcripts Plakophilin and PatJ regardless of shRNA background 
(n=3). Fibronectin transcript levels returned to normal levels in LY-treated shMeg3 myotubes. 
LY treatment intensified upregulation of Snai2 transcripts in shMeg3 cells, but did not affect 
Twist2 or Mmp9 levels relative to shMeg3 myotubes. shLacZ + LY myotubes displayed reduced 








Figure 4.9 Pharmacological inhibition of TGFβR1 modulates mesenchymal N-cadherin 
levels in shMeg3 and shLacZ C2C12 myotubes A. qPCR indicated that LY2157299 (LY) 
treatment resulted in reduced E-cadherin (Cdh1) transcripts regardless of shRNA treatment, with 
simultaneous upregulation of N-cadherin (Cdh2) transcripts (n=3). B. Western blot revealed 
modest Cdh1 band detection, and quantification of β-tubulin-normalized signal revealed that LY-
treatment restored Cdh1 levels to shMeg3 myotubes, while Cdh1 in shLacZ myotubes remained 
unchanged. While LY treatment did not change Cdh2 expression in shLacZ myotubes, LY-







Figure 4.10 Pharmacological inhibition of TGFβR1 modulates mesenchymal marker 
vimentin in shLacZ, but not shMeg3 C2C12 myotubes. Western blot quantification of 
Vimentin suggests that LY treatment reduced Vimentin expression in shLacZ controls, but did not 







Figure 4.11 Pharmacological inhibition of TGFβR1 modulates mesenchymal marker Snai2 
in shLacZ and shMeg3 C2C12 myoblasts and myotubes. Subconfluent C2C12 myoblasts and 
day 3 differentiated myotubes were examined for Snai2 nuclear intensity, with or without 10µM 
TGFβR1 inhibitor LY2157299 (LY) treatment. Snai2 was significantly enriched in control 
shMeg3 myoblasts for both timepoints, and LY treatment significantly downregulated Snai2 







Figure 4.12 siRNA targeted degradation of Snai2. Treatment with 500ng siRNA targeting 
Snai2 transcripts (siSnai2) resulted in significant Snai2 protein in all siSnai2-treated cells, as 







Figure 4.13 Snai2 knockdown is sufficient to improve fusion to shMeg3 C2C12 myotubes. 
Differentiation of siSnai2 treated cells revealed enhanced fusion index, and while MYH4 was 
enhanced in shLacZ + siSnai2 myotubes relative to shLacZ controls, no change in MYH4 was 







Figure 4.14 Combinatorial Snai2 knockdown and pharmacological p53 inhibition is 
sufficient to rescue differentiation and fusion in shMeg3 C2C12 myotubes. Differentiation of 
myoblasts co-treated with siSnai2 and pifithrin (Pif.) co-treated cells revealed improved 







Figure 4.15 Pharmacological inhibition of Smad3 is not sufficient to restore MYH4 or 
fusion competence in shMeg3 C2C12 myotubes. Following incubation with 5µM Smad3 
inhibitor (SIS3), myoblasts were induced to differentiate. MYH4 expression and fusion index 







Figure 4.16 Pharmacological inhibition of p38 MAPK is not sufficient to restore MYH4, but 
modestly improves fusion competence in shMeg3 C2C12 myotubes. Following incubation 
with 5µM 10µM p38 inhibitor (SB203580), myoblasts were induced to differentiate and 
examined for MYH4 expression and fusion index. SB203580-treated shMeg3 myotubes adopted 
an elongated spindle-like morphology, and fusion quantification indicated decreased myotubes 
with 1-nuclei, and increased myotubes with 2- and ≥3 nuclei relative to shMeg3 control (n=3). 







Figure 4.17 Pharmacological inhibition of Rho GTPase effectors ROCK1/2 is not sufficient 
to restore MYH4, but restores fusion competence in shMeg3 C2C12 myotubes. Following 
incubation with 40µM ROCK1/2 inhibitor (Y-27632), myoblasts were induced to differentiate 
and examined for MYH4 expression and fusion index. Y-27632-treated shMeg3 myotubes 
adopted an elongated morphology, and fusion quantification indicated decreased myotubes with 
1-nuclei, and increased myotubes with 2- and ≥3 nuclei relative to shMeg3 control (n=3). While 
MYH4 expression was enhanced in shLacZ + Y-27632 myotubes, MYH4 levels remained 







Figure 4.18 α-actinin is ventrally enriched in shMeg3 myotubes, and pharmacological 
inhibition of Rho GTPase effectors ROCK1/2 is sufficient to improve α-actinin distribution 
in shMeg3 C2C12 myotubes. Following incubation with 40µM ROCK1/2 inhibitor (Y-27632), 
myoblasts were induced to differentiate and examined by confocal microscopy. Z-stack analysis 
revealed uniform α-actinin distribution in shLacZ controls, but ventral enrichment in shMeg3 
myotubes, which resembled focal adhesions (puncta). Following Y-27632 treatment, shMeg3 







Figure 4.19 Ezh2 is located in the cytoplasm by day 3 differentiation. Immunofluorescent 
analyses of Ezh2 in proliferating myoblasts and day 3 differentiated myotubes indicated 
cytoplasmic export of Ezh2 with myogenic differentiation. Cytoplasmic Ezh2 was reduced in 







Figure 4.20 Meg3 interacts with Ezh2 in myoblasts, but not myotubes. RNA 
immunoprecipitation (RNA-IP) was performed on subconfluent C2C12 myoblast lysates to 
examine for Meg3-PRC2 interaction. Immunoprecipitated RNA was quantified by qPCR, using 
supernatant as an internal normalization control. Compared to normal IgG controls, Meg3 was 
enriched in anti-Ezh2 immunoprecipitates, whereas Rian and Mirg were not (n=3 sets of 60 
pooled plates). Identical examination on differentiation day 3 revealed no significant enrichment 







Figure 4.21 Few Ezh2-immunoprecipitated loci are enriched in shMeg3 C2C12 myotubes. 
ChIP-qPCR of Ezh2 immunoprecipitates revealed that Ezh2 immunoprecipitation was only above 








Figure 4.22 Numerous H3K27me3-immunoprecipitated loci are differentially-enriched in 
shMeg3 C2C12 myotubes. ChIP-qPCR of H3K27me3 immunoprecipitates revealed dynamic 








Figure 4.23 Meg3 knockdown dysregulates Ezh2 activity on TGFβ loci. Analysis of day 3 
differentiation myotubes revealed modulations of H3K27me3 enrichment in the transcription start 







Figure 4.24 shMeg3 C2C12 myotubes are unresponsive to BMP4 treatment. Myoblasts pre-
treated with 5ng/mL BMP4 (BMP) were subjected to differentiation, and examined for changes in 
MYH4 expression and fusion index. BMP4 treated shMeg3 myotubes had improved MYH4 








Figure 4.25 H3K27me3 intensity is upregulated in shMeg3 C2C12 cells in an Ezh2-
dependent manner. Immunofluorescent quantification of H3K27me3 revealed enriched 
H3K27me3 signal in shMeg3 myoblasts and day 3 myotubes, relative to the shLacZ controls. 







Figure 4.26 Pharmacological Ezh2 inhibition is sufficient to improve MYH4, fusion, and 
normal Snai2 levels to shMeg3 myotubes. Differentiation of Unc1999-treated myoblasts 
revealed that shMeg3 MYH4 signal and fusion are both improved with Ezh2 inhibition (n=3). 
Furthermore, immunofluorescent quantification of nuclear Snai2 at this timepoint (bottom graph) 







Figure 4.27 Summary of in vitro Meg3 knockdown findings. In normal C2C12 myoblasts (top 
panel), cells proliferate normally, and during differentiation (arrow) Meg3 interacts with Ezh2 to 
suppress TGFβ1 signaling, which suppresses EMT. In the absence of Meg3, myoblasts exhibit 
increased adhesion and apoptosis, and also display impaired proliferative capacity, mitochondrial 
deficiency, and reduced cell-cell contacts. Upon differentiation, shMeg3 C2C12 myoblasts are 
subjected to abnormal Ezh2 activity, which results in increased H3K27me3 signal. Moreover, 
lack of Meg3-mediated TGFβ1 repression results in upregulation of Snai2, which suppresses 
myogenic fusion and differentiation, as well as aberrant non-canonical TGFβ1 signaling p38 and 
ROCK1/2, which suppress fusion. Not pictured is p53 activity, which contributes to myogenic 








CHAPTER FIVE: MEG3 IN SKELETAL MUSCLE REGENERATION 
 
5.1 Introduction  
 In the event of injury, muscle regeneration is a complex microenvironment, 
wherein numerous cell phylogenies interact to mediate clearance of necrotic tissue and 
postnatal mygogenesis. Although the previous chapters emphasized a role for Meg3 in 
myoblasts in vitro, it is very possible that shMeg3 myoblasts behave differently when 
exposed to microenvironmental cues and substrates. In this chapter, I demonstrate that 
Meg3 is enriched in regenerating muscle, and show that Meg3 expression is required for 
normal muscle regeneration to progress. Using RNAseq, I found parallels between in 
vitro and in vivo transcriptomes of Meg3 knockdown samples, with EMT dysregulation 
among the top pathways dysregulated in vivo. Using immunostaining, I characterize EMT 
perturbations in the regenerating milieu of shMeg3 muscle, and demonstrate that MEG3 
overexpression downregulates a subset of EMT marker transcripts. While satellite cell 
populations did not change with shMeg3 treatment, I found that mesenchymal stromal 
cell populations, and resultant fibrosis, are increased in shMeg3 muscle regeneration. 
Taken together, these findings suggest that Meg3 regulates a variety of functions 
important for postnatal myogenesis in vivo.   
 
5.2 Meg3 knockdown delays skeletal muscle regeneration  
 Based on the striking differentiation impairments imposed by chronic Meg3 




muscle tissue. To this end, I injured mouse Tibialis anterior (TA) muscles by cardiotoxin 
injection (CTX), and profiled temporal changes in Meg3 expression in regenerating 
muscle tissue via qPCR. As shown in Figure 5.1, Meg3 was upregulated relative to 
uninjured controls during time points corresponding with muscle regeneration (Figure 
5.1). I then co-injected CTX with either shMeg3- or shLacZ-specific adenovirus to 
downregulate Meg3 in the regenerating milieu. Considering Meg3 is enriched in 
proliferating myoblasts, I followed up with an additional adenoviral injection 24-hours 
post-injury, such that expanded interstitial cell populations would be subject to adenoviral 
treatment. Whole TA muscles were isolated from mice at various timepoints to assess for 
shMeg3-dependent regeneration perturbations, which revealed prominent fibrotic regions 
(Figure 5.2, arrowheads). RNA collected from day 3 regeneration, 48-hours post-
transduction, revealed that knockdown of Meg3, but not Rian or Mirg was achieved, 
suggesting this phenotype was specific to Meg3 downregulation. Interestingly, Meg3 
transcript levels were upregulated by post-injury day 7 (Figure 5.2). 
 To assess for regeneration defects, I stained transverse muscle sections with 
laminin and measured the cross-sectional area of regenerating myofibers. As shown in 
Figure 5.3, cross-sectional area was reduced in shMeg3 muscle for all timepoints 
surveyed. This was further corroborated by myofibers size and distribution plots, which 
indicated enrichment of small-diameter regenerating myofibers in shMeg3, but not 




5.3 Transcriptomic profiling of regenerating shMeg3 skeletal muscle  
 To evaluate for transcriptomic perturbations in an unbiased fashion, I performed 
RNAseq, GSEA, and IPA on day 7 regenerating shMeg3 muscle. Global transcriptomic 
analysis revealed thousands of significantly up- and down-regulated transcripts (Figure 
5.5), on par with transcriptomic perturbations observed in vitro (Figure 3.14). Hallmark 
GSEA highlighted EMT as a top upregulated pathway (Table 5.1), and both p53 and 
TGFβ1 were among the top upstream regulators identified by IPA (Table 5.2). 
Furthermore, analyses suggested myogenic and mitochondrial deficiencies, increased 
apoptosis (Table 5.1, Table 5.2, Figure 5.6), and upregulation of actin-cytoskeleton 
dynamics (Figure 5.6). Taken together, these data reflect extensive transcriptomic 
perturbations in shMeg3-treated muscle regeneration, and highlight considerable parallels 
between shMeg3 transcriptional dysregulation in vivo and in vitro. 
5.4 EMT marker dysregulation in shMeg3 skeletal muscle  
 Noting that EMT was among the upregulated Hallmark pathways, I examined 
shMeg3 muscle for perturbations in EMT marker expression. Expression profiling by 
qPCR revealed no change in epithelial markers, and that a subset of mesenchymal 
markers, namely Fibronectin, Snai2, and N-cadherin were transcriptionally upregulated 
in day 7 shMeg3 regenerating muscle (Figure 5.7).  
 To more thoroughly evaluate EMT marker dysregulation, I immunostained day 7 
transduced muscle sections and quantified the frequency of mesenchymal marker-
presenting interstitial cells, as well as the abundance per interstitial cell, in the 




cadherin protein at the cellular level revealed that its expression was largely restricted to 
Pax7+ satellite cells. Although N-cadherin intensity per satellite cell was unchanged, the 
percentage of satellite cells expressing N-cadherin was significantly increased in shMeg3 
muscle (Figure 5.8). Muscle sections were also stained for E-cadherin, but this protein 
was undetectable. These data suggest that Meg3 is required to downregulate the 
prevalence of N-cadherin-expressing satellite cells in regenerating muscle. 
 Snai2 was detected in both Pax7+ satellite cells and Pax7- interstitial cells, as well 
as regenerating myofibers with centrally located nuclei, but the abundance of these 
Snai2+ cell populations did not change with shMeg3 treatment (Figure 5.9). All Snai2+ 
cells displayed increased cytoplasmic Snai2, however only satellite cells displayed 
increased nuclear Snai2 signal in comparison to shLacZ controls (Figure 5.9). These data 
suggest that Meg3 is required for downregulation of Snai2 transcriptional repressor 
activity in Pax7+ satellite cells. 
As shown in Figure 5.10, the intermediate filament protein vimentin was detected 
in both Pax7+ satellite cells and Pax7- interstitial cells in the regenerating muscle 
microenvironment. While the overall percentage of vimentin+ cells was increased, 
vimentin+ satellite cells were modestly reduced (Figure 5.10). Interestingly, vimentin 
stain appeared morphologically abnormal in shMeg3 samples, and vimentin protein 
signal per cell was reduced in Pax7- interstitial cells (Figure 5.10). Analysis of vimentin 
at a later day 14 timepoint revealed more pronounced abundance of vimentin+ cell 
populations in regenerating shMeg3 muscle, and in contrast to day 7 (Figure 5.10), 




which may be attributable to an increased abundance of satellite cells at this time point 
(Figure 5.11). Moreover, while vimentin levels were uniform in satellite cells, Pax7- 
interstitial cells displayed vimentin enrichment, whichi could reflect increased 
mesenchymal character in these cells (Figure 5.11).  
Importantly, while day 7 regenerating muscle transduced with human MEG3 did 
not show regeneration defects or changes in satellite cell abundance (Figure 5.12), 
expression profiling of EMT markers by qPCR indicated that MEG3 overexpression 
downregulated mesenchymal markers N-cadherin, Twist2, Snai2, and Mmp9 (Figure 
5.13).Taken together, these data suggest that Meg3 negatively regulates the expression of 
several EMT markers in the regenerating milieu. 
 
5.5 Mesenchymal stromal cells increase with Meg3 knockdown  
 Noting that the abundance of satellite cells was increased at day 14 post-injury 
(Figure 5.11), I examined an earlier time point to discern whether this increased 
abundance was the result of increased satellite cell proliferation. Immunofluorescent 
analysis of the proliferation marker Ki67 indicated that this protein was enriched in 
shMeg3 muscle regeneration, yet this signal was not specific to Pax7+ satellite cells 
(Figure 5.14). This was further corroborated by evaluating the frequency of Ki67+ cell 
populations, which showed that Pax7- interstitial cells, but not satellite cells, harbored 
Ki67 signal at increased frequencies (Figure 5.14). Importantly, no change in the 
abundance of Pax7+ satellite cells was observed at this timepoint (Figure 5.14). Taken 




regenerating muscle, but may be required to suppress proliferation of other interstitial cell 
types. 
 Considering Meg3 is expressed in mesenchymal stromal cells (Figure 1.9), I 
quantified the abundance of these cells using mesenchymal stromal cell-specific marker 
PDGRα in day 7 regenerating muscle. As shown in Figure 5.15, both the overall amount 
PDGFRα protein signal and the abundance of PDGFRα+ cells were upregulated in 
shMeg3 regenerating muscle. These data indicate that Meg3 is required to maintain the 
appropriate abundance of mesenchymal stromal cells in the regenerating 
microenvironment. 
 While mesenchymal stromal cells are required for muscle regeneration, their 
abnormal accumulation is associated with fibrosis, a feature observed in dystrophic and 
aged muscle tissue. I therefore assessed day 14 muscle sections for fibrosis using Sirius 
red stain, and confirmed that shMeg3 muscle harbors increased fibrotic collagen 
deposition on day 14 (Figure 5.16). Taken together, these date suggest that, in addition to 
satellite cells, Meg3 regulates mesenchymal stromal cell activity in postnatal skeletal 
muscle regeneration. 
5.6 Discussion  
 The regenerating microenvironment harbors increased complexity for assessing 
the biological relevance of Meg3 in muscle regeneration. Here, I report that Meg3 is 
upregulated with skeletal muscle injury, and show that Meg3 is required for normal 




regenerating muscle, with numerous aspects of regeneration modulated with shMeg3 
treatment.  
IPA indicated enhanced p53 activation, which has been shown to drive satellite 
cell reversion from activation to quiescence (Flamini et al. 2018). Therefore, it is very 
much possible that muscle regeneration impairments were a consequence of activated 
satellite cell reversion, wherein satellite cells expanded normally, but failed to commit to 
myogenic differentiation. Indeed, cell populations appeared to accumulate at day 14 post-
injury, with reduced myofiber cross-sectional area – a readout of myogenic fusion – 
observed at every time point analyzed. This interpretation would be consistent with the 
increased prevalence of N-cadherin observed in shMeg3 satellite cells, as this 
mesenchymal marker anchors quiescent satellite cells to the basal lamina of established 
myofibers (Goel et al. 2017). Moreover, increased Snai2 activity, which prevents 
myogenic differentiation, was observed in regenerating satellite cells. This mesenchymal 
marker is driven by TGFβ signaling, which was predicted by IPA to be an upstream 
regulator of the shMeg3 phenotype. Accordingly, in addition to inputs from p53 and N-
cadherin, the enhanced Snai2 activity in satellite cells likely stunted the progression 
towards myogenic differentiation. In a complementary experiment, both N-cadherin and 
Snai2 transcripts were downregulated in regenerating muscle treated with MEG3 ectopic 
expression. Finally, the observed vimentin enrichment in day 14 shMeg3-treated satellite 
cells may reflect fibrogenic conversion – a consequence of prolonged failure to fuse or 
return to the satellite cell niche (Stearns-Rider et al. 2017, Zhou et al. 2019). Thus, Meg3 




while the precise behavioral changes in satellite cells require more detailed investigation, 
these data suggest that Meg3 is required for satellite cell-mediated myogenesis in vivo.  
While shMeg3 treatment did not impact proliferation of satellite cells, its 
downregulation resulted in expansion of mesenchymal stromal cell populations at day 7, 
and subsequent fibrotic collagen deposition at day 14 post-injury. Mesenchymal stromal 
cells are vital regulators of satellite cell expansion and activition (Bentzinger et al. 2012, 
Murphy et al. 2011), so it is feasible that expansion of mensenchymal populations 
enabled satellite cells to overcome shMeg3-mediated perturbations in proliferation and 
activation. Lastly, it is important to acknowledge that increased mesenchymal stromal 
cell abundance skewed the transcriptomic profile observed in RNAseq analyses, and 
moreover, that these measurements are an average of multiple cell population 
transcriptomes. Thus, while the regenerating microenvironment is complicated by its 
multicellularity, it appears that Meg3 modulates cellular activities, including EMT 






Figure 5.1 Meg3 is upregulated in regenerating skeletal muscle. Temporal Meg3 expression 
profiling by qPCR was performed on regenerating mouse Tibialis anterior (TA) muscle tissue 
harvested before (uninjured), and on the indicated days after cardiotoxin injection (+CTX). Meg3 
lncRNA transcripts were upregulated following CTX-induced injury, which are injury timepoints 






Figure 5.2 Meg3 knockdown impairs injury-induced skeletal muscle regeneration. qPCR 
analysis of Dlk1-Dio3 lncRNAs (left panel) suggests adenoviral shMeg3 specifically targeted 
Meg3, without affecting other lncRNAs derived from the polycistron at day 3 post-injury (n=3). 
Whole mount morphology of regenerating muscles (middle panel) injected with shLacZ or 
shMeg3 adenovirus are shown at timepoints examined. Black arrows indicate injured regions. At 
day 7 post-injury, endogenous Meg3 levels are elevated in shMeg3 relative to shLacZ controls, 






Figure 5.3 Cross-sectional area is reduced in shMeg3 knockdown TA muscle regeneration. 
Cross-sectional area (CSA) of laminin-ensheathed regenerating myofibers was measured for days 







Figure 5.4 Small myofibers are abundant in shMeg3 TA muscle regeneration. Size and 
distribution of myofibers corroborated cross-sectional area findings shown in Figure 5.4, with 







Figure 5.5 Transcriptomic profiling of shMeg3 TA muscle regeneration. RNAseq yielded a 
global heatmap (left) of 6,307 dysregulated transcripts, with 3,285 significantly upregulated (red) 
and 3,022 significantly downregulated (blue) as defined by p<0.05. Heatmap of Broad GSEA 
Hallmark analysis (right) indicated coherent upregulation coherent upregulation of well-







Figure 5.6 Dysregulated biological pathways in shMeg3 TA muscle regeneration indicated 
by Ingenuity Pathway Analysis. Stacked bar graphs indicate proportions of upregulated (red) 
and downregulated (green) genes that comprise the top 20 dysregulated biological pathways, 
which include metabolic pathways (Mitochondrial dysfunction, Sirtuin signaling, Oxidative 
phosphorylation, Protein Kinase A Signaling), RhoA-related pathways (Rac signaling, Signaling 
by Rho Family GTPases) and EMT-related pathways (Molecular Mechanisms of Cancer, 







Figure 5.7 Mesenchymal transcripts are modulated in shMeg3 TA muscle regeneration. 
Expression profiling by qPCR indicated no change in E-cadherin, while day 7 shMeg3 muscle 







Figure 5.8 Mesenchymal N-cadherin is upregulated in shMeg3 TA muscle regeneration. 
Immunofluorescence revealed that, while numerous satellite cells were not N-cad+ (red 
arrowheads), N-cad signal was largely restricted to Pax7+ satellite cells in regenerating muscle 
(white arrowheads). Cell quantification (% mononuc. cells) revealed that shMeg3 muscle 
harbored increased abundance of N-cadherin+ satellite cells, whereas levels of N-cadherin per 







Figure 5.9 Mesenchymal Snai2 is upregulated in shMeg3 TA muscle regeneration. 
Immunofluorescence revealed the presence of satellite cells lacking Snai2 (red arrowheads), 
Snai2+ satellite cells (white arrowheads), Snai2+ non-satellite cells (green arrowheads), and 
Snai2+ nuclei in regenerating myofibers (green asterisks). Quantification of Snai2+ cells 
indicated no change in the occurance of Snai2+ nuclei (bar graph, % Snai2+ nuclei). Generalized 
analysis (DAPI) indicated significant upregulation of cytoplasmic Snai2 signal per cell, but no 
change nuclear intensity; Snai2 signal in satellite cells (Pax7+) was increased for both 







Figure 5.10 Mesenchymal Vimentin is modestly upregulated in day 7 (D7) shMeg3 TA 
muscle regeneration. Immunofluorescence revealed the presence of satellite cells lacking 
Vimentin (red arrowheads), Vimentin+ satellite cells (white arrowheads), and Vimentin+ non-
satellite cells (green arrowheads). Cell quantification (% mononuc. cells) revealed increased 
abundance of Vimentin+ mononucleated cells at D7, which could be ascribed to an increase in 
Pax7-/vimentin+ cells. Pax7+/vimentin+ cells were modestly reduced at D7. Vimentin signal per 
cell was downregulated in mononucleated cells at D7, which may reflect shMeg3-specificic 







Figure 5.11 Mesenchymal Vimentin is upregulated in day 14 (D14) shMeg3 TA muscle 
regeneration. Immunofluorescence revealed the presence of satellite cells lacking Vimentin (red 
arrowheads), Vimentin+ satellite cells (white arrowheads), and Vimentin+ non-satellite cells 
(green arrowheads). Cell quantification (% mononuc. cells) revealed increased abundance of 
Vimentin+ mononucleated cells at D14, which could be ascribed to an increase in Pax7-
/vimentin+ cells and Pax7+/vimentin+ cells. Vimentin signal per cell was upregulated in Pax7- 
mononucleated cells, which may reflect shMeg3-specificic differences in Vimentin+ cell 








Figure 5.12 Ectopic MEG3 expression does not adversely impact TA muscle regeneration. 
Ectopic MEG3 expression was observed by qPCR (top left panel) in CTX-injured muscle co-
treated with CMV-MEG3 adenovirus (n=3). Morphology appeared normal (top right), and MEG3 
overexpression did not change day 7 + CTX cross-sectional area (bottom left panel), size & 
distribution of myofibers (bottom middle panel), or Pax7+ cell abundance (red arrowheads, 






Figure 5.13 Mesenchymal markers are downregulated with ectopic MEG3 expression in TA 
muscle regeneration. Expression profiling by qPCR suggests that MEG3 overexpression was 








Figure 5.14 Satellite cell numbers are unchanged in day 7 (D7) shMeg3 TA muscle 
regeneration, but proliferation is upregulated in other interstitial cells. Immunofluorescence 
quantification indicated shMeg3 TA sections harbor increased Ki67 signal (left bar graph). Co-
staining for satellite cell label Pax7 indicated no change in satellite-cell specific Ki67 signal (left 
graph) and no change in satellite cell abundance (white, red arrowheads). Marker quantification 







Figure 5.15 Mesenchymal stromal cells are enriched in shMeg3 TA muscle regeneration. 
Immunofluorescence quantification indicated an increase in PDGFRα signal, as well as increased 







Figure 5.16 Fibrosis is enriched in day 14 (D14) shMeg3 TA muscle regeneration. Sirius red 
fibrosis stain on D14 muscle sections revealed increased fibrotic are in shMeg3 skeletal muscle, 







Figure 5.17 Summary of in vivo Meg3 knockdown findings. A. In normal muscle regeneration 
(top panel), mesenchymal stromal cell populations facilitate skeletal muscle regeneration, and 
populations recede by day 14. However, when Meg3 is depleted, these populations are expanded, 
and correlate with increased collagen deposition and fibrosis. B. Myogenic satellite cells normally 
expand and fuse to repopulate skeletal muscle in the event of injury (top panel). However, when 
Meg3 levels become depleted, myofibers cross-sectional area is strikingly reduced, which 
suggests reduced functional contribution of satellite cell populations. Moreover, an abnormally 
large proportion of satellite cells express the mesenchymal marker N-cadherin on day 7, and 
Snai2 nuclear enrichment is upregulated, which has been shown to suppress myogenic 
differentiation. By day 14 regeneration, satellite cells accumulate and a larger subset display 






Table 5.1 Hallmark gene set summary for shMeg3 TA muscle regeneration. Table conveying 
the top 10 up (red) and down (blue) - regulated Hallmark biological states and cellular processes, 







Table 5.2 Ingenuity Pathway Analysis summary for shMeg3 TA muscle regeneration. 
Qiagen Ingenuity Pathway Analysis (IPA) software performed with significantly 
dysregulated transcripts (p<0.05) lists TGFβ1 and p53 activation as Top Upstream 






CHAPTER SIX: COMPARISON OF MEG3-DEFICIENT TRANSCRIPTOMES 
WITH LITERATURE-BASED PHENOTYPES  
 
6.1 Introduction  
 In the field of muscle biology, basic research can inform strategies that enhance 
myogenesis for real-world applications ranging from in vitro meat production to muscle 
regeneration therapeutics. Existing literature has shown that Meg3 is downregulated with 
muscle aging (Kimmel et al. 2020, Liu et al. 2013), wherein aged satellite cells harbor 
internal defects that preclude their ability to contribute to postnatal myogeneis. In this 
chapter, I relate my in vitro and in vivo shMeg3 experiments to a variety of publications 
in the field of muscle biology. First, I examine genes that facilitate myogenic fusion, and 
show that while only a subset of fusion genes are dysregulated, a variety of transcription 
factors required for myogenic fusion are significantly downregulated in shMeg3 samples. 
Using gene sets enriched for various phases of satellite cell activation, I show that 
shMeg3 transcriptomes most closely resemble early phases of satellite cell activation as 
profiled by Liu et al. 2013. To evaluate signaling pathway perturbations in a myogenic 
context, I compared shMeg3 transcriptomes to muscle-specific profiles of p38, p53, Erk, 
TGFβ, and Ezh2 signaling pathways, which are consistent with phenotypic observations 
reported in previous chapters. Considering transcriptional perturbations could reflect cell 
identity shifts, I evaluated for dysregulation of Hox genes and compared shMeg3 
transcriptomes to gene sets specifically enriched with well-characterized cell ontologies, 
including limb-muscle and non-muscle tissues, and show that, strikingly, shMeg3 




directly compare my shMeg3 transcriptomes to gene sets dysregulated in aged muscle, 
and show that a large subset of shMeg3-dysregulated genes parallel age-related gene 
expression trends in both mouse and human geriatric muscle.  
 
6.2 Satellite activation and fusion  
 During muscle regenerations, satellite cells undergo a series of cell-identity 
transitions that facilitate muscle regeneration, and given the striking differentiation 
defects, I sought to examine which satellite cell state most closely resembles the 
transcriptomes of differentiated shMeg3 samples. To this end, I collected gene sets 
enriched for three phases of satellite cell activity: quiescent satellite cells, which 
corresponds with inactivated satellite cells occupying the stem cell niche, early activation 
(36 hrs) which corresponds with mitotic expansion of satellite cells and transient 
suppression of differentiation genes, and late activation (60 hrs), which corresponds with 
cell cycle exit and commitment to the myogenic lineage (Liu et al. 2013). Interestingly, 
both C2C12 shMeg3 myotubes and shMeg3 TA were most positively enriched for early-
activation, whereas their gene enrichment was negatively enriched for quiescence relative 
to shLacZ controls (Figure 6.1, 6.2). This enrichment was most striking for shMeg3 TA 
muscle, where the vast majority of genes in the 36 hrs set were upregulated, and the 
markedly downregulated in the control (Figure 6.2). These data suggest that, while 
shMeg3 samples exhibited myogenesis defects, their gene expression does not reflect 
failure to activate (i.e. stay quiescent), but rather a failure to advance towards late phases 




 Given the dramatic fusion defect in vitro, I next examined fusion genes in shMeg3 
samples to evaluate for deficits in fusion-complex components. As shown in Table 6.1, 
numerous transcripts that directly facilitate myogenic fusion were not affected by shMeg3 
treatment in both C2C12 and TA samples. Notably, Myomaker and Myomixer were 
unchanged with Meg3 knockdown, which was surprising given ectopic expression of 
these proteins is sufficient to induce fusion in non-muscle cell lines (Millay et al. 2014, 
Sampath et al. 2018). Moreover, in spite of observed fusion defects, several fusion-
complex transcripts such as Kirrel, Ehd2, and Fer1L5 were upregulated in either C2C12 
or TA samples. However, the junctional adhesion protein Jam2 was significantly 
downregulated in both TA and C2C12 samples (Table 6.1). Given Jam2 is required for 
myogenic fusion in vertebrates (Currie et al. 2011), it is possible this is a rate-limiting 
defect in shMeg3 fusion competence. 
 To further examine for drivers of shMeg3 fusion impairments, I next explored the 
expression of transcription factors that dictate myoblast fusion in vitro. To this end, I 
compiled a list of transcription factors (TFs) that Rajan et al. experimentally classified as 
being required for C2C12 myoblast fusion, where knockdown of individual TFs in the 
“moderate” category resulted in reduced fusion competence, and knockdown of 
individual TFs in the “severe” category completely blocked C2C12 fusion in vitro. 
Although C2C12 myotubes had already undergone fusion by day 3 differentiation, a large 
subset of TFs were still enriched in shLacZ control compared to shMeg3 C2C12 
myotubes, with numerous TFs in the “severe” category downregulated in shMeg3 




indicated that “moderate” fusion defect TFs were predominantly downregulated, with a 
much smaller subset of “severe” TFs downregulated in shMeg3 TAs (Figure 6.4). These 
findings are consistent with the observed differences in severity of fusion defects, where 
fusion is severe in shMeg3 C2C12 cells, and reduced in shMeg3 TA samples.  
6.3 Myogenic signaling 
 While cell signaling pathways are shared across diverse cell ontologies, the 
functional outputs of their expression can have context-dependent effects on gene 
expression. To better characterize cell signaling dysregulation in shMeg3 samples, I 
compared transcriptomic gene expression profiles to gene sets derived from muscle-
specific cell signaling. 
 Evaluation of p38-dependent signaling in both C2C12 (Figure 6.5) and TA 
(Figure 6.6) samples revealed extensive down-regulation of p38-dependent expression, 
and up-regulation of p38-dependent repression. In light of the modest fusion 
improvements observed with p38 inhibition (Figure 4.16), these findings suggest that, 
while p38 signaling was not highlighted as a dysregulated pathway by standard GSEA 
(Table 3.1, Table 5.1), myblast-specific outputs of p38 activity was severely dysregulated 
in shMeg3 samples. 
 Activated satellite cells exhibit considerable transcriptional heterogeneity in 
activation, which has been attributed to their propensity to revert from activation to 
quiescence, and vice versa, throughout early stages of the muscle regeneration process 
(Cho et al. 2017, Motohashi et al. 2014, Tierney et al 2016). Considering p53 has been 




observed role in driving shMeg3 myogenic differentiation impairments (Figure 4.3, 
Figure 4.14), I examined expression profiling related to these processes in myoblasts. As 
shown in Figures 6.7 and 6.8, both C2C12 and TA shMeg3 transcriptomes showed 
enrichment for genes driven by p53 in myofiber-associated myoblasts, which are thought 
to be activated satellite cells reverting towards quiescence (Flamini et al. 2018). 
Interestingly, genes downregulated by p53 were only negatively-enriched for C2C12 
samples (Figure 6.7), but examination of the shMeg3 TA heatmap for this small gene set 
indicated a large proportion of downregulated transcripts as well (Figure 6.8). 
Examination of genes modulated by ERK1/2 signaling in dispersed myoblasts, which are 
thought to be committed to myogenic differentiation, were coordinately up- and down-
regulated in shMeg3 TA samples in a manner consistent with dispersed myoblasts (Figure 
6.8), whereas C2C12 samples were not (Figure 6.7). Taken together, these expression 
trends may reflect differences in relative proportions of committed vs uncommitted 
myoblasts that drive myogenic differentiation in these two model systems. 
 Given TGFβ1 activation was a major bottleneck to myogenic differentiation in 
vitro, I compared shMeg3 transcriptomes with gene sets derived from TGFβ-stimulated 
myotubes. Suprisingly, the TGFβ-upregulated gene set was negatively enriched in 
shMeg3 C2C12 samples (Figure 6.9), which could reflect the general absence of 
completely differentiated myotubes in shMeg3 C2C12 samples. However, in shMeg3 TA 
datasets, TGFβ-up- and down-regulated gene sets were positively and negatively 




and GSEA (Table 5.1, Table 5.2), these data further suggest that TGFβ signaling is 
upregulated in shMeg3 myotubes in vivo.  
 In previous chapters, I showed that Meg3 interacts with the PRC2 catalytic 
subunit Ezh2 in C2C12 myoblasts, and that inhibition of Ezh2 was sufficient to improve 
myogenesis in shMeg3 C2C12 cells, suggesting Ezh2 function is altered in the absence of 
Meg3. To further evaluate genes dysregulated by loss of Meg3-dependent Ezh2 function, 
I compared shMeg3 samples to genes enriched in Ezh2 knockout satellite cells, which 
display severe proliferation impairments (Woodhouse et al. 2013). A large subset of 
satellite cell Ezh2-repressed transcripts were upregulated in both shMeg3 C2C12 (Figure 
6.11) and TA (Figure 6.12) samples, which may correlate with loci that Meg3 targets for 
PRC2 activity. Indeed, Nfatc1 was the only gene in the Ezh2-dependent set with a locus 
surveyed via ChIP experiments (Figure 4.21), and Nfatc1 transcripts were not only 
upregulated in shMeg3 samples (Figure 6.11, 6.12), but also observed to have reduced 
H3K27me3 enrichment in shMeg3 C2C12 myotubes (Figure 4.21). These findings 
suggest that satellite-cell specific Ezh2 activity is altered in shMeg3 samples, and 
encourage further investigation via ChIP qPCR. 
 Collectively, these data indicate that numerous signaling mechanisms, specifically 
p38, p53, and Ezh2, are at least in-part dysregulated by shMeg3 treatment in C2C12 
differentiation and TA muscle regeneration.  
6.4 Muscle and non-muscle cell ontologies  
 Hox genes are important regulators of the body plan, and their misexpression has 




satellite cell dysfunction (Schworer et al. 2016). I therefore examined for Hox gene 
misexpression in shMeg3 RNAseq data (left panels Figure 6.13, 6.14). In muscle 
progenitor cells, Hoxc10 is normally expressed in quiescent and activated myoblasts 
(Schworer et al. 2016), and Hoxc10 expression was significantly enriched in shMeg3 
C2C12 cells, which may reflect a more nascent progenitor-like state in these samples 
relative to shLacZ controls (Figure 6.13). In contrast to C2C12 shMeg3 samples, Hoxc10 
was downregulated in shMeg3 TA muscle, which may reflect reduced proportions of 
progenitor cells relative to other interstitial cells, such as mesenchymal stromal cells, in 
these samples (Figure 6.14). Examination of other limb-enriched Hox paralogs (Pineault 
et al. 2014), revealed that the chondrocyte-enriched Hoxc11 & keratin-related Hoxc13 
were significantly upregulated in shMeg3 C2C12 cells (Figure 6.13). Importantly, 
Hoxa13 expression has been shown to suppress MyoD expression in C2C12 myoblasts 
(Yamamoto et al. 2004), and while this Hox paralog was downregulated in TA samples 
(Figure 6.14), its expression was upregulated in C2C12 samples (Figure 6.13), suggesting 
Hox gene misexpression reinforced differentiation impairments in this model system. All 
other significantly dysregulated homologs for both shMeg3 model systems were 
downregulated. Taken together, these data suggest that a subset of Hox paralogs were 
differentially expressed in both shMeg3 samples, and suggests that Hoxa13 upregulation 
in shMeg3 C2C12 cells likely reinforced differentiation impairments. 
 Tabula Muris (Figure 1.?) indicated that Meg3 is enriched in two limb muscle 
interstitial cell ontologies: satellite cells and mesenchymal stromal cells. To examine for 




GSEA for genes reported as uniquely enriched in these limb muscle ontologies. As 
shown in the bottom righthand panel of Figures 6.15, the transcriptomic profile of shLacZ 
C2C12 cells was only enriched for a minority of satellite cell genes, and likely reflects 
that these myoblasts are in the process of taking on a myotube cell identity. In contrast, 
shMeg3 C2C12 clones showed enrichment for satellite cell genes, and surprisingly, even 
more enrichment for mesenchymal cell transcripts including various collagen-encoding 
genes, which likely reflects increased mesenchymal character observed in these cells. In 
regenerating TA samples, which harbor both limb muscle ontologies, the majority of 
satellite-cell specific transcripts were upregulated in shLacZ muscle, and mesenchymal 
cell signatures were variable (Figure 6.16). However, for shMeg3 TA samples, satellite 
cell transcripts were negatively enriched, and furthermore, the majority of mesenchymal 
stromal cell transcripts in the gene set were upregulated. These data strongly suggest 
enrichment of mesenchymal stromal cell transcripts in shMeg3 samples, which are 
presumably due to increased mesenchymal character in shMeg3 C2C12 cells, and 
mitotically expanded mesenchymal cell populations in shMeg3 TA regeneration. 
 Considering Ezh2 is an important regulator of cell identity, and that shMeg3 
treatment led to profound transcriptomic dysregulation, I sought to examine for gene 
expression associated with alternative cell types. To this end, I used the BioGPS Mouse 
Cell Type and Tissue Gene Expression Profiles dataset provided by Harmonizome to 
generate gene sets comprised of roughly 300 transcripts upregulated in a spectrum of cell 
and tissue types. GSEA using these Harmonizome-derived gene sets yielded ranked 




evaluated for proportions of up- and down-regulated transcripts for each gene set in the 
list. As expected, skeletal muscle-enriched transcripts were predominantly upregulated 
for both shLacZ C2C12 (Figure 6.17) and TA (Figure 6.18), confirming the presence of 
muscle cell identities in these samples, whereas shMeg3 counterparts were negatively 
enriched for skeletal muscle gene sets – most strikingly in shMeg3 C2C12 cells, where 
the sample lacks preexisting myofibers. A similar trend was observed when examining 
C2C12-enriched gene sets, though it is interesting to note that shLacZ TA samples were 
not as robustly enriched as C2C12 counterparts, which highlights source-specific 
differences between in vitro and in vivo model systems. Of all non-muscle ontologies and 
tissue types surveyed, osteogenic and bone tissue types were markedly enriched in 
shMeg3 samples, and in spite of source-specific differences, this enrichment was 
consistent between C2C12 and TA shMeg3 transcriptomes. Taken together, these 
findings imply that Meg3 is not only important for maintaining a myogenesis-competent 
cell identity, but is also required to safeguard myoblasts from adopting an alternative 
osteoblast-like transcriptomic profile. 
6.5 Aged skeletal muscle 
 Meg3 is significantly downregulated in aged muscle, but muscle aging itself is a 
complicated and poorly understood process (Kimmel et al. 2020, Liu et al. 2013). 
Therefore, rather than examining any particular pathway dysregulated with aging, I 
aimed to compare my transcriptomic datasets with published transcriptomic datasets from 
aged myogenic samples. First, I collected significantly upregulated gene sets derived 




approximately half age-related transcripts were upregulated in control C2C12 myotubes, 
and for all gene sets, a larger subset of these transcripts were enriched with shMeg3 
treatment. Interestingly, while shMeg3 treatment broadly correlated with enrichment of 
age-related transcripts, shLacZ TA samples were more enriched than shMeg3 TA samples 
for the gene set derived from Kimmel et al. Nevertheless, these findings suggest that 
Meg3 is required to suppress a subset of genes aberrantly expressed in aged satellite cells. 
 To further compare shMeg3-treated samples with geriatric muscle, I performed 
GSEA using gene sets up- and down-regulated in mouse (Su et al. 2015) and human 
(Zhou et al. 2019) aged muscle. While age-upregulated transcripts were not positively 
enriched for mouse muscle samples, shMeg3 C2C12 myoblasts displayed positive 
enrichment for human aged-muscle transcripts, and negative enrichment for both mouse 
and human transcripts downregulated with aging (Figure 6.21). Moreover, enrichment 
trends for shMeg3 TA samples paralleled age-related gene sets relative to shLacZ 
controls. These data suggest that, while a considerable proportion of aging-enriched 
transcripts are certainly abundant in control samples, Meg3 knockdown samples more 
strongly resemble age-related expression trends. 
6.6 Discussion  
 Transcriptional stability is essential for cell homeostasis, and thousands of 
transcripts were dysregulated in shMeg3-treated models of myogenesis. In this chapter, I 
utilized publicly available datasets to examine a breadth of transcriptional perturbations 
in shMeg3 samples, and identified transcriptional trends related to muscle-specific 




fusion were counter-intuitively upregulated in fusion-deficient shMeg3 cells, and 
identified Jam2 as the only significantly downregulated fusion gene for both TA and 
C2C12 data sets, which highlights the significance of epithelial adhesion proteins in 
facilitating myoblast fusion. I also found that a variety of transcription factors required 
for C2C12 fusion are significantly downregulated in shMeg3 samples both in vitro and in 
vivo, which further imply that Meg3 is required for fusion. Using gene sets enriched for 
various phases of satellite cell activation, I showed that, relative to shLacZ control 
samples, shMeg3 transcriptomes more closely resemble early phases of satellite cell 
activation in vitro and in vivo. I also examined muscle-specific signaling trends, and 
found that shMeg3 treatment led to abnormal p38-dependent signaling, enhanced 
quiescence-reversion p53 signaling, reduced pro-myogenic Erk1/2 signaling, which 
collectively resemble impaired commitment to myogenic differentiation. Moreover, I 
observed an enriched for a transcriptional profile resembling TGFβ-treated myotubes in 
shMeg3 TA muscle, and derepression of numerous Ezh2-dependent transcripts for both 
model systems, which was consistent with phenotypic observations reported in previous 
chapters. While evaluating cell identity shifts, I identified Hoxa13 upregulation as a 
possible driver of myogenic impairments in shMeg3 C2C12 cells, and observed changes 
in satellite-cell enriched Hoxc10. By comparing shMeg3 transcriptomes to gene sets 
specifically enriched with well-characterized cell ontologies, I found that shMeg3 
samples more closely resemble mesenchymal stromal cells than satellite cells, in 
comparison to shLacZ controls. Strikingly, shMeg3 samples more closely resemble 




myoblasts from adopting an osteogenic cell fate. Finally, I directly compare my shMeg3 
transcriptomes to gene sets dysregulated in aged muscle, and found that a large subset of 
shMeg3-dysregulated genes parallel age-related gene expression trends in both mouse 
and human geriatric muscle. Taken together, these findings suggest that Meg3 modulates 






Figure 6.1 Enrichment of satellite cell state gene sets in shMeg3 C2C12 myotube 
transcriptome. Gene sets were derived from significantly enriched transcripts for stages of 







Figure 6.2 Enrichment of satellite cell state gene sets in shMeg3 TA muscle transcriptome. 
Gene sets were derived from significantly enriched transcripts for stages of satellite cell activity 






Figure 6.3 Enrichment of fusion-competence gene sets in shMeg3 C2C12 myotube 
transcriptome. Gene sets were derived from transcription factor (TF) loss-of-function 






Figure 6.4 Enrichment of fusion-competence gene sets in shMeg3 TA muscle transcriptome 
Gene sets were derived from transcription factor (TF) loss-of-function experiments, which 







Figure 6.5 Enrichment of myoblast-specific p38 gene sets in shMeg3 C2C12 myotube 
transcriptome. Gene sets were derived from satellite cell transcriptomic profiling of p38-







Figure 6.6 Enrichment of myoblast-specific p38 gene sets in shMeg3 TA muscle 
transcriptome. Gene sets were derived from satellite cell transcriptomic profiling of p38-







Figure 6.7 Enrichment of quiescence-activation commitment gene sets in shMeg3 C2C12 
myotube transcriptome. Gene sets were derived from satellite cell transcriptomic profiling of 








Figure 6.8 Enrichment of quiescence-activation commitment gene sets in shMeg3 TA muscle 
transcriptome. Gene sets were derived from satellite cell transcriptomic profiling of p53-







Figure 6.9 Enrichment of myotube-specific TGFβ gene sets in shMeg3 C2C12 myotube 
transcriptome. Gene sets were derived from differentiated myotubes stimulated with TGFβ in 







Figure 6.10 Enrichment of myotube-specific TGFβ gene sets in shMeg3 TA muscle 
transcriptome. Gene sets were derived from differentiated myotubes stimulated with TGFβ in 







Figure 6.11 Enrichment of satellite cell-specific Ezh2 gene sets in shMeg3 C2C12 myotube 








Figure 6.12 Enrichment of satellite cell-specific Ezh2 gene sets in shMeg3 TA muscle 









Figure 6.13 Expression of Hox gene paralogs in shMeg3 C2C12 myotube transcriptome. All 







Figure 6.14 Expression of Hox gene paralogs in shMeg3 TA muscle transcriptome. All 







Figure 6.15 Enrichment of Tabula Muris limb muscle cell ontology gene sets in shMeg3 
C2C12 myoutube transcriptome. Gene sets were derived from Tabula muris consortium 








Figure 6.16 Enrichment of Tabula Muris limb muscle cell ontology gene sets in shMeg3 TA 
muscle transcriptome. Gene sets were derived from Tabula muris consortium supplementary 








Figure 6.17 Enrichment of Harmonizome cell ontology gene sets in shMeg3 C2C12 myotube 
transcriptome. Gene sets were derived from Harmonizome for cell and tissue ontologies, which 








Figure 6.18 Enrichment of Harmonizome cell ontology gene sets in shMeg3 TA muscle 
transcriptome. Gene sets were derived from Harmonizome for cell and tissue ontologies, which 







Figure 6.19 Enrichment of aged satellite cell gene sets in shMeg3 C2C12 myotube 
transcriptome. Gene sets were derived from geriatric satellite cell transcriptomic data evaluating 







Figure 6.20 Enrichment of aged satellite cell gene sets in shMeg3 TA muscle transcriptome. 
Gene sets were derived from geriatric satellite cell transcriptomic data evaluating significantly 






Figure 6.21 Enrichment of aged muscle gene sets in shMeg3 C2C12 myotube transcriptome. 
Gene sets were derived from geriatric whole muscle tissue transcriptomic data, evaluating 
significantly dysregulated transcripts in aged vs young muscle tissue for mouse (Su et al. 2015) or 






Figure 6.22 Enrichment of aged muscle gene sets in shMeg3 TA muscle transcriptome. Gene 
sets were derived from geriatric whole muscle tissue transcriptomic data, evaluating significantly 
dysregulated transcripts in aged vs young muscle tissue for mouse (Su et al. 2015) or human 













Table 6.2: C2C12 Harmonizome cell and tissue ontologies. This table shows the full spectrum 






Table 6.3 TA Harmonizome cell and tissue ontologies. This table shows the full spectrum of 





CHAPTER SEVEN: DISCUSSION 
7.1 Discussion  
 Meg3 is an evolutionarily conserved lncRNA encoded by the polycistronic Dlk1-
Dio3 noncoding RNA locus, and Meg3 transcripts are enriched in embryonic tissues that 
give rise to skeletal muscle (Schuster-Gossler et al., 1998). While two recent publications 
have shown that Meg3 overexpression facilitates myogenesis in skeletal muscle (Cheng 
et al. 2019, Liu et al. 2019), muscle-specific functional characterization of this lncRNA is 
severely lacking. In non-muscle stem cells and cancer tissues, Meg3 functions via 
evolutionarily conserved interactions with tumor suppressor protein p53 and the 
chromatin-remodeling protein PRC2 (Uroda et al. 2019, Sherpa et al. 2018), which have 
muscle-specific functions in satellite cells (Flamini et al. 2018, Juan et al. 2011, 
Woodhouse et al. 2013).Meg3 is classified as a tumor supressor, which has led some 
biologists to speculate that Meg3 could function to restrict myoblast proliferation, yet 
increased Meg3 expression positively correlates with the severity of skeletal muscle 
cancers (Schneider et al. 2014), suggesting the role of Meg3 in muscle progenitors is 
more complex. Therefore, direct characterization of this lncRNA in skeletal muscle 
differentiation is required to begin unraveling its role in muscle biology. 
 In Chapter Three, I generated Meg3-deficient C2C12 cell lines (shMeg3), and 
demonstrated that this lncRNA is required for myogenic differentiation, fusion, and 
homeostasis in vitro. While examining the effect of Meg3 on various cellular processes, I 
found that, despite its classification as a tumor suppressor, shMeg3 treatment surprisingly 




other Dlk1-Dio3 miRNAs, also reduced metabolic activity. While reduced cell-cell 
contacts are known to impair fusion competence, I showed that increased myoblast 
seeding density was not sufficient to overcome differentiation impairments, suggesting 
Meg3 knockdown robustly impaired the formation of syncytial myotubes.  
 To identify cellular pathways affected by Meg3 knockdown in myogenic 
differentiation, I performed RNAseq, and transcriptomic analyses revealed that shMeg3 
treatment dysregulated thousands of transcripts and numerous pathways, with EMT 
among the most aberrantly upregulated gene sets. I then showed that the mesenchymal 
adhesion protein N-cadherin, as well as the EMT-promoting transcriptional repressor 
Snai2, were abnormally upregulated in shMeg3 C2C12 cells during myogenic 
differentiation.  
I then sought to determine whether EMT marker enrichment correlated with 
enhanced mesenchymal behavior. Adhesion is functionally modified by EMT, where 
mesenchymal cells reduce cell-cell adhesion and predominantly engage with ECM 
substrate; I found that shMeg3 myoblasts required significantly more time to trypsinize to 
completion, and while invasiveness was unchanged, shMeg3 myoblasts shared fewer cell-
cell contacts during scratch-wound assays. To examine whether the presence of ECM 
substrate modified myogenic differentiation, I differentiated myoblasts atop a glass 
substrate, and while control cells were negatively affected by this treatment, shMeg3 
myoblasts had modestly improved fusion index. Collectively, these data suggest that 




In Chapter Four, I further interrogated the molecular mechanisms of shMeg3-
differentiation impairments identified in Chapter Three. Guided by transcriptomic 
analyses, I transduced shMeg3 cells with constitutively active Notch and Shh signaling 
transgenes and determined these treatments were unable to restore myogenic 
differentiation to shMeg3 C2C12 cells. Furthermore, I used chemical inhibitors to reduce 
the activity of upstream regulators p53 and TGFβ, which are also well-characterized 
Meg3-interacting proteins. I determined that aberrant p53 signaling suppressed 
expression of differentiation markers, whereas TGFβR1 inhibition predominantly 
restored fusion. Detailed characterization of shMeg3 TGFβR1-inhibited cells revealed 
that numerous hallmarks of myogenic differentiation increased with inhibitor treatment, 
suggesting aberrant TGFβ1 activation is an anti-myogenic consequence of shMeg3 
treatment.  
To evaluate for TGFβ1-mediated EMT upregulation, I examined EMT marker 
expression in TGFβR1-inhibited C2C12 cells, and found that Snai2 upregulation was 
contingent on TGFβ1 signaling in shMeg3 C2C12 cells. I subsequently targeted Snai2 for 
siRNA-mediated degradation, and demonstrated that this EMT marker modulates 
myogenic fusion impairments. Furthermore, I showed that siSnai2 and p53 inhibitor co-
treatment improved both fusion and myogenic differentiation in shMeg3 cells. These 
findings demonstrate that TGFβ1 activation contributes to myogenic fusion impairments 
via EMT marker Snai2 upregulation in shMeg3 C2C12 cells. 
Noting the extent of TGFβ1-mediated fusion impairments, I inhibited canonical 




TGFβ signaling-complex Smad3 had no effect on the shMeg3 phenotype, whereas 
inhibition of the non-canonical TGFβ pathway p38 resulted in modestly improved fusion. 
Chemical inhibition of the non-canonical TGFβ RhoA pathway, ROCK1/2, completely 
restored fusion. Noting this branch of signaling regulates actin-cytoskeleton dynamics, I 
further examined the distribution of α-actinin, a muscle-specific, actin-bracing protein. I 
showed that shLacZ myotubes have ubiquitous α-actinin distribution, whereas shMeg3 
C2C12 cells display ventral α-actinin enrichment, suggesting the presence of stress-
fibers. Importantly, I showed that ROCK1/2 inhibition normalized the distribution of α-
actinin in shMeg3 cells, where fusion was fully restored. These findings demonstrate that 
aberrant non-canonical TGFβ signaling in shMeg3 cells modified actin-cytoskeleton 
dynamics in a way that restricted fusion-competence, and favored incorporation of α-
actinin into stress-fibers, rather than sarcomeric scaffolding.  
Mindful that Ezh2-interacting motifs of Meg3 are evolutionarily conserved, I 
performed RNA-IP and confirmed that Ezh2 interacts with Meg3 in proliferating C2C12 
myoblasts. I then evaluated for Ezh2-dependent H3K27me3 recruitment in shMeg3 
myotubes, and found that repressive marks were changed for numerous loci. Several 
TGFβ-promoting loci exhibited modest derepression, whereas extracellular regulators of 
TGFβ signaling were modestly enriched for H3K27me3. These findings reinforce that 
Meg3 has an evolutionarily conserved role in recruiting PRC2 to TGFβ-related loci in 
C2C12 myoblasts.  
I then assessed the functional outputs of modified Ezh2 recruitment by inhibiting 




Ezh2 reduced aberrant H3K27me3 accumulation, and improved both fusion and 
differentiation marker expression in shMeg3 C2C12 cells. This suggests that loss of 
Meg3-mediated Ezh2 recruitment results in anti-myogenic Ezh2 activity. 
In Chapter Five, I investigated the role of Meg3 in muscle regeneration in vivo, 
and determined that Meg3 knockdown, but not overexpression, resulted in reduced cross-
sectional area and increased fibrosis. RNAseq analysis for these samples harbored 
numerous parallels to the in vitro knockdown model, including EMT and TGFβ 
activation. I then immunostained EMT markers in regenerating muscle, and found that N-
cadherin and Snai2 were upregulated in day 7 shMeg3 muscle, whereas vimentin was 
upregulated in late day 14 muscle regeneration. While the abundance of Pax7+ satellite 
cells was increased at day 14, no difference in satellite cell abundance or proliferation 
was observed in day 7 samples. Therefore, increased satellite cell abundance at day 14 
may reflect lingering satellite cell populations that failed to form multinucleated 
myofibers. Taken together, these data demonstrate that Meg3 regulates muscle 
regeneration and mesenchymal marker expression in vivo. 
Noting that Meg3 is also enriched in mesenchymal stromal cells, I examined this 
cell population in regenerating muscle. I found that day 7 shMeg3 samples harbored 
increased numbers of proliferating interstitial cells lacking Pax7+ satellite cell marker, 
and that PDGFRα+ cells accumulated in the regenerating microenvironment. 
Furthermore, I showed that fibrotic collagen is enriched in shMeg3 tissue at day 14, 
which is consistent with increased mesenchymal stromal cell numbers and TGFβ activity. 




mesenchymal stromal cell numbers, and highlights cell-type specific roles of Meg3 in 
modulating skeletal muscle regeneration in vivo. 
In Chapter Six, I compared transcriptomic data from shMeg3 C2C12 and TA 
samples with published data on satellite cell activation, myogenic signaling, cell 
ontologies, and geriatric muscle. I found that numerous transcription factors required for 
C2C12 fusion were downregulated in shMeg3 samples, and while a subset of myogenic 
fusion proteins were upregulated with shMeg3 treatment, Jam2 was significantly 
downregulated in both C2C12 and TA samples. By comparing my datasets to 
transcriptomic profiles of distinct satellite cell states, I showed that shMeg3 C2C12 and 
TA samples were enriched for transcripts associated with early, but not late satellite cell 
activation, which may reflect stunted myogenic differentiation progression.  
I further examined these transcriptomes for changes in muscle-related signaling 
pathway outputs, and found that pro-myogenic p38 and Erk1/2 signaling was reduced in 
shMeg3 samples relative to shLacZ. Moreover, anti-myogenic p53 signaling outputs were 
enriched. Taken together, these transcriptional correlations may point to suppressed 
myogenic differentiation in shMeg3 samples.  
Transcripts that were specifically repressed by Ezh2 in satellite cells were 
enriched in shMeg3 samples, and considering Ezh2-mediated repression has been shown 
to maintain transcriptional fidelity in satellite cells (Woodhouse et al. 2013), I evaluated 
for transcriptional changes that reflect non-myogenic ontologies. While only a subset of 
Hox genes were enriched with shMeg3 C2C12 cells, it was notable that anti-myogenic 




which may reflect an identity shift towards an alternate cell fate. Moreover, 
transcriptomic analyses based on Meg3-expressing limb muscle interstitial cells indicated 
that mesenchymal stromal cell transcripts were enriched for both in vitro and in vivo 
samples, which not only corroborates increased mesenchymal stromal cell populations 
observed in vivo, but also suggested that shMeg3 C2C12 myoblasts resemble 
mesenchymal stromal cells more than satellite cells when compared to shLacZ controls. 
Noting this could indicate a cell identity shift, I expanded transcriptional analyses to 
compare shMeg3 transcriptomes to a spectrum of cell and tissue types. These analyses 
revealed that shLacZ transcriptomes were strongly enriched for skeletal muscle-specific 
gene sets, whereas shMeg3 transcriptomes were more enriched for osteogenic gene sets. 
These findings suggest that shMeg3 samples have deviated from muscle-specific 
transcriptional profiles. Considering that Meg3 enrichment in the somite is increasingly 
restricted to myogenic territories (Schuster-Gossler et al. 1998), it is quite feasible that 
Meg3 safeguards muscle progenitor cells from adopting an alternative paraxial 
mesoderm-derived cell identity.  
Meg3 is downregulated in aged skeletal muscle (Mikovic et al. 2018) and 
geriatric satellite cells (Kimmel et al. 2020, Liu et al. 2013), which is also associated with 
differentiation impairments and loss of identity. Accordingly, I evaluated shMeg3 
transcriptomes for transcripts enriched with aged satellite cells, as well as geriatric 
muscle tissue from mice and humans. For all data sets, a large subset of shMeg3 enriched 
transcripts were associated with gene expression in aged muscle. These findings 




muscle aging, and while decline of Meg3 expression could underlie age-related muscle 
regeneration impairments, further experiments are required to determine whether Meg3 
downregulation plays a role in aging pathology.  
 
 
7.2 Future Perspectives 
Coupling transcriptional dysregulation to epigenetics 
Myoblasts undergo considerable epigenetic and transcriptional reprogramming to 
differentiate, which facilitates profound cytoarchitectural remodeling and cell identity 
shifts. My findings show that Meg3 knockdown drastically modifies the transcriptional 
landscape of myoblasts and regenerating muscle, and that Meg3 interacts with the Ezh2 
subunit of PRC2, yet genome-wide characterization of the epigenetic landscape for these 
samples would broaden these findings in an unbiased manner. Therefore, I propose ChIP-
seq for identifying Meg3-dependent changes in Ezh2 recruitment, and coupling this 
enrichment to transcriptional perturbations observed in these cells. Specifically, I would 
analyze H3K27me3-immunoprecipitated loci from day 3 C2C12 samples, as well as 
Ezh2-immunoprecipitated loci from proliferating C2C12 samples, and evaluate for 
overlap in loci enriched for these samples in shLacZ samples to identify loci targeted for 
PRC2-mediated chromatin remodeling in C2C12 differentiation. Subsequently, 
Ezh2/H3K27me3 enriched loci can be examined in shMeg3 samples to identify the subset 
of loci specifically targeted by Meg3-Ezh2 complexes, as well as genetic loci aberrantly 




on how Meg3 modulates the epigenetic landscape to facilitate myogenic differentiation, 
and could also identify novel targets for muscle regeneration strategies. 
 
Cell-specific dysregulation in skeletal muscle 
While in vitro experiments restricted Meg3 gene expression manipulations studies 
to myogenic cells, in vivo samples were comprised of numerous cell ontologies, and 
transcriptomic data from these samples were unfortunately a pooled collection of diverse 
transcriptomes. To examine how diverse cell populations are modulated by shMeg3 
treatment, I propose several experiments. First, I would recommend single-cell RNAseq 
to examine transcriptional perturbations at the single-cell resolution. This would enable 
us to distinguish transcriptional disturbances in satellite cells from transcriptional changes 
in mesenchymal stromal cells. Furthermore, I would generate Cre-lox mice for inducible 
Meg3 deletion, with Cre expression under the satellite cell-specific Pax7 promoter, and 
repeat experiments conducted in Chapter Five to characterize the satellite cell specific 
role of Meg3 in myogenic differentiation. Similarly, given the emerging importance of 
mesenchymal stromal cells in regulating muscle regeneration, I would generate mice for 
inducible Meg3 manipulations in mesenchymal stromal cells and evaluate for their Meg3-
dependent contributions to satellite cell crosstalk and fibrosis. Finally, given the 
limitations of single cell RNA-seq, I would modulate Meg3 expression in differentiated 
myotubes, and evaluate for perturbations in the muscle regeneration process. Such 




and enhance our understanding of which cell types are worth targeting for therapeutic 
strategies.  
Investigation of p53-mediated dysregulation 
Meg3 contains evolutionarily conserved sequences that have been shown to interact with 
and modulate p53 activity in non-muscle cells (Zhang et al 2010, Uroda et al. 2019, 
Sherpa et al. 2018). Moreover, p53 signaling is required for mitotic expansion of satellite 
cells (Liu et al. 2018), and has been shown to redirect activated satellite cells towards 
adhesion to preexisting myofibers, which is thought to promote return to quiescence 
(Flamini et al. 2018). Given Meg3 is enriched in skeletal muscle cancers (Schneider et al. 
2013), it is possible that Meg3-p53 interactions are not anti-tumorigenic, but rather 
geared towards satellite cell expansion – which could imply that Meg3 downregulates 
p53 activity in this context to safeguard satellite cell expansion. In both shMeg3 model 
systems, expression profiling suggested that p53 signaling was upregulated, yet p53 
inhibition was only sufficient to restore MYH4 expression to shMeg3 cells. These 
findings indicate that p53 plays complex roles in myogenic differentiation, and 
exploration of Meg3-dependent p53 activity would provide insight to how Meg3 
putatively fine-tunes p53 activity to facilitate myogenic differentiation.  
 To this end, I would first confirm that Meg3 interacts with p53 in muscle 
progenitor cells by RNA-IP. I would then ectopically express a library of MEG3 splice 
variants in myoblast cells, and evaluate for changes in functional readouts of p53 activity, 
including proliferation and apoptosis. Moreover, I would perform ChIP-seq with p53 




well-characterized p53 targets, as well as p53 targets unique to myogenesis. To validate 
Meg3-dependent changes in p53 activity, I could transfect Meg3-deficient myoblasts with 
pre-incubated p53-MEG3 complexes, and evaluate for changes in the aforementioned 
functional assays and ChIP-seq profiles. These experiments would further describe the 
modulatory role Meg3 has in myogenic differentiation, while also examining for p53-
targets that directly modulate myoblast activity.  
Meg3 in myogenic cell fate restriction 
Embryonic tissues called somites harbor progenitors for muscle, cartilage, dermis, and 
bone; in the somite, Meg3 expression is increasingly restricted to somite territories that 
correspond with myogenic progenitors (Schuster-Gossler et al. 1998). Moreover, the 
chromatin-remodeling protein PRC2 deposits H3K27me3 to restrict gene expression and 
fortify myoblast cell fate (Juan et al. 2011). In Chapter Five, I showed that Meg3 interacts 
with Ezh2, and modulates PRC2 activity in C2C12 myoblasts. Considering shMeg3-
treated samples consistently expressed osteoblast-enriched transcripts, and that shMeg3 
C2C12 cells also expressed chondrocyte-enriched Hox genes, it is possible that Meg3 is 
required to suppress alternative cell fate trajectories in embryonic myoblasts.  
 To evaluate for changes in the inclination for shMeg3 myoblasts to adopt an 
alternative cell-fate, I propose several experiments. First, I would perform directed-
differentiation for non-myogenic cell fates in shMeg3 C2C12 myoblasts, and examine for 
Meg3-dependent changes in differentiation potential for bone cells. In parallel, I would 
overexpress MEG3 in precursor cells for various cell ontologies to examine for changes 




somite organoids (or better yet, mouse embryos undergoing somitogenesis), and perform 
marker analysis to quantify relative proportions of somite-derived lineages. These 
experiments would better evaluate the role of Meg3 in fortifying myogenic identity.  
Meg3 in aged skeletal muscle regeneration 
Age-related muscle decline is a debilitating condition that results in devastating 
loss of autonomy, and with geriatric populations ballooning, it is urgent that the field of 
muscle biology devises efficacious treatments for curbing, or even reversing age-related 
muscle decline. Interestingly, shMeg3-treated samples shared numerous phenotypic 
features with aged myblasts. Though the mechanisms are unclear, activated geriatric 
satellite cells exhibit reduced migration efficiency that is punctuated by fewer protrusions 
and increased latency in actin-cytoskeleton dynamics (2012 Collins Hooper), which 
parallels RhoA-mediated impairments in shMeg3 C2C12 myoblasts. Aged muscle also 
experiences increased TGFβ signaling (Rathbone et al. 2011), and given my findings that 
Meg3 is required to downregulate TGFβ activity, it is feasible that Meg3 is required to 
counteract this increased anti-myogenic signaling during postnatal myogenesis in aged 
muscle. In addition to myogenic impairments, aged muscle is more fibrotic, which is due 
to TGFβ-induced mesenchymal stromal cell expansion (Baghdadi et al. 2018) as well as 
satellite cell trans-differentiation to a myofibrotic lineage (Zhou et al. 2019); Noting that 
shMeg3 treatment increased mesenchymal stromal cell expansion and fibrosis in vivo, it 
also appears likely that loss of Meg3 in geriatric muscle tissue would exacerbate fibrosis. 
To evaluate the putative role of Meg3 in muscle aging, it would be informative to 




suppressing age-related muscle decline. To this end, I propose three aims: First, I would 
generate a transgenic mouse harboring MEG3 under the Pax7 promoter, allow mice to 
reach geriatric age (24 months), and subsequently evaluate these mice for functional 
readouts of muscle aging: sarcopenia, fibrosis, grip strength, and regeneration efficacy. 
Second, to better evaluate its clinical relevance for treating aged populations, I would 
conduct MEG3 overexpression experiments on geriatric wild type mice, and examine 
aforementioned readouts of muscle aging. Finally, to evaluate for functional relevance to 
human myogenesis, I would obtain primary myoblasts from geriatric human muscle 
biopsies, treat with constitutive MEG3 expression, and evaluate for changes in 
proliferation, fusion, and differentiation capacity in vitro, and use lineage tracing to 
measure their contribution to regenerating myofibers when transplanted to humanized 
mice in vivo. Collectively, evaluating these parameters will inform the therapeutic 
potential of Meg3 in suppressing age-related muscle decline. 
 
7.3 Conclusion  
 The experiments proposed in this chapter will enable for a broadened 
understanding of Meg3 in skeletal muscle formation and homeostasis. Detailed 
characterization of the mechanisms by which lncRNAs modulate gene expression in 
myogenesis can only expand the library of tools at our disposal for restoring muscle mass 
to patients suffering from debilitating muscle loss, and advancing preexisting 
therapeutics. Meg3 specifically appears to play a nodal role in modulating p53 signaling 




important to disentangle cell-specific roles this lncRNA in facilitating myogeneis. 
Overall, phenotypes associated with loss of Meg3 expression had striking parallels with 
age-related muscle decline, and considering Meg3 is downregulated in geriatric muscle, 
further work is absolutely required to evaluate its therapeutic potential. In doing so, we 
are better equipped to devise and implement treatments that restore muscle function, and 
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